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Abstract 
Protein aggregation into cytotoxic oligomers and fibrils in vivo is linked to cell degeneration 
and the pathogenesis of more than 25 uncurable diseases, which are often called amyloid 
diseases, while the high aggregation propensity and insolubility of several bioactive 
polypeptides and proteins in vitro prevents their therapeutic use. Aggregation of human islet 
amyloid polypeptide (IAPP) into pancreatic amyloid is strongly associated with pancreatic 
cell-degeneration and the pathogenesis of type II diabetes (T2D). IAPP is a 37-residue 
polypeptide which acts physiologically as a neuroendocrine regulator of glucose homeostasis. 
However, IAPP misfolds and self-associates into cytotoxic aggregates and fibrils even at 
nanomolar concentrations. Brain amyloid plaque formation, cell degeneration and the 
pathogenesis of Alzheimer’s disease (AD) are associated with cytotoxic misfolding and self-
assembly of β-amyloid peptide (Aβ). Aβ is a ubiquitary expressed, 40 (Aβ(1-40))  to 42  
(Aβ(1-42)) residue polypeptide of yet unknown physiological function. Aβ is found in serum 
and cerebrospinalfluid in subnanomolar concentration. Both Aβ and IAPP are short, natively 
unfolded polypeptides which share a sequence similarity of 50% but have been so far thought 
to be functionally unrelated. Clinical and pathophysiological observations indicate that the 
two major cell degenerative diseases AD and T2D might be linked to each other. However, 
direct evidence for a molecular link has been missing.  
Compounds that block cytotoxic protein/polypeptide self-assembly and amyloidogenesis are 
important targets of therapeutic intervention in protein aggregation diseases. The concept 
underlying the here presented studies was based on the hypothesis that bifunctional soluble 
IAPP mimics which combine bioactivity with the ability to block and reverse IAPP cytotoxic 
self-assembly could be promising candidates for treatment of diabetes.  
Using a recently developed minimalistic conformational restriction strategy, four double N-
methylated IAPP analogues, [(N-Me)G24, (N-Me)I26]-IAPP (IAPP-GI), [(N-Me)A25, (N-
Me)L27]-IAPP (IAPP-LA), [(N-Me)F23, (N-Me)A25]-IAPP (IAPP-FA) and [(N-Me)I26, (N-
Me)L27]-IAPP (IAPP-LI), have been designed and synthesized. Their design approach was 
based on the hypothesis that NFGAIL is a crucial “amyloid core” and self-recognition 
sequence of IAPP and consisted of the introduction of two N-methyl residues into selected 
amide bonds within the NFGAIL region of full length IAPP. 
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In fact, the studies presented in this thesis show that these four IAPP analogues are highly 
soluble, non-amyloidogenic, and non-cytotoxic molecular analogues of a non-amyloidogenic 
IAPP conformation and full IAPP receptor agonists.   
In addition, the studies show that all four designed IAPP analogues are able to interact with 
IAPP and to suppress IAPP cytotoxic self-assembly and fibrillogenesis. The potencies of the 
effects of the different IAPP analogues differ significantly, consistent with a conformational 
specificity of the IAPP-analogue interaction causing their inhibitory effects. Most importantly, 
it is also shown that all four analogues are able to interfere with Aβ(1-40) and to suppress 
with varying potencies Aβ(1-40) self-assembly and fibrillogenesis. Thereby, IAPP-GI is 
proved to be the most potent analogue with regard to inhibition of self-assembly of both IAPP 
and Aβ(1-40). These findings suggest that IAPP-GI and/or the other IAPP analogues might 
become lead compounds for the development of therapeutics in T2D and/or AD. 
In addition, the studies presented in this thesis also suggest that hetero-association of early 
prefibrillar and likely non-toxic IAPP and Aβ(1-40) species into soluble hetero-complexes 
attenuates cytotoxic self-association of both polypeptides. Hetero-association of early 
prefibrillar and nontoxic IAPP and Aβ(1-40) species may “protect” both polypeptides from 
pathogenic misfolding and self-association in vivo, offering thus a molecular link between the 
pathogenesis of AD and T2D and suggesting that effective therapeutic strategies targeting 
both diseases might be possible. 
Taken together, the results in this thesis offer a proof-of-principle of a novel concept for 
designing potent amyloid disease therapeutics and of a chemical engineering approach to 
redesign a natively amyloidogenic and bioactive polypeptide sequence into a soluble, non-
cytotoxic, and bioactive analogue which is also a highly potent inhibitor of cytotoxic self-
assembly of the native amyloidogenic sequence it has been derived from. Therefore, the 
inhibitor design concept tested in this thesis might applicable to other disease-related self-
associating polypeptides too.  
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1. Introduction  
1.1 Amyloid associated diseases and the relevant fibril-forming protein 
Considerable attention focuses presently on a group of protein misfolding diseases known as 
amyloidoses. The term “amyloidosis” describes a group of diseases that are characterized by 
the deposition of fibrillar amyloid aggregates as intracellular inclusions or extracellular 
plaques in various organs and tissues [1-5]. A common property of the aggregates is the 
induction of tissue damage [2, 6-10]. To the amyloid diseases belong the Alzheimer's disease 
(AD), the transmissible spongiform encephalopathies (TSEs), the serpin-deficiency disorders, 
the Huntington’s disease (HD), cystic fibrosis, type II diabetes (T2D), amyotrophic lateral 
sclerosis (ALS), Parkinson’s disease (PD), and dialysis-related amyloidosis. Amyloid deposits 
can form in the brain, in vital organs such as the liver, pancreas and spleen, or in skeletal 
tissue, depending on the disease involved. Such deposits can be identified using a radioactive 
tracer in vivo or post-mortem by staining of tissue sections with Congo red (CR). Tissue 
amyloid deposits of the various different diseases are shown in Fig.1 [9, 11]. To date, more 
than 20 different polypeptides and proteins have been identified in vivo occurring as 
constituents of amyloid plaques. These polypeptides/proteins include the full length proteins 
(e.g. lysozyme or immunoglobulin light chains), biologically active polypeptides (human islet 
amyloid polypeptide (IAPP)) and fragments of larger proteins produced by specific proteolytic 
processing (e.g. the Alzheimer’s amyloid β-peptide (Aβ)) or of more general degradation (e.g. 
poly(Q) stretches). There is no structural similarity between the amyloid forming proteins but 
they are all relatively small proteins. The peptides and proteins associated with known 
amyloid diseases are listed in Table 1. 
 
 
1.2 The physicochemical characteristics and the structural features of the amyloid fibrils 
Despite the facts that various different proteins form amyloid and all of them have unique and 
different native folds (Fig. 2), the generated amyloid fibrils exhibit a number of common 
physicochemical characteristics. These included the typical unbranched fibrillar structure, 
a predominantly β-sheet secondary structure, birefrigence upon staining with the dye CR, 
insolubility in a number of solvents and detergents, and in some cases (prion protein (PrP)) 
protease resistance. An in vitro sample that satisfies three important criteria of amyloid fibrils 
is shown in Fig.3 [12]. Amyloid fibrils are ordered aggregates of a normally soluble peptide 
or protein. Although earlier studies have focused on the possible cytotoxicity of the amyloid 
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fibrils, it is now believed that the oligomeric precursors to amyloid may be more toxic than 
amyloid itself [13-18]. Even if this is the case, knowledge of the molecular structures of amyloid 
fibrils is essential for understanding their formation mechanism and stability of amyloid 
fibrils, and thus possibly their relationship to the pathogenesis of the amyloidoses. 
Determination of the structure of amyloid fibrils is important for the development of 
compounds that inhibit or reverse protein aggregation and amyloid formation and which may 
thus be applied as preventive or therapeutic agents in amyloid diseases.  
 
Fig. 1. Amyloid deposits from different degenerative diseases. Extracellular amyloid plaques (white arrows) and 
intracytoplasmic neurofibrillary tangles (yellow arrows) are the pathological signature of Alzheimer’s disease [9]. 
Intracytoplasmic aggregates are typically present in the neurons of people affected by Parkinson’s disease and 
amyotrophic lateral sclerosis [9]. Intranuclear inclusions of huntingtin are observed in Huntington’s disease patients 
and extracellular prion protein amyloid plaques that are located in different brain regions are present in some cases 
of transmissible spongiform encephalopathy [9]. Amyloid fibrils are also deposited in the pancreatic islets of type II 
diabetes [11]. In spite of the different protein compositions, the ultrastructure of these deposits seems to be similar 
and is composed mainly of fibrillar protein. The figure shown is modified from ref. [9] and [11]. 
Huntington’s intranuclear inclusions 
Alzheimer’s plaques and tangles Parkinson’s Lewy bodies 
Prion amyloid plaques 
Amyotrophic lateral sclerosis aggregates Islet of a Type 2 diabetic subjects 
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Table 1.  A summary of the main amyloidoses and the proteins or peptides involved [3].  
Disease Main aggregate component 
Alzheimer’s disease      Aβ peptides (1–40, 1–41,1–42, 1–43); Tau 
Spongiform encephalopathies  Prion protein (full-length or fragments) 
Parkinson’s disease  α-synuclein (wild type or mutant) 
Primary systemic amyloidosis  Ig light chains (full-length or fragments) 
Fronto-temporal dementias  Tau (wild type or mutant) 
Huntington’s disease  Huntingtin 
Secondary systemic amyloidosis  Serum amyloid A (fragments) 
Familial Mediterranean fever  Serum amyloid A (fragments) 
Senile systemic amyloidosis  Transthyretin (wild-type or fragments) 
Familial amyloid polyneuropathy I  Transthyretin (over 45 mutants) 
Hereditary cerebral amyloid angiopathy  Cystatin C (minus a 10-residue fragment) 
Haemodialysis-related amyloidosis  β2-microglobulin 
Familial amyloid polyneuropathy III  Apolipoprotein AI (fragments) 
Finnish hereditary systemic amyloidosis  Gelsolin (fragments of the mutant protein) 
Type II diabetes  IAPP 
Medullary carcinoma of the thyroid  Calcitonin (fragment) 
Lysozyme systemic amyloidosis  Lysozyme (full-length or fragments) 
Insulin-related amyloid  Insulin (full-length) 
Amyotrophic lateral sclerosis  Superoxide dismutase 1 (wild-type or mutant) 
Kennedy disease  Androgen receptor (polyQ expansion) 
 
Fig. 2. The tertiary fold of the structured part of the prion protein (residues 124 to 227), full length lysozyme and 
transthyretin. Note how different their native folds are, despite the fact that they show the same structural 
features in their amyloid fibrillar form. The figure shown is from http://www.umu.se/medfak/utbildning. 
Prion Transthyretin Lysozyme 
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Fig. 3. A protein aggregate formed in vitro that satisfies the three criteria to define the sample as amyloid fibrils 
is shown on the right. The sample has fibrillar morphology by TEM, β-sheet secondary structure by FTIR, and 
green birefringence under polarized light upon staining with CR. The protein aggregate on the left does not 
satisfy any of these criteria [12]. The figure shown is from ref. [12]. 
 
The structural features of the fibrils have been studied by a wide variety of techniques, 
including transmission electron microscopy (TEM) and cryo-electron microscopy, atomic 
force microscopy (AFM), X-ray diffraction, and solid state NMR (ssNMR). Increasingly 
convincing models have been derived based on studies on amyloid fibrils from various 
proteins such as Aβ, insulin, PrP, IAPP, and human transthyretin (TTR) [19-29]. Electron 
microscopy (EM) and AFM have shown that amyloid fibrils are long, and unbranched.  
Amyloid fibrils have usually a length of 100 nm to many microns, and a width of 6–12 nm. 
They consist of a variable number of “protofilaments” (narrower fibrillar units making up 
the mature fibril) around 1.5–2.0 nm in diameter and they often show variations in twist or 
the numbers of “protofilaments” or sheet-like/ribbon assemblies [27, 30-34] (see Electron 
micrographs in Fig.4). X-ray diffraction data derived from oriented fibrils suggest an 
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ordered cross-beta structure in which β-sheets run parallel to the fibril axis, while 
individual peptide strands are oriented perpendicular to the long axis of the fibril. The 
distance between β-strands of the peptide chains are 4.7 Å and the separation between constitute 
sheets which are approximately 10 Å. The organised core structure is composed of β-sheets 
having strands running perpendicular to the fibril axis [27, 28, 31, 35, 36]. Fibrils also show 
an overall long-rang twist. Using ssNMR a high resolution structure of a single peptide chain,  
 
Fig. 4. Electron micrographs of negatively stained amyloid fibrils from different polypeptides and close-up 
view of the structural organization of an amyloid fibril. Schematic diagrams show the probable hierarchical 
assembly of structures making up a mature amyloid fibril from the continuous hydrogen-bonded β-sheet 
structure within a protofilament to the organization of the protofilaments. Several protofilaments are wound 
around each other and their core structure is a row of β-sheets where each strand runs perpendicular to the 
fibril axis [22, 37]. The figure shown is modified from ref. [37] and [22]. The Electron micrographs of Aβ (1-
40), Aβ (1-42), amylin, insulin, lysozyme , and α-synuclein shown in the figure are from ref. [20],  [38], [20], 
[39], [40], and [41], respectively. 
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including the conformations of the side chains, within an amyloid fibril has been recently 
elucidated showing an extended beta-strand conformation [24, 42, 43]. According to these 
results, a model that describes fribrils consisting of a small number of “protofilaments” is 
shown in Fig. 4. Amyloid fibrils are composed of two or more “protofilaments” and are held 
together by hydrophobic surface contacts and/or specific electrostatic interactions, the 
“protofilaments” twisting around one another. All of the amyloid fibrils which have been 
reported have a left-handed helical twist [20, 30, 37, 44-46]. Principally, all types of amyloid 
fibrils share this structure in spite of a high diversity between amyloid fibril proteins [21, 47-
50]. However, the exact molecular structure of the fibrils of each of the different proteins 
varies depending on the protein. 
 
 
1.3 The mechanism of protein misfolding, aggregation, and fibril formation 
Understanding the molecular mechanism of protein misfolding, aggregation and amyloid 
formation may assist in preventing these processes under physiological conditions and is thus 
important for developing therapeutic strategies against amyloid-associated pathologies. A 
great deal of research has been performed to understand the molecular mechanism of the 
amyloid diseases and recent findings strongly support the hypothesis that the assembly of 
misfolded proteins into aggregates is a key step. The molecular basis of protein aggregation is 
protein misfolding, where specific peptides or proteins fail to fold or to remain correctly 
folded (misfolding) and then aggregate so as to give rise to amyloid deposits in tissue [1, 6, 10, 
14, 51-54]. Proteins must properly fold into three dimensional structures in order to carry out 
their proper functions within the cell and organism. In general, the natural protein is folded in 
the native and active conformation which is a mixture of different secondary structure 
elements (for example a mixture of α-helical and random structure), whereas the misfolded 
protein is often rich in β-sheet content. The β-sheet structure is one of the more prevalent 
repetitive secondary structures in folded proteins and is formed of alternating peptide pleated 
strands linked by hydrogen bonding between the NH and CO groups of adjacent strands 
(Fig.5). Several studies have shown that proteins unrelated to any amyloid disease aggregated 
in vitro into fibrillar structures closely similar to those formed in amyloid disease, including 
well-known proteins such as myoglobin and also homopolymers such as polythreonine or 
polylysine [18, 55-59]. These observations suggested that amyloid-fibril formation is a 
generic property of peptides and proteins and that the ability to form amyloid structures is not 
an unusual feature of the small number of proteins associated with amyloid diseases. It has 
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been thus suggested that perhaps all proteins are potentially able to form amyloid fibrils under 
suitable conditions [1, 14, 60, 61]. Although the initial process of amyloid formation might be 
different in different diseases, a common trend is that during the formation of aggregates, α-
helical domains disappear, leading to an increase of β-sheet-dominated secondary structure 
and one of the common consequences of protein misfolding into β-sheets is protein 
aggregation. Similar fibrillar products may arise from two different driving forces: 
hydrophobic interactions or polar hydrogen bonding among side-chain groups [1, 9, 62]. The 
structural studies have also shown that a large conformational rearrangement of the 
polypeptide chain occurs during misfolding and aggregation, but the molecular and energetic 
basis of protein misfolding and amyloid fibrillogenesis is still largely unknown. These 
changes might be possible by a relative “instability” of the protein folding process induced by 
various factors acting separately or synergistically. It has been observed that one or many 
genetic and environmental factors can be associated with protein misfolding and aggregation. 
Environmental factors that can catalyse protein misfolding include changes in concentration 
of metal ions, temperature, ionic strength, pH or oxidative stress, while the local concentration 
of the protein can also play a crucial role [3, 10, 19, 62, 63].  
 
 
Fig. 5. Secondary structures of proteins (A) A model alpha-helix shows the hydrogen bonds (dotted lines) 
between oxygen and hydrogen atoms of the fourth amino acid up the chain. (B) beta-sheets are also held together 
by hydrogen bonds. The transparent arrows show the direction of individual beta-strands. Chains running in the 
same direction (left pair) form parallel beta sheets; strands running in opposite directions (right pair) are said to 
form anti-parallel beta-sheets. The atom coloring is as follows: carbon = green, oxygen = red, nitrogen = blue, 
and white = hydrogen. The figure shown is from http://www.faseb.org/opa/ . 
 
It is increasingly clear that protein aggregation is a complex process, involving several kinds 
of intermediates. Studies on the characterization of early stages of the aggregation process 
have revealed a basically conserved fibrillization pathway, characterized by the built-up of 
various different ordered prefibrillar aggregates. These fibrillization intermediates, designated 
protofibrils, were first described based on studies on Aβ aggregation [19, 64, 65] and they 
also seem to form during aggregation of other proteins too [18, 19, 29, 45, 66-68]. The earlier 
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formed metastable protofibrils often comprise 15–40 monomers and appear to be spherical in 
nature. These spheres appear to anneal to form chain-like protofibrils, which can then form 
annular (some pore-like) species and/or amyloid fibrils (Fig. 6). In generally, there are 
striking similarities between pathways leading to misfolding and aggregation of different 
proteins (Fig. 6) [7, 9, 53, 69, 70]. The first phase of protein misfolding may be the formation 
of an unfolded or misfolded intermediate that exposes hydrophobic surface to the aqueous 
environment. This intermediate has a high tendency to aggregate and becomes stabilized by the 
formation of soluble β-sheet oligomers. These in turn give rise to protofibrils and finally to 
mature cross-β amyloid fibrils by incorporation of additional monomers. In this pathway two 
scenarios are possible: First, largely unstructured peptide monomers in solution cluster and 
form nuclei. After the cluster reaches a so-called critical “nucleus”, it grows further to form 
full length fibrils by the addition of monomers to the existing fibril ends. In the second pathway,  
 
Fig. 6. A schematic representation of the general mechanism of aggregation to disease-associated amyloid deposits. 
The natively folded protein forms a misfolded conformation that self-associates oligomeric β-sheet structures which 
undergo further assembly into small, soluble aggregates. These aggregates have a high tendency to aggregate and to 
form protofibrils and mature amyloid fibrils. Some of the early aggregates seem to be amorphous or micellar in 
nature, although others form ring-shaped species [7, 9, 69]. The figure shown is modified from ref. [9] and [69]. 
The electron microscope images of  amyloid plaques in AD and lewy bodies in PD are from ref. [7]. 
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first the peptide “protofibrils” of intermediate length form. Such protofibrils associate then to 
form full length fibrils. Once the full length fibrils are formed, additional amyloid peptide 
monomers may add directly to existing fibrils. Alternatively, monomers may associate to 
form micelles [71-73]. These micelles may convert to fibril nuclei upon reaching a critical 
size [74]. The kinetics of the assembly leading to fibril formation is well described by 
the nucleated polymerization model (Fig. 7) [2, 7, 75-79]. In this model, the critical event is 
the formation of early protein oligomers that act as a nucleus to facilitate protein misfolding 
and promote protein polymerization and eventually fibril formation. Nucleation-
dependent polymerization is characterized by a slow lag phase in which a series of 
kinetically unfavorable interactions occur to form a stable oligomeric nucleus. In the lag 
phase, the native and the misfolded states are in equilibrium in solution, but the misfolded 
state is less populated and unstable.  
 
Fig. 7 Kinetics of fibril formation of an amyloidogenic protein [75, 76]. (A) Formation of aggregates according 
to the nucleation-dependent process above the critical concentration. The black line indicates the formation of 
amyloid fibrils, beginning from a solution of monomeric proteins, which may temporarily assume an 
amyloidogenic conformation. Initially, conditions do not favor aggregation, and this period corresponds to the 
lag phase that precedes the formation of fibrils. Once a critical nucleus has been generated, the conditions change 
to favor aggregation with very fast kinetics. Any available monomers in the amyloidogenic conformation quickly 
become entrapped in the fibril. The red line represents a similar condition in which preformed fibrils are added. 
Addition of nucleus or seed eliminates the requirement for nucleation and also results in rapid polymerization. (B) 
Simple mechanistic scheme for nucleation-dependent polymerization of an amyloidogenic protein. The figure 
shown is modified from ref. [75] and [76] 
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The rate-limiting step is not the conformational conversion but the chance for association of a 
sufficient number of misfolded monomers to form a stable, polymerization-competent nucleus. 
Once a nucleus is established, rapid assembly occurs by the addition of “assembly competent” 
monomers to the growing end of the fibril. Polymerization will not occur when the monomer 
concentration is below the critical concentration [75, 78]. The lag phase can be eliminated by 
addition of pre-formed nuclei, a process known as “seeding”. Kinetic studies have shown that 
the aggregation processes of Aβ, PrP, α-synuclein, IAPP and of some other proteins too 
follow a nucleation-dependent mechanism [80-85]. However, several intermediates have been 
also identified in vitro aggregation pathways (Fig. 6, 7), mostly in the case of Aβ, such as 
low-molecular weight oligomers and short, flexible, rod-like structures termed protofibrils [19, 
29, 65, 86]. 
 
 
1.4 Inhibitors of protein aggregation and toxicity 
The mechanism of pathogenesis of protein aggregation diseases remains unclear and effective 
therapies are currently unavailable. The possibility that protein aggregation is a cause, rather 
than an effect, of neurodegeneration is supported by overwhelming circumstantial evidence 
from a variety of sources including pathology, genetics, animal models, biophysics, 
mathematical modelling, and disease onset and progression [1, 7, 9, 14, 62]. The cell 
dysfunction or death caused by the amyloid depositions may have different origins. The 
deposition itself can mechanically interfere with the target cell or the misfolded protein and 
prefibrillar aggregates can be toxic and lead to cell death (Fig. 8) [3, 5, 10, 51, 70, 87, 88]. 
Numerous groups have been developing strategies to block various key steps in the 
amyloidosis process. There are several specific therapeutic approaches currently under 
development, for exemple, limiting the expression or availability of the amyloidogenic protein; 
inhibiting release of the amyloidogenic peptide from its parent protein; stabilizing the native 
form of the native protein using small organic ligands; destabilizing the misfolded 
conformation of protein or peptide [5, 8, 9, 89-92]. 
Strong evidence indicates that the conversion of a normal soluble protein into beta-sheet-rich 
oligomeric structures and fibrillar aggregates are key events in the pathogenic process of 
amyloidosis and that the most cytotoxic aggregates are the early prefibrillar assemblies or, 
possibly in some cases, the misfolded protein molecules rather than the mature fibrils [13-17]. 
Therefore, an attractive therapeutic strategy should aim to inhibit and/or reverse the 
protein/peptide misfolding into β-sheet aggregates, which should not be associated with some 
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important natural biological function. Amyloid is formed when partially unfolded proteins or 
polypeptides interlink as strands of β-sheets which then grow to form large polymers. Thus, 
the first strategy would be to use small molecules that can either stabilize the normally folded 
structure or refold abnormal conformations back to the native state (Fig. 8 (1)), and an 
alternative strategy would be to prevent the monomeric intermediate assembly into potentially 
cytotoxic oligomers (Fig. 8 (2)). If this fails, fibril growth can be blocked by destabilizing the 
early β-sheet oligomers and inhibiting aggregation of monomeric and oligomeric species (Fig. 
8 (3)) or the fibrillogenesis equilibrium might be shifted toward dissociation of cytotoxic 
assemblies (Fig. 8) [5, 9, 10, 88]. 
 
 
Fig. 8. Potential dangerous intermediates and possible therapeutic intervention strategies in the pathway of 
protein aggregation. A conformational change of a normal protein seems to be the hallmark event in a group of 
amyloidoses. Protein misfolding may be associated to disease by causing either the mitigation of biological 
activity of the folded protein or a gain of toxic activity of the misfolded protein or an inflammatory stimulus. 
Aggregation of the misfolded protein may also contribute to the disease pathogenesis. Some approaches to attack 
protein misfolding and aggregation include: (1) Stabilizing the monomeric native state of protein and/or 
inhibition and reversion of protein conformational changes (2) Inhibition of β-sheets assembly into small 
oligomers (3) inhibition of further oligomerization by β-sheet extension. Fibrillogenesis equilibrium can also be 
shifted toward dissociation of cytotoxic assembly by binding of fibrillogenesis intermediates The images of 
oligomers and fibrils shown in the figure are from ref. [9] and [22] 
soluble oligomers 
Conformational  
change 
disease-associated protein 
(misfolded structure) 
Gain of toxic activity
and /or 
Loss of biological function 
or 
Inflammatory stimulus 
Self-association 
x 
1 
x
2 
Indefinite β-sheet extension 
x 3
Small oligomers 
Normal protein 
(folded structure) 
protofibirils fibirils 
                                                                                              Introduction 
 12
Based on these strategies several approaches have been proposed to attack protein misfolding 
and aggregation (Fig. 9) [9]. A small molecule that binds to the native protein and stabilizes 
its native structure is one attractive idea (Fig. 9 A). Considering that in most amyloid diseases 
the misfolded protein is rich in β-sheet structure, it is an effective approach to destabilize the 
pathological β-sheet conformation of misfolded proteins, for example by using β-sheet 
breaker peptides to prevent and to reverse β-sheet formation (Fig. 9 B). Diverse small 
molecules have been designed to inhibit or reduce protein aggregation by competitively 
blocking protein–protein interactions. Two classes of competitive inhibitor can be designed: 
compounds that block the interaction between monomers (Fig. 9 C) and molecules that stack 
at the edges of β-sheet aggregates, preventing their growth (Fig. 9 D). Increasing the clearance 
of misfolded and aggregated proteins (Fig. 9 E) is an interesting approach that has been 
based on findings showing that accumulation of protein aggregates depends on a balance 
between deposition and clearance. 
 
Fig. 9. Schematic representation of different therapeutic strategies to arrest protein misfolding and aggregation 
[9]. (A) Stabilization of the folding of the native protein. (B) Inhibition and reversal of protein misfolding by 
compounds that can specifically destabilize β-sheet structures. (C) Competitive inhibition of protein 
oligomerization by compounds that bind to the monomeric protein. (D) Competitive inhibition of aggregation by 
molecules that bind to aggregated β-sheets and block further incorporation of monomers. (E) Increased clearance 
of the misfolded/aggregated protein by compounds that boost clearance mechanisms or decrease the stability of 
protein aggregates. The figure shown is from ref. [9]. 
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Peptides designed to specifically bind to the pathogenic protein and block and/or reverse its 
abnormal conformational change, through stabilization of the amyloidogenic precursor by 
direct binding, the inhibition of enzymes involved in the amyloidogenic pathway or the 
destabilization of common elements present in the natural amyloid fibrils, constitute a new 
class of drugs. Some low molecular mass chemical compounds that stabilize protein 
conformation against thermal and chemical denaturation might help to correct folding defects. 
These compounds are collectively called chemical chaperones. Chemical chaperones are 
reagents designed to be similar to the sequence of the protein region responsible for self-
association and contain residues that specifcally favor or disfavor a particular structural motif 
to stabilize native conformation of proteins [10]. Chemical chaperones have been shown to 
reverse the intracellular retention of several different misfolded proteins. Recently, some of 
these compounds have been shown in cell culture models to correct folding and trafficking 
defects in Aβ, PrP, and TTR [93-95]. β-Sheet breakers are short synthetic peptides containing 
the self-recognition motif of the protein undergoing misfolding and are engineered to arrest 
the folding of the polypeptide chain in a β-sheet structure [9]. β-Sheet breaker peptides have 
been designed as aggregation inhibitors to block the conformational changes and aggregation 
of several proteins. β-Sheet breaker peptide inhibitors of Aβ aggregation mainly were derived 
by substituting key residues of Aβ for prolines within the hydrophobic central sequence 16–
20 of Aβ, and were able to reduce Aβ fibril formation and toxicity [96-99]. Similarly, several 
short peptides homologous to the central and C-terminal regions of PrP have been shown to 
be effective at inhibiting conversion of soluble PrP to the β-sheet-rich protease-resistant form 
or at inhibiting PrP toxicity in vitro [100, 101]. For example, proline-containing β-sheet 
breaker peptides were generated by using prion protein 114-122 as a template to prevent the 
conformational change of the prion protein to its toxic form. A series of nonsteroidal anti-
inflammatory drugs (NSAID's) have been shown to be inhibitors of TTR amyloidosis by 
stabilization of the native tetramer, thus preventing subsequent fibril formation [102]. It has 
also been shown that NSAID's prevent the β-sheet folding of human IAPP and Aβ [103, 104]. 
A number of compounds have been found to directly target the amyloid deposits and to 
induce amyloid resorption or disassembly. CR is a symmetrical sulfonated azodye with a 
hydrophobic center consisting of a biphenyl group spaced between the negatively charged 
sulfate groups. CR been shown to inhibit Aβ fibril formation and toxicity [105-107]. It is also 
reported that CR inhibits fibrillogenesis of huntingtin [108] and the structural conversion of 
normal prion protein into its aggregation-competent pathogenic form [109, 110] and to 
significantly disrupt formation of polyglutamine oligomer [111]. Several small molecules 
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with an affinity for fragments of the proteins undergoing misfolding and specific antibodies 
and proteins capable of interacting with β-sheet aggregated proteins have been reported to 
prevent protein aggregation [112-114]. Iodinated anthracycline, 4'-iodo-4'-deoxydoxorubicin 
(IDOX), is one potential drug exhibiting effective inhibition of aggregation and can bind 
specifically and with very high affinity to amyloid fibrils of different chemical types. IDOX 
has been reported to dissolve pre-formed aggregates of several proteins [115, 116], to reduce 
human immunoglobulin light chain amyloidosis[117] and to decrease PrP accumulation and 
improve survival time in Syrian hamster’s innoculated with scrapie-infected brain 
homogenate [118]. Tetracycline-type molecules have been shown not only to inhibit Aβ 
misfolding and fibrillization, but to also disassemble the pre-formed fibrils. These compounds 
have in common the ability to adopt a specific three-dimensional pharmacophore 
conformation that might be essential for binding to Aβ and preventing it from forming fibrils 
[119, 120]. Tetracyclines have also been shown to prevent aggregation and acquisition of 
protease resistance of prion protein peptides [121]. Another approach for inhibiting aggregate 
formation that has met with some success is the use of specific antibodies targeted against the 
peptide domain assumed to be essential for aggregation. Antibodies can be an effective 
method of preventing protein aggregation. An antibody with conformation-specific 
recognition raised to soluble oligomers of Aβ has been reported. It inhibited the toxicity of 
oligomers of Aβ, α-synuclein, IAPP and polyglutamate proteins [122]. Coexpression of a 
huntingtin fragment and a single-chain variable region fragment antibody targeted to the N-
terminus of huntingtin greatly reduced nuclear inclusion formation of huntingtin in cells, and 
an anti-huntingtin antibody recognizing the polyP domains of huntingtin, significantly inhibits 
aggregation as well as the cell death induced by mutant huntingtin protein [123, 124]. 
 
 
1.5 Alzheimer’s disease and β-Amyloid peptide 
AD is one of the most well know amyloidoses. AD is named after the psychiatrist and neuro-
pathologist Alois Alzheimer. In 1907, he presented the clinical and neuropathological 
characteristics of the disease in a famous paper called “Über eine eigenartige Erkrankung der 
Hirnrinde” (about a peculiar disease of the brain cortex) [125, 126]. AD is now the most 
common neurodegenerative disease characterized by the progressive loss of cognitive 
function and death of nerve cells in several areas of the brain, leading to loss of mental 
functions such as in the description of Alzheimer: progressive memory impairment; 
disordered cognitive function; altered behaviour including paranoia, delusions and loss of 
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social appropriateness; and a progressive decline in language function [127, 128]. AD mostly 
occurs in people over age 65 with approximately 24 million cases worldwide. One 
characteristic pathological hallmark of AD is the deposition of insoluble, aggregated protein 
in the brain tissue. These deposits include the neurofibrillary tangles that accumulate 
intracellularly and the senile amyloid plaques that are deposited extracellularly in the neuropil 
[129, 130] (Fig. 10 A). In normal aging, nerve cells in the brain are not lost in large numbers. 
In contrast, AD destroys neurons in parts of the brain that control memory, especially the 
hippocampus and related structures, and many other areas of the brain are involved and there 
is an overall shrinkage of brain tissue in AD (Fig.10 B, C). The neurofibrillary tangles are 
composed of hyperphosphorylated microtubule associated protein tau which assembles in 
paired helical filaments and accumulates in the cytoplasmic compartments in neurons. The 
senile amyloid plaques are extracellular deposits in the brain parenchyma of which most 
abundant protein is Aβ which forms the core of the plaque [131].  
 
Fig. 10. Pathological charactertics in Alzheimer's Disease. (A) Neuritic plaques and neurofibrillary tangles in 
Alzheimer’s disease. Aggregated protein forms long fibers that wrap themselves around the base of the nerve 
cells (The figure shown is from www.ahaf.org/alzdis/about/AmyloidPlaques.htm). (B) Positron emission 
tomography images (The figure shown is from the Alzheimer's Disease Education and Referral Center/National 
Institut); (C) Postmortem images, Cross-section of the brain from a normal individual (left) and from an AD 
patient (right) (The figure shown is from Edward C. Klatt, Florida State University College of Medicine). 
 
It has been hypothesized that Aβ contributes to the neurodegeneration associated with AD due 
to the toxicity of the peptide in aggregated form. Due to the increasing body of genetic, 
physiologic, and biochemical evidence which supports the hypothesis that aggregation of the 
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Aβ peptide is an important event in AD, much research on Aβ peptides has been carried out in 
the past 20 years [129]. Aβ is produced by specific endoproteolytic cleavages of the much 
larger amyloid precursor protein (APP), a transmembrane glycoprotein of unknown function 
[132, 133]. The most common isoforms are Aβ(1-40) and Aβ(1-42) while Aβ(1-40) form 
accounts for 90-95% of the Aβ peptides in normal individuals [134]. The two Aβ peptides 
differ in their neurotoxicity, solubility and their tendency to undergo fibrillogenesis. The less 
common Aβ(1-42) is more fibrillogenic than Aβ(1-40), and has a tendency to aggregate more 
rapidly into small clusters, or oligomers and ultimately into fibrils and plaques and is believed 
to be especially neurotoxic [74, 135, 136].  
 
 
1.5.1 The solution structure of Aβ   
The detailed structural characterization of Aβ peptides both in solution and in fibrils is a 
crucial step towards understanding the formation and stability of ordered fibrillar peptide 
aggregates. Understanding the relationship between Aβ structure, Aβ aggregation, and 
cytotoxicity will be essential to develop new strategies to prevent the formation of Aβ toxic 
species. Knowledge of structural details of Aβ should in particular facilitate the design of 
inhibitors of fibril formation. For example, therapeutic strategies based on the rational design 
of aggregation inhibitors require knowledge of the molecular structure of aggregates and 
fibrils. Although complete, high-resolution structures have not yet been obtained, key features 
of structural conformations and supramolecular organization within amyloid fibrils formed in 
vitro from various synthetic Aβ peptides sequences have been elucidated using a variety of 
novel experimental methods, including EM, circular dichroism (CD) spectroscopy, magnetic 
resonance spectroscopy, X-ray fibre diffraction, AFM, ssNMR, and fourier transform infrared 
spectroscopy (FTIR).  
The primary sequence of Aβ(1-40) is: 
 
NH2-DAEFRHDSGY10EVHHQKLVFF20AEDVGSNKGA30IIGLMVGGVV40-COOH 
In the amyloid precursor protein, residues 1-28 domain is extracellular with a high proportion 
of charged residues (46%) (blue). The C-terminal residues 28-40 domain is associated with 
the cell membrane in the amyloid precursor protein (red) [137]. The hydrophobicity profiles 
of Aβ(1-40), calculated using the Kyte-Doolittle method show that Aβ(1-40) has a 
hydrophilic N-terminal region and hydrophobic C-terminal region [138] (Fig. 11 A). Amino 
acid sequence analyses of the Aβ peptide using secondary-structure prediction algorithms 
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indicate that the probability of finding a β-strand conformation in Aβ is high within the C-
terminal region after residue 28. The region between amino acids 10 and 24 presents a high 
and similar probability to display either an α-helix or β-strand conformation. In addition, there 
are a disordered N-terminal region and two β-turn regions between residues 6 and 8 and 
residues 24 and 29 [139-141] (Fig. 11 B).  
 
Fig. 11 (A) Kyte-Doolittle hydropathy profiles. Residues below the dotted line are characterized as having 
hydrophilic side chains; residues above the dotted line are considered as having hydrophobic side chains. The 
figure shown is from ref. [138]. (B) Schematic representation of the conformational equilibrium between 
alternative structures for Aβ. The structure shown at left should be the soluble form of  Aβ. The structure shown 
at right could be the form of Aβ able to form aggregates. The figure shown is modified from ref. [142]. 
 
Although conformational studies on Aβ peptides in aqueous solution are complicated by their 
tendency to aggregate, the solution structures of monomeric polypeptides related to Aβ using 
synthetic peptides and spectroscopic techniques have been reported by a number of 
investigators [142-146]. To structurally characterize the non-aggregated state of Aβ, full-
length peptides or smaller fragments have also been studied in aqueous solutions in non-
physiological conditions (pH, presence of strong organic solvents or detergents) to avoid 
protein aggregation [142, 145-147]. Aβ undergoes substantial conformational shifts 
depending on its environment and can easily convert among disordered, α-helical, and β-sheet 
conformers as solution conditions change (pH, concentration, temperature and incubation 
time) [142, 146, 148, 149]. Under membrane-mimicking conditions, Aβ contains a significant 
amount of α-helical character [145, 147]. In physiological buffers, α-helical, random coil and 
β-sheet secondary structure are observed, with the β-sheet content increasing dramatically 
with peptide concentration. Aβ conformation is both pH- and salt-sensitive, with an increase 
in β-sheet content in the presence of salt and in slightly acidic conditions [146, 148]. In fact, 
the hydrophobic segment in the C-terminal domain of Aβ invariably adopts a β-strand 
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structure in aqueous solutions, regardless of pH or temperature and the hydrophilic N-terminal 
sequence can form α-helix, random coil, and β-sheet structures, strongly depending on solution 
conditions. These experimental results indicated that Aβ may exist in two alternative 
conformations depending on the environment (Fig. 11 B). These alternative conformations 
have different solubility properties and may determine changes in the rate of amyloid fibril 
formation [141, 142]. The NMR-derived three-dimensional structure of the Aβ(1-42) consists 
of an extended chain (Asp1-Gly9), two alpha-helices (Tyr10-Val24 and Lys28-Ala42), and a 
looped region (Gly25-Ser26-Asn27) in a membrane-mimicking system. The most stable 
alpha-helical regions reside at Gln15-Val24 and Lys28-Val36 [147]. Aβ(1-40) in aqueous 
SDS micelles is unstructured between residues 1 and 14 and the rest of the protein adopts an 
alpha-helical conformation between residues 15 and 36 with a kink or hinge at 25-27 [150]. In 
aqueous solutions of fluorinated alcohols, the 3D NMR structure of Aβ(1-42) shows two 
helical regions encompassing residues 8–25 and 28–38,connected by a regular type I β-turn 
[151]. NMR structure of Aβ(1-40) determined in 40 % (by vol.) trifluoroethanol/water 
showed two helices, Gln15-Asp23 and Ile31-Met35, whereas the rest of the peptide was in 
random-coil conformation [152]. One NMR structure of Aβ(1-40) is shown in Fig. 12.  
 
Fig. 12. One NMR structure of Aβ(1-40). There are a disordered N-terminal and two helical regions between 
residues 15 and 23 and between residues 31 and 35 connected through a flexible kink. The figure shown is from 
ref. [152].  
 
NMR studies have shown that there are no significant structural differences between the 
Aβ(1-40) and Aβ(1-42). All these data hint to the presence of two helical regions 
encompassing residues 8–25 and 28–38, connected through a flexible kink, but it proved 
difficult to determine the length and position of the helical stretches with accuracy and, most 
of all, to ascertain whether the kink region has a preferred conformation [151]. 
Amyloid-β (1-40) peptide 
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1.5.2 The structure of the Aβ fibrils 
Characterization of the amyloid fibril requires unusual experimental approaches, due to their 
inherent noncrystalline and insoluble nature. The structure of amyloid fibril in AD has been 
examined from ex vivo aggregates by EM and X-ray fiber diffraction [35, 153]. It has been 
shown that the amyloid deposits in AD share many common features of core structure and 
morphology with amyloid formed from different protein precursors in other amyloid diseases. 
In order to study the structural features of the AD amyloid fibril without contamination or risk 
of disruption during the purification procedure from tissue, in vitro assembled amyloid fibrils 
from the full-length Aβ peptide were used. Much of the high-resolution detailed structural 
data has been obtained from EM, X-ray diffraction, AFM, ssNMR, scanning transmission 
electron microscopy (STEM) and electron paramagnetic resonance [24, 32, 33, 38, 154-156]. 
Negative stain TEM of amyloid fibrils assembled from Aβ show a mixture of smooth or 
regularly twisted fibrils even in the same field of view [38, 137, 156-158]. Left-handed helical 
structures formed by two or more strands are frequently observed in fibrils prepared in vitro 
[159, 160]. The diameter of the fibrils averages ~70 Å (Fig.13). X-ray diffraction of Aβ fibrils 
has shown the cross-β pattern [137, 161, 162]. The diffraction pattern indicates that the 
distance between β-strands in a β-sheet is 4.76 Å, the varying distance between β-sheets is 
around 10.6 Å, and the β-strands run perpendicularly to the fibril axis. Interpretation of X-ray 
diffraction patterns from Aβ(1-40) suggested an arrangement of five or six cross-β cylinders, 
28 Å wide, protofilaments arranged around a central core, separated by 55 Å.  
 
Fig. 13. Electron micrographs of negative-stained Aβ fibrils, (A and B) “Aged” Aβ(1-40) samples exhibited a 
multitude of long fibrils, falling primarily into one of two types: regularly twisted fibrils (arrows) and straight, 
relatively smooth fibrils (arrowheads). (C) Higher magnification of two twisted fibrils from an “aged” sample of 
Aβ(1-40). (D) Two helical structures forming a four-protofilament species formed by Aβ(1–42), and (E) an 
association of several helical structures; the arrows in (D) indicate the point where two pairs of intertwined 
protofilaments merge into a four-stranded, noncoiled fibril. The Electron micrographs shown are from ref. [137] 
(A,B, and C) and [38] (D and E). 
D E
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Fig. 14. Structural model for Aβ(1-40) protofilament, consistent with solid state NMR constraints on the molecular 
conformation and intermolecular distances and incorporating the cross-β motif common to all amyloid fibrils [20, 
24, 160]. (A) One NMR structural model of Aβ(1-40). Residues 1-8 are conformationally disordered, residues 10–
22 and 30–40 have β-strand conformations, and residues 23-29 form a bend. The figure shown is from ref. [24]. (B) 
All-atom representation of a pair of peptide molecules. Residues 10–22 and 30–40 have β-strand conformations, 
forming two separate in-register, parallel β-sheets. Blue double-headed arrows indicate side-chain–side-chain and 
side-chain–backbone contacts. Purple double-headed arrows indicate salt-bridge interactions between side-chain 
amino groups of K28 residues and side-chain carboxylate groups of D23 residues, and the contacts of the ‘external’ 
quaternary interface (i.e. the interface between the two layers). Residues 1-8 are conformationally disordered and 
are omitted. The figure shown is from ref. [160]. (C) Schematic representation of a pair of molecular layers and 
cross-β unit. The protofilament is a four-layered β-sheet structure. The cross-β unit is a double-layered structure, 
with in-register parallel-β sheets formed by residues 12–21 (red ribbons) and 30–40 (blue ribbons). The figure 
shown is from ref. [160]. (D)  A cartoon representation of a full fibril, viewed parallel to the fibril axis. A left-
handed twist is imposed. The figure shown is from ref. [160]. 
 
Recently a structural model of amyloid fibrils formed by Aβ(1-40) has been challenged by a 
set of measurements including ssNMR, STEM and electron paramagnetic resonance [20, 
24, 155, 156, 160]. It described more details how the β-sheets are arranged within the amyloid 
fibril protofilament. A molecular level structural model of Aβ(1-40) protofibril (defined as the 
fibril with minimum dimensions and minimum mass-per-length that can be observed 
experimentally) is shown in the Fig. 14. The residues 1-8 are structurally disordered, residues 
10-22 and 30-40 form β-strands, and residues 23-29 form a bend. The two β-strands form two 
separate in-register, parallel β-sheets, which can make contact with one another through side 
chain-side chain interactions and stabilized by a salt-bridge between Asp23 and Lys28. STEM 
C 
A  B
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of the Aβ(1-40) fibrils date have shown that the basic structural unit in these fibrils contains 
two layers of Aβ(1-40) molecules folded over one another in a cross-β motif, and each layer 
of molecules consists of two β-sheet layers. Thus, the protofilament in Aβ(1-40) fibrils is a 
four-layered- sheet structure with both “internal” and “external” quaternary contacts. The 
four-layered β-sheet structure is stabilized primarily by hydrophobic interactions in the core 
of the protofilament. Polar and charged side-chains are on the exterior, with the exception of 
oppositely charged K28 and D23 side-chains, which form salt bridges. This model has 
important mechanistic implications about the way Aβ molecules aggregate, even before they 
form fibrils. 
 
 
1.5.3 Oligomerization and fibrillogenesis of Aβ  
A growing number of in vitro and in vivo studies have shown that not only the mature fibrils 
themselves, but also to the soluble oligomers formed early in the process of fibrillogenesis are 
related to the pathogenic cascade of AD [18, 78, 163, 164]. The soluble oligomeric 
intermediates and protofibrils with high β-sheet content are cytotoxic and have been 
suggested to play an important role while mature fibrils might be not the most toxic species 
[13, 15, 17, 68, 165-169] (Fig. 15).  This raises the interest in studying the early steps of the 
aggregation process. In addition, knowing the mechanisms of Aβ oligomer formation is 
critical for understanding how Aβ acquires toxicity and for developing therapeutic agents. 
The fibrillogenesis of the more soluble peptide sequence, Aβ(1-40), has been most 
extensively studied. Many studies have shown that monomeric Aβ peptides first undergo 
oligomerization and then further aggregation into soluble oligomers, protofibrils and 
eventually into insoluble amyloid fibrils with high β-sheet content [2, 19, 170]. Aβ 
fibrillogenesis has been shown to follow kinetics that are consistent with a nucleation-
dependent protein polymerization mechanism. The kinetics of Aβ(1-40) fibril formation is 
typically preceded by a lag phase and large conformational changes [75, 76, 78]. A number of 
different intermediates are possibly involved in the assembly process from either an α-helical 
or a collapsed-coil Aβ monomer to Aβ fibrils with a high β-sheet content [74, 86, 142, 171, 
172]. Aβ protofibrils have been described to contain 45 to 50% of β-sheet structure and to 
give rise to mature amyloid fibrils [64, 65, 74, 79, 86, 173]. Studies aiming at the 
characterization of early stages of the aggregation process, based on the kinetic studies of in 
vitro Aβ aggregation have revealed a basically conserved fibrillization pathway, characterized 
by the intermediacy of ordered prefibrillar aggregates of distinct morphology [19, 64, 65, 79, 
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86, 174]. Previous structure studies in physiological buffers have shown that Aβ aggregation 
and precipitation was observed to occur following β-sheet formation [142, 146, 171]. The β-
sheet content increased dramatically with peptide concentration indicating that the β-sheet-
containing conformers are oligomeric. These results indicated that formation of β-sheet 
structure is directly related to peptide aggregation. The evidence for a conformational switch 
from an α-helical state to β-strand is observed in a NMR study of Aβ(1-28) [144]. Recently, 
an Aβ analogue which contained a lactam bridge between Asp23 and Lys28 was synthesized 
[175]. It was found that the presence of that bridge eliminated the lag period and accelerated 
fibril formation by ~1000-fold as compared to unmodified Aβ(1-40). This result highlights the 
importance of the bend in the Val24-Lys28 region and the associated salt-bridge Asp23-
Lys28 in Aβ(1-40) fibrillogenesis. Other studies of Aβ(1-40) in aqueous solutions showed 
that soluble Aβ(1-40) existed as a stable dimer at concentrations below a critical micelle 
concentration of approximately 25 µM [176, 177]. These results as well as other studies [71, 
178] suggested that dimerization may be an initial event in amyloid aggregation and such a 
dimer may be a fundamental building block for further fibril assembly [179]. Interestingly, 
Aβ is also present as stable soluble dimmers and trimers which are detected in both brain 
homogenates and cell culture media, the purified dimeric and trimeric components of Aβ(1-
40)/Aβ(1-42) from AD amyloid exhibit toxic effects in cultures of rat hippocampal neurons 
[180, 181]. The conformation of the Aβ(1-40) dimers is not precisely known, although 
various experimental studies indicate that soluble Aβ has a substantial β-sheet content 
suggesting that the dimer may adopt a β-sheet structure [146, 178, 179]. Aβ dimers, trimers, 
tetramers and larger oligomers were also observed by gel filtration, SDS gel electrophoresis 
and electron, atomic force microscopy and photoinduced cross-linking of unmodified proteins 
(PICUP) [71, 146, 182-184]. Some these soluble oligomers have the properties of peptide 
micelles because Aβ is an amphipathic, surface-active peptide, and oligomer formation is 
characterized by the formation of a hydrophobic core [71, 73, 185]. It was recently 
demonstrated that Aβ(1-40) and Aβ(1-42) have different behaviour at the earliest stage of 
assembly, monomer oligomerization. Solutions of Aβ(1-40) were found to display a rapid 
equilibrium among monomers, dimer, trimers, and tetramers, whereas Aβ(1-42) preferentially 
forms pentamer/hexamer units (paranuclei), which further assemble into beaded 
superstructures similar to early protofibrils [136, 184]. Together, recent in vitro studies have 
identified three main types of Aβ oligomers: 1) very short oligomers ranging from dimer to 
hexamer size [176, 181, 184, 186]; 2) a nonfibrillar intermediate of Aβ(1-42) termed Aβ-
derived diffusible ligands (ADDLs), which are small oligomers ranging from 17 to 42 kDa 
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(from tetramers to decamers) [38, 169]; and 3) protofibrills, short, flexible fibril intermediates 
of < 8 nm in diameter and < 150 nm in length which have  high β-sheet content and can be 
seen in EM and AFM [38, 64, 65, 79, 86, 173]. Protofibrils are transient structures observed 
during in vitro formation of mature amyloid fibrils and are the direct precursor of mature 
amyloid fibrils (Fig. 15). There are morphological similarities between ADDLs and spherical 
protofibrils [33, 79]. The structure of the rather newly discovered oligomeric species and what 
structural rearrangements occur on the pathway from the monomer folding to protofibril and 
fibril formation is not known in detail.  
 
Fig. 15. Fibrillization of Aβ(1-40) involves formatiom of discrete protofibrillar intermediates, including 
spherical protofibrils, which anneal to form chains and pore-like annular species (amyloid pores). The precise 
mechanism of amyloid pore formation is not known. All of the protofibrillar species seem to be consumed by 
fibril formation (see right panel) [7]. The figure shown is from ref. [7] 
 
Also, detailed relationships between these different oligomers are not clear yet. Finally, these 
structures anneal or undergo a conformational change to form mature cross-β fibrils (Fig. 15). 
The fibrillogenic pathway from Aβ monomers through early aggregates and on to protofibrils 
and fibrils is complex and a number of different intermediates are involved in the assembly 
process [19, 66, 187]. The combination of these studies led to a model for fibril formation and 
elongation in which a largely α-helical peptide undergoes a conformational transition to a β-
sheet structure, which then forms mature fibrils (Fig.16). Soluble oligomers are a common 
feature of amyloid assembly. Monomeric Aβ peptides first self-assemble through dimers, 
trimers, tetramers and other low moleculer weight (LMW) oligomers and then further 
aggregate into higher-order multimers (Fig.16 D-F). Or, largely unstructured peptide 
pores  
Atomic force microscopy images 
Electron microscopy images 
Aβ(1-40)  
Amyloid fibrills Protofibrills 
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monomers in solution cluster and form nuclei which then grow by the addition of monomers 
to form oligomeric aggregates (Fig.16 C-E). Monomers may also associate to form micelles,  
and these micelles may convert to fibril nuclei upon reaching a critical size [188]. Aβ 
oligomers may aggregate further by addition of Aβ monomers or by addition of oligomers 
perpendicular to the protofibril axis and build up protofibrils. Protofibril association and/or 
direct monomer addition and gives finally rise to mature fibrils. Other “off-pathway” self-
association to unstructured aggregates could also occur [138] (Fig.16 B). 
 
Fig. 16. Schematic representation of steps in Aβ fibrillogenesis [88, 135, 189]. An unstructured, monomeric peptide 
(A) or a peptide with an unstructured, flexible or highly dynamic loop must undergo conformational changes (C to 
E and/or  D to F) and self-associate into oligomeric intermediates (E and F) in order to evolve into a fibril (G). Self-
association is often depicted as preceding conformational changes (C to E), but the order of these events is 
generally not known (for D to F). Micelles (B) and other “off-pathway” species could also occur. In addition, the 
figure shows only two pathways toward fibril formation, but all steps could be multiple. The figure shown is 
modified from ref. [135]. The images of oligomers and fibrils shown in the figure are from ref. [22] and [160]. 
B 
Micelle-like Aβ 
or 
unstructured 
Aβ aggregate 
C 
D
A
Monomeric Aβ 
E 
F
F
F
F
F
Oligomer 
N = ?
Conformational 
changes 
oligomerization
F 
Amyloidogenic monomer 
D
Dimer 
F
Protofibril 
 
Oligomer 
Protofibril
Amyloid fibril 
                                                                                              Introduction 
 25
1.5.4 Inhibition of Aβ fibrillogenesis and cytotoxicity 
Aβ aggregation appears to be one early step in the pathogenic process of AD. All oligomeric 
Aβ assembly intermediates: oligomers, ADDLs, protofibrils and also mature Aβ fibrils are 
neurotoxic and may be the key effectors of neurotoxicity in AD [18, 78, 165, 168, 190]. 
Inhibiting Aβ assembly to toxic Aβ oligomers and/or redissociating existing fibrils can be 
thus an important strategy for AD therapy. Studies on the molecular mechanism of Aβ self-
assembly indicated that compounds with the ability to stabilize the native Aβ conformation, to 
destabilize the altered amyloidogenic conformer, and to prevent the required conformational 
transition could be effective inhibitors of Aβ aggregaton and amyloid fibril formation and 
thereafter promising drug candidates for AD treatment.  
A number of different compounds have been found to reduce Aβ aggregation and toxicity. 
One class of compunds for interference with self-assembly of Aβ is CR, that binds 
specifically to amyloid fibrils in an as yet unidentified manner. It has also been reported that 
CR inhibits Aβ fibril formation and toxicity [105, 106]. CR binds to proteins with β-sheet 
structure and may disrupt the pathway leading to protein misfolding and aggregation [191]. 
Studies on CR binding have also suggested that CR stabilized Aβ monomers before they 
formed oligomers and inhibits Aβ aggregation and toxicity [107]. Chrysamine G, a more 
lipophilic variant of CR, was also effective against Aβ [192]. More recently, a bifunctional 
molecule [SLF (synthetic ligand for FK506-binding protein)–CR] has been reported to be able 
to inhibit Aβ aggregation and toxicity by borrowing the surface and steric bulk of a cellular 
chaperone [193]. A great number of small molecules, typically with highly conjugated cyclic 
groups, have been successful to different degrees as inhibitory compounds. Rifampicin, 
benzofurans and anthracycline 4'-iodo-4'-deoxydoxorubicin (IDOX) reportedly interfered 
with Aβ aggregation also toxicity [115, 194, 195]. Some compounds from a large library of 
imidazopyridoindoles were found to be able to inhibit the random coil to β-sheet 
conformational transition of Aβ and to inhibit Aβ aggregation and prevent neurtoxicity [196]. 
1,2-(dimethoxymethano)fullerene was found to be able to bind specifically to the 16–20 
region of Aβ peptides with high affinity and to inhibit Aβ aggregation during the early stages 
[197]. Some metal-binding compounds were also developed to inhibit the in vitro generation 
of hydrogen peroxide by Aβ and were also found to be able to reverse the aggregation of Aβ 
both in vitro and in human brain post-mortem specimens [198]. An anti-amyloidogenic 
protein, gelsolin, which is found in plasma and central system fluids, has been shown to be 
able, by making complexes with Aβ, to inhibit fibril formation and even to break down 
already formed fibrils [199]. Antibodies raised against the N-terminus of Aβ prevented Aβ 
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fibril formation, and inhibited cytotoxicity in vitro [200]. Finally, an antibody raised against 
soluble oligomers of Aβ has been reported to block Aβ aggregation and toxicity [122].  
Base on knowledge of the molecular mechanism of Aβ self-assembly, an attractive strategy to 
develop amyloid aggregation inhibitors is to start with the wild-type peptide as a lead, as this 
peptide has the property to bind to itself. Abundant findings support that it is possible to target 
the peptide specifically by using for example a short peptide derived from an important self-
recognition segment of the full-length peptide. The detailed knowledge which has been 
accumulated about the molecular structures of amyloidogenic peptides both in solution and in 
fibrils guides the design of specific inhibitors that block aggregates or fibril formation. The 
design strategies developed to date included using short sequences related to the native 
sequence of the fibril forming protein and have taken advantage of the structural information 
available, that is, that these proteins polymerize through the association of β-strands to form a 
cross β-sheet structure. Several variations on this theme have been investigated with some 
success including blocking hydrogen bonding within a β-sheet by using short peptides 
containing N-methyl amino acids or ester bonds in alternate positions along the peptide 
backbone, by inserting prolines within a β-strand peptide sequence as β-breakers, by using 
peptides which had a bulky group, or a combination of these strategies (Fig. 17) [90, 201].  
A small effective inhibitor of Aβ polymerisation has been established through analysing many 
truncated variants of Aβ with a variety of different N-terminal modifications. This strategy 
was to find a peptide that could bind to Aβ and had a bulky group, such as a steroid [e.g. 
cholyl or poly(lys)], at its terminus to hinder further Aβ association [202]. One strategy is 
based upon substituting key residues of the self-recognition sequence for prolines to reduce 
the β-propensity of the peptide while retaining its hydrophobicity. The “β-sheet breaker” 
peptides (for example iAβ5 (LPFFD)), proline-containing short Aβ sequence based on the Aβ 
amyloid core region (17–21), bind to aggregated Aβ and are able to inhibit and disassemble 
amyloid fibrils in vitro, to prevent Aβ neurotoxicity in cell culture, to arrest deposition of 
amyloid lesions, and to induce dissolution of preformed plaques in a rat brain model of 
amyloidosis [96, 98, 99, 203]. Recently, the studies of a series of chemically modified 5-
residue β-sheet breaker peptides with improved pharmacological properties have shown that 
the pharmacological profile of “β-sheet breaker” peptides can be improved to produce 
compounds with drug-like properties that might offer a new promise in the treatment of AD 
[204, 205]. The detailed mechanism of these “β-sheet breaker” peptides interacting with Aβ 
and Aβ fibrils require further study. The strategy of N-methylation of peptide amide bonds 
has been a well-known protein-design approach to suppress the H-bonding ability of an NH 
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group and to restrict the conformation of the backbone [206-208]. N-methylated sequences of 
Aβ as inhibitors of Aβ amyloid formation by preventing further intermolecular hydrogen 
bonding have been reported. These peptides again are devised from a region that is a key 
recognition region of the amyloidogenic protein.  Mono-N-methylated Aβ(25–35) peptides 
are able to prevent Aβ fibrillogenesis and inhibit Aβ cytotoxicity in PC-12 cells [209]. N-
methylated peptides based on a region corresponding to residues 16–22 and 16–20 of the Aβ 
amyloid “core domain” region can prevent Aβ fibrils from forming and they also break down 
preformed fibrils [210, 211]. However, no effects on Aβ cytotoxicity have been reported. 
 
Fig. 17. Inhibition of amyloidosis by synthetic peptide derivatives [90, 201]. (A) Proline introduced as β-sheet 
breaker. (B) Terminal blocking group [e.g. cholyl or poly(lys)]. (C) N-methylated amides to block one edge of β-
strand. (D) Solid-state 13C NMR of the Aβ(1-40)-[NH3+-RGTFEGKF-CONH2] complex. Structure of the 
inhibitor bound to a monomer of Aβ(1-40). The two aromatic side chains of the inhibitor (Phe4 and Phe8) pack 
against Gly33 and Gly37 of the Aβ(1-40) peptide (The figure shown is from ref. [201] ). 
 
They have the added advantages of high proteolytic resistance, solubility, blood-brain barrier 
permeability and propensity to form β-structure at the N-methylated site. Recently, three N-
methylated Aβ analogues based on the NMR model of Aβ fibril, 2NMe(NTerm) with N-
methyl amino acids at positions Leu17 and Phe19, 2NMe-(CTerm) with N-methyl amino 
acids at Gly37 and Val39, and 4NMe with N-methyl amino acids at all four positions, Leu17, 
Phe19, Gly37, Val39, were synthesized [212]. Studies on their fibrillogenesis suggested that 
disruption of the N-terminal β-sheet has a more profound effect on fibrillogenesis than 
disruption of the C-terminal β-sheet, suggesting that the N-terminal β-sheet domain is the 
more critical domain for fibrillogenesis; that disruption of both β-sheet domains renders the 
peptide monomeric and unable to form fibrils. These results indicated that the most effective 
inhibition of Aβ(1-40) fibrillogenesis may require that inhibitors of fibril formation target 
both β-sheet regions rather than only one [212]. Aβ fibrils have a cross β-sheet structure, in 
which Met35 packs against Gly33 in the C-terminus of Aβ(1-40) and against Gly37 in the C-
terminus of Aβ(1-42). These packing interactions suggest that the protofilament subunits are 
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displaced relative to one another in the Aβ(1-40) and Aβ(1-42) fibril structures. A new class 
of peptide inhibitors based on a GxFxGxF framework that prevent fibril formation by placing 
alternating glycine and aromatic residues on one face of a β-strand were designed [201]. They 
disrupt sheet-to-sheet packing, inhibit the formation of mature Aβ fibrils, and significantly 
reduce their toxicity (Fig. 17). 
 
 
1.6 Type II diabetes and islet amyloid polypeptide 
T2D is a progressive pancreatic β cell-degenerative disease that affects more than 170 million 
people worldwide, and the number of people with diabetes is steadily increasing [213-215]. 
Pathological features of this disease, which is the most common form of diabetes, include an 
increasing peripheral insulin resistance and the progressive decline of β-cell function. A 
characteristic pathophysiological feature of T2D is the formation of amyloid deposits in the 
islets of Langerhans [213, 216-219] (Fig. 18). Pancreatic amyloid deposits are found in the 
pancreata of more than 95% of the T2D patients [217, 218, 220]. Pancreatic amyloid 
colocalizes with areas of cellular degeneration and amyloid formation has been strongly 
associated with β-cell dysfunction and the progress of disease [217-219, 221-223]. A direct 
causal relationship, however, between amyloid formation and disease has not been shown and 
the pathogenic role of amyloid in T2D still remains unclear [213, 221, 223, 224].  
 
Fig. 18. Pancreatic islet structure in non-diabetic and T2D subjects [213]. (a) Islet of a non-diabetic subject 
immunolabelled for insulin (brown); insulin-containing β-cells occupy more than 80% of the islet space. (b) Islet 
of a diabetic subject labelled for insulin (brown) and stained with congo red for amyloid (pink); more than 50% 
of the islet space is filled with congo red stained, amorphous amyloid deposit (asterisk). The remaining L-cells 
are localised at the edges of the deposits. The figure shown is from ref.[213].  
 
The major component of pancreatic amyloid fibrils, the 37 amino acid residue β-cell derived 
polypeptide called IAPP or amylin has been identified and characterised in the years 1986 and 
1987 [218, 220, 225]. IAPP acts, in its soluble form, together with insulin as a regulator of 
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glucose homeostasis [4, 226]. IAPP is mainly expressed in the islets of Langerhans in the 
pancreas and is believed to be genetically, structurally and functionally related to both 
calcitonin (Ct) and calcitonin gene-related peptide (CGRP) [227, 228]. IAPP is expressed as 
an 89-residue containing pre-propeptide and is stored in the form of the 67-residue propeptide 
ProIAPP in secretory vesicles of the β-cells together with insulin and proinsulin [229-231]. 
IAPP is secreted together with insulin following proteolytic processing of the pro-region in 
response to insulin secretagogues [227, 229, 230, 232, 233]. The IAPP primary sequence 
(Scheme 1) features a disulfide bridge between Cys2 and Cys7 and a C-terminal amide [218, 
220, 225, 228]. More than 80% of the IAPP sequence is broadly conserved in mammals 
(Scheme 1) suggesting a significant biological function for this polypeptide [234]. 
 
 
1.6.1 Molecular model of IAPP 
Although more than 80% of the IAPP sequence is conserved in mammals (Scheme 1), only a 
few species such as humans, primates, cats, dogs, monkeys, and racoons develop islet 
amyloid while rodents do not develop IAPP-derived islet amyloid. There is a clear species- 
and sequence-specificity of the amyloidogenic potential of the IAPP sequence [228, 235-238]. 
The sequence of rat IAPP (rIAPP) differs from that of IAPP in 6 out of 37 amino acids and 5 
of these 6 amino acids are located in the region between residues 20 and 29 (Scheme 1). Two 
to three of the five different amino acids in the rodent sequences are proline residues (Scheme 
1), proline being a known β-sheet-breaking residue [239]. In vitro studies have shown that 
synthetic IAPP and the decapeptide sequence IAPP(20-29) easily form amyloid fibrils, 
whereas synthetic rIAPP and the corresponding rIAPP(20-29) sequences are not able to 
form amyloid fibrils [228, 235, 238, 240]. However, more recent studies have identified 
another two regions, IAPP(30-37) and IAPP(8-20), that are able to form fibrils [36, 241]. 
These observations indicated that the IAPP sequence can be dissected into three distinct 
amyloidogenic regions: IAPP(8-20), IAPP(20-29), and IAPP(30-37). At the C-terminus of the 
molecule, the sequences of rIAPP 30-37 and IAPP 30-37 are exactly the same. The region (8-
20) of rIAPP contains a single amino acid substitution, His18Arg, which has been shown to 
have no effect on formation of fibrils from rIAPP(8-20). Thus, in the rIAPP peptide, only two 
of these three regions, i.e. regions (8-20) and (30-37), are amyloidogenic while rIAPP is 
unable to aggregate into amyloid fibrils. These observation suggest that the sequence 
IAPP(20-29) in IAPP peptide is responsible for the amyloidogenic propensities of full length 
IAPP [228, 235, 236, 238, 240, 242].  
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SCHEME 1: Comparison between the primary structures of the various IAPP sequences from humans (blue in 20-
29), rats, hamsters, cats, dogs, and monkeys. IAPP contains a free N-terminal amino group, a C-terminal amide, and 
a disulfide bridge between Cys2 and Cys7. Amino acid residues in red in the sequences of the various species except 
for human IAPP indicate those residues that differ from the correponding residues of human IAPP [234]. 
 
IAPP(20-29) has been broadly applied as a IAPP model sequence to identify the molecular 
determinants of IAPP amyloidogenicity at the level of primary and secondary structure [235, 
236, 238, 240, 242-245]. The amyloidogenic properties of a series of hybrids of IAPP(20-29) 
sequences containing one or two positions exchanged for certain rodent residues and 
hybrids of rat and hamster IAPP(20-29) sequences containing two human (or cat) residues 
have been studied. It has been shown that a P28-for-S28 substitution in IAPP(20-29), as it 
occurs in rIAPP, results in a pronounced reduction of amyloidogenicity of IAPP(20-29). In 
addition, other studies have shown that the sequence between residues A25 and S29 of 
IAPP plays a very important role in amyloidogenicity [235]. The kinetics and 
thermodynamics of amyloid formation of [F23L]-IAPP(20-29) and [S29P]- IAPP(20-29) as 
compared to the corresponding native human and cat sequences has been studied. These 
studies demonstrated that each of the two substitutions significantly affected the rate and the 
stability of amyloid fibril formation by IAPP(20-29). The rate of amyloid formation and 
stability of the cat IAPP(20-29) is strongly reduced as compared to that of the human 
sequence and the above mentioned “mutants”. There is a “coupling” effect of the two 
substitutions on amyloidogenicity of IAPP(20-29). These results suggested that residues 
F23 and S29 play a very important role in the kinetics and thermodynamics of IAPP(20-29) 
amyloid formation and stability [240]. Replacing F23 by alanine completely inhibited 
aggregation of the IAPP(22-29) into amyloid fibrils have also suggested a crucial role of 
                                      1                        10                          20                     29                    37 
    Human       NH2-KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-CONH2      
                                   1                      10                       20                    29                  37 
    Rat             NH2-KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY-CONH2  
                                  1                      10                        20                    29                  37 
   Hamster      NH2-KCNTATCATQRLANFLVHSNNNLGPVLSPTNVGSNTY-CONH2   
                           1                      10                       20                   29                  37 
Cat            NH2-KCNTATCATQRLANFLIRSSNNLGAILSPTNVGSNTY-CONH2     
                               1                     10                       20                   29                  37 
 Dog            NH2-KCNTATCATQRLANFLVRTSNNLGAILSPTNVGSNTY-CONH2      
                                   1                     10                        20                  29                  37 
    Monkey      NH2-KCNTATCATQRLANFLVRSSNNFGTILSSTNVGSDTY-CONH2     
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F23 in amyloid formation of IAPP(22-29) [240, 243]. The importance of each residue of 
IAPP(20-29) for its β-sheet and amyloidogenic potential has been systematically studied by 
performing “sequential” proline substitutions. While all ten substitutions affected 
amyloidogenicity of IAPP(20-29), the most active effects were caused by proline 
substitutions at positions  N22, I26, L27 and S28. It has been shown by FTIR spectroscopy 
these latter analogues exhibited no or very low β-sheet-forming potential in contrast to 
IAPP(20-29) and were not able to form amyloid fibrils. The substitutions at G24 and F23 
also affected the β-sheet-forming propensity of IAPP(20-29) but did not completely inhibit 
its amyloid-forming potential. Finally, the substitution of residues S20, N21, A25, and S29 
by proline did mainly affect (slow down) the kinetics of amyloid formation [243]. The 
substitutions at I26 and L27 by alanine in IAPP(22-29), which is also amyloidogenic by 
itself, results in a reduction of amyloidogenicity. However, the amyloid-forming ability of 
IAPP(22-29) was not completely inhibited [246]. It has been thus suggested that the H-
bonding ability of I26 and L27 and/or the backbone flexibility in region 25-28 defines the 
amyloid-forming potential of IAPP(20-29), while the side chains of these hydrophobic 
residues may mainly affect amyloid fibril stability [234]. Hydrophobic interactions between 
side chains are well known to stabilize β-sheet structures and have been suggested to play an 
important role in aggregation and amyloid fibril formation processes [53, 56, 242, 247, 248].  
Based on the results of biophysical [27, 44, 45, 249, 250] and molecular modelling [213, 251] 
studies, a serpentine molecular model for full-length IAPP fibrils has been proposed [23]. The 
arrangement of the model is shown in Fig. 19. IAPP has a disulfide bond between cysteine 
residues 2 and 7, implying a loop conformation that would be incompatible with extending the 
serpentine on this side. The first eight residues appear thus to be rather not important for 
fibrillogenesis [23, 252]. The three β-strands are assigned to positions 12–17, 22–27 and 31–
37, matching the regions 8–20, 20–29 and 30–37 previously proposed as potential strand 
formers. This arrangement also places the C-terminal Tyr37 in proximity to Phe15 and Phe23, 
consistent with near-uv CD and fluorescence energy transfer studies and suggests that long-
range interactions are critical for IAPP fibril formation and stability [85, 250, 253]. This 
model also explains why rIAPP(20-29) is non-amyloidogenic. In the model, position 25 is 
located in the middle of the central strand, and the β-sheet-breaking residue proline at this site 
would be expected to inhibit protofilament formation. Residue 28 is also predicted to be 
involved in inter-strand H-bonding, and proline at this site may also prevent formation of the 
β-structural H-bonds and decrease fibrillogenesis. This molecullar model of IAPP fibrils and the 
studies on the amyloidogenicity of partial IAPP sequences suggest that a potential role of 
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IAPP(20-29) in the process of amyloid fibril formation might include “directing” the two 
other amyloidogenic parts of IAPP into appropriate positions that allow for inter- or 
intramolecular interactions underlying fibril formation [234]. This might occur for example 
via the participation of IAPP(20-29) in a β-sheet structure while rIAPP(20-29) is unable to act 
in such a manner. Alternatively, the sequences of IAPP(8-20) and/or IAPP(30-37) might 
direct IAPP(20-29) into an appropriate position for β-sheet formation and amyloidogenesis 
which would then also occur only with IAPP. This process would not occur in the case of 
rIAPP because the two regions (8-20) and (30-37) are separated by the proline rich rIAPP(20-
29).  
 
Fig. 19. (a) Diagram of the proposed β-serpentine fold for IAPP [23]. The model has three β-strands. Charged residues 
are circled. The first 11 residues, which contain a disulfide-bonded loop that would be incompatible with extending the 
serpentine on this side, are shown by a thin line. Accordingly, the first 11 residues are not considered to be part of the 
serpentine core. (b) Ball-and-stick representation of the β-serpentine model. The dotted contour around the peptide 
shows close packing in the fibril structure. The backbones of the β-strands and the loops are in purple and blue, 
respectively. Carbon, oxygen, nitrogen and sulfur atoms are in green, red, blue and yellow, respectively. The figure 
shown is from ref. [23].  
 
 
1.6.2 Structural model of IAPP amyloid fibril  
The macromolecular structure of synthetic IAPP-derived amyloid has been studied by detailed 
EM and AFM studies [27, 44, 45, 252]. TEM showed the IAPP fibrils are straight, long and 
with a diameter of approximately 10 nm (Fig. 20). The protofibril found by EM and AFM 
examination of preformed IAPP fibrils had an apparent width of 5 nm. This species exhibited a 
strong tendency to spontaneously self-assemble into higher order fibrils. EM studies have 
shown that the 5 nm protofibrils laterally associate into broad ribbon-like or sheet-like fibrils, 
while another fibrillar population consisted of helical or coiled fibrils of variable widths (Fig. 20). 
Major fibrillar populations included one population with a width of 8 nm, that formed by the 
twisting of two protofibrils, and another one having a width of 13-18 nm, that most likely 
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consisted of 3 to 4 twisted protofibrils, and each one of these assemblies exhibited a distinct 
axial periodicity of 25 and 50 nm, respectively [44]. 
 
Fig. 20. Negative stain transmission electron microscopy [27] (A) shows the presence of very long straight 
fibrils of IAPP. Platinum carbon rotary shadowing (B) shows the IAPP fibrils with higher degree of contrast and 
reveals that some fibrils have a regular twist, suggesting the presence of more than one protofilament. Narrow 
protofilaments associated in a sheet like arrangement. The figure shown is from ref. [27].  
 
IAPP amyloid fibrils bind to CR and exhibit green birefringence characteristic of amyloid 
[254]. A shift in fluorescence after staining with Thioflavine T (ThT) is also observed [255, 
256]. Both FTIR and CD spectrum of a synthetic IAPP amyloid-containing solution indicated 
the presence of significant amounts of β-sheet structure [234]. Data from X-ray diffraction, 
electron diffraction and cryo-electron microscopy from IAPP amyloid fibrils has shown that 
IAPP amyloid fibrils conform to the cross-β arrangement of the core structure in which the β-
strands run perpendicular to the fibre axis. The pattern has the cross-β diffraction fingerprint 
with 4.7 Å meridional and an equatorial signal at 9.5 Å corresponding to the hydrogen 
bonding spacing between the β-strands and the intersheet spacings, respectively [27]. Electron 
paramagnetic resonance spectroscopy of spin-labeled derivatives of IAPP indicates a parallel 
arrangement of β-strands within in the fibril [249]. Important information with regard to the 
structural model of the IAPP fibril has been obtained by the mass-per-length analysis of IAPP 
fibrils. These studies have shown that 1 nm of protofibril length contains about 2.6 molecules 
of IAPP [44]. Based on these bio-physical studies and the molecular model, modelling studies 
have suggested that IAPP amyloid fibrils can be modelled as ‘parallel superpleated beta’ 
structures, in which the peptide folds into “serpentines” linking β-strands between adjacent β-
sheets. These units then stack to form several β-sheets that gradually twist around one another 
in a left-handed direction. Stereo views of the protofilament model of IAPP and a fibril model 
formed by three protofilaments are shown in Fig. 21 [23].  
A B 
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Fig. 21 (A) Stereo view of the protofilament model of IAPP [23]. The N terminals contain disulfide-bonded loops 
and are shown as thin tubes protruding from the core of the protofilament. These loops do not observe the same 
regular axial stacking as the serpentines in the core. The three β-strands of the serpentine are marked by arrows with 
different colors (blue, yellow and purple). Ladders formed by H-bonding of Asn22, -31 and -35, Ser19 and Tyr37 
are shown by red broken lines. (B) Electron micrograph of a IAPP fibril prepared by unidirectional shadowing 
reveals that the coiling is left-handed as well as the crossover spacing of 37 nm alongside a fibril model formed by 
three protofilaments having the superpleated β-structure. The individual protofilaments are coded in different colors. 
The figure shown is from ref. [23]. 
 
 
1.6.3 Molecular mechanism of IAPP amyloid formation in vitro 
The conversion of a monomeric and soluble polypeptide into insoluble amyloid fibrils is a 
multi-step process which has not yet been clarified in detail. Various structural and assembly 
states of the polypeptide sequence are involved. The kinetics of the conversion of soluble 
IAPP into insoluble amyloid have been studied using a filtration assay [85, 257]. These 
studies showed that IAPP insolubilization is a time- and concentration-dependent process and 
exhibits a lag-time that can be completely eliminated by seeding. Thus, the kinetics of 
formation of insoluble IAPP amyloid were consistent with a nucleation-dependent protein 
polymerization mechanism [78, 258]. Nucleation dependence of the conversion of monomeric 
IAPP into insoluble and or multimeric amyloid aggregates has been further confirmed by 
studies using a ThT binding assay and electrospray ionization mass spectrometry, respectively, 
to follow the aggregation kinetics of IAPP [252, 259]. Studies of characterization of the 
conformational events underlying the transition of soluble IAPP into insoluble amyloid in 
vitro have shown that IAPP belongs to the most amyloidogenic peptides known to date, as it 
almost spontaneously aggregates into amyloid fibrils under very low concentration and a 
number of different experimental conditions [44, 45, 85, 251, 252, 257, 259]. The CD studies 
showed that a conformational transition of soluble IAPP, which appears to be predominantly 
A B
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in a random coil conformeric state, into soluble β-sheets precedes insoluble amyloid fibril 
formation [36, 85, 252]. This transition was found to exhibit a lag-time and could be 
completely eliminated by seeding with traces of preformed amyloid fibrils. During the lag-
phase no changes in overall conformation of human IAPP were observed. However, 
immediately following seeding, a fast increase of β-sheet contents ensued and a massive IAPP 
insolubilization into amyloid fibrils occurred. Similarly to Aβ, at the time point before IAPP 
insolubilization the β-sheet contents are 40-50% corresponding to a two to three fold higher 
increase as compared to the β-sheet contents during the lag time [85]. IAPP amyloid 
formation was also studied using 1-anilino-8-napthalenesulfonic acid (ANS) binding. A 
strong and time-dependent increase of ANS-binding was found to occur parallel to the 
increase in β-sheet contents indicating an increase in exposure of hydrophobic surface [85]. 
The results of the CD, ANS-binding and ThT binding studies have suggested that the pathway 
of IAPP insoluble amyloid formation includes a nucleation-dependent conformational 
transition of mainly random coil polypeptide into soluble β-sheet state(s) with strongly 
solvent-exposed hydrophobic patches. Formation of the partially folded amyloidogenic state 
was thermodynamically reversible at very low IAPP concentrations, suggesting that it might 
correspond to a self-associated state of a partly folded amyloidogenic population that is in 
eqiuilibrium with native human IAPP. Based on these findings, the molecular steps of IAPP 
that underly the transition of random coil into soluble β-sheets and amyloid via partially 
folded states have been proposed (Fig. 22) [85]. Accordingly, monomeric soluble IAPP exists 
in a predominantly random coil conformation in solution. A partly folded state and its self-
associated forms (Fig. 22, (2) and (4) respectively) are in a concentration-dependent equilibrium 
with native non-amyloidogenic IAPP ((1) in Fig. 22) and correspond to early and soluble 
precursors of β-sheets (a mixture of α-helix and β-sheet structure). These states are suggested 
to further associate into β-sheet-rich protofibrillar (5) and fibrillar assemblies or these 
oligomeric structures act as nuclei for fibril elongation. The identification of a partly folded 
IAPP states as an early amyloidogenic intermediate state in the pathway of IAPP amyloid 
formation is consistent with several other recent reports about a crucial role of partly folded 
states of other amyloid-forming polypeptides and proteins as intermediates of amyloid 
formation [53, 54, 56, 77, 163].  
The protofibril of IAPP has been proposed to be a “building block” of the thicker higher order 
mature fibrils of variable widths. Two possible amyloidogenesis pathways have been 
proposed: the fibrils assemble by lateral association of long preformed protofibrils, or they 
form by longitudinal growth of full width structures.  
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Fig. 22. A model of possible molecular events in IAPP amyloid formation pathway via partially folded state(s) 
[234].  At equilibrium or during folding (from unfolded (U) (3) to folded (N) (1)) or unfolding, a partially 
folded conformeric state (I) (2) forms. (I) is not stable as a monomer but is stabilized by self-association into 
an oligomeric state (x-mer) (4). (I) and its self-associated forms are early, soluble, α-helix and β-sheet-
containing precursors of amyloid fibrils and will further associate in an enviroment and concentration 
dependent manner into β-sheet-rich protofibrillar (5) and fibrillar assemblies (6). Questionmarks (?) indicate 
that the intermediate steps and IAPP conformeric and assembly species participating in the conversion of the 
x-mer (4) to insoluble fibrillar aggregates have not yet been characterised. Also, the exact structure, the 
assembly state and the biophysical properties of the partly folded species (2) and (4) have not yet been 
completely characterized. The figure shown is modified from ref. [234]. 
 
Time-lapse AFM studies have been used to directly and contineously follow the amyloid 
formation process on the mica substrate and have shown that a 2.4 nm protofibrillar species 
and a variety of thicker fibrils formed under the conditions used [45]. These studies also 
showed that the growth of IAPP protofibril is bidirectional. Recently, two distinct phases of 
fibril formation were observed in the experiment with synthetic IAPP using time-lapse AFM 
studies: oligomer growth followed by fibril elongation [260]. IAPP oligomers predominantly 
increased in height with increasing incubation periods. The smallest oligomers visualized 
have a height of 2.3 ± 1.9 nm and a length 23 ± 14 nm, and consist of an estimated 16 
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molecules. The fibrils started elongating only after oligomers had grown to a height of ~6 nm. 
Based on these data and the data of previous studies [85, 252], a model for the assembly of 
IAPP fibrils was proposed [260] (Fig. 23). Oligomers of IAPP tend to grow to form full-width 
nuclei, giving rise to thicker fibrils as the primary product of IAPP assembly. The oligomers 
first grow to reaching slightly variable heights prior before they begin to significantly 
elongate into fibrils. The oligomeric species which act as nuclei for fibril elongation appear to 
have a critical size of about 6 nm in height, they may also grow larger concomitantly with 
elongation, leading to fibrils 8–10 nm high and giving rise to the previously observed fibril 
polymorphisms. This model can also explain the different fibril polymorphisms of IAPP that 
had been described previously. For example, an oligomer that grows to 6.9 nm in height 
before it elongates could give rise to the prominent 25-nm-repeat left-handed coiled fibril, 
thought previously to assemble by coiling two protofibrils around each other. Oligomers that 
grow larger in height than this could give rise to mature fibrils consisting of three or more 
protofibrils. 
 
Fig. 23. The assembly pathway of IAPP fibrils via oligomeric intermediates [260]. Monomeric IAPP, which 
initially has a random coil structure in solution, self-associates to form oligomers (Fig. 22). The oligomers 
initially grow in height, presumably by self-association, before elongating further into mature fibrils. The 
resulting fibrils can be composed of two or more protofibrils, depending on to what extent the nuclei initially 
grew in height. Protofibrils are seldom observed in solution but can be stabilized when growth is constrained to a 
mica surface (dashed line). In solution, mature fibrils often have distinctive fibril polymorphisms, whereas on a 
mica surface, mature fibrils without any coiling are observed, as indicated within the image. The figure shown is 
from ref. [260]. 
 Oligomer 
(4) and/or (5) 
in Fig.22? 
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1.6.4 Cytotoxicity of IAPP aggregates 
The role of IAPP in T2D pathology is yet not clarified. The causal relationship between islet 
amyloid and disease progress still remains to be understood [213, 221, 224]. A number of in 
vitro studies showed that IAPP aggregates are strongly cytotoxic in a dose-dependent manner 
to various different cells including pancreatic β-cells [87, 257, 261-267]. The potential 
cytotoxic species consist of insoluble or “mature” amyloid fibrils of IAPP, soluble oligo- and 
multimeric fibrillar aggregates, the soluble, “proto- or prefibrillar”, oligomeric assembly and 
conformeric states that may correspond to intermediates of the amyloid formation pathway. 
Identification of these latter species and understanding their role in cellular toxicity of IAPP is 
a very difficult task due to their short life span, the concentration and enviromental 
dependence of their formation rates and stabilities, and the extremely low peptide 
concentrations necessary to elicit cell damage. A number of studies on IAPP-mediated 
cytotoxicity on human and rat β-cells have demonstrated that IAPP-derived insoluble amyloid 
fibrils and soluble oligomers are cytotoxic [106, 262]. Of note, synthetic rIAPP that is not 
able to aggregate into amyloid is not cytotoxic which also supports the notion that the 
aggregated state of IAPP, is the mediator of cytotoxicity. Increasing amounts of evidence 
suggest that cytotoxic IAPP species rather consist of soluble pre- or protofibrillar oligomers 
that may form early in the aggregation pathway of IAPP into amyloid but not of mature, 
multimeric, and/or insoluble fibrils [85, 87, 244, 268, 269]. Soluble oligo- or multimeric 
aggregates have been proposed to be early fibrillar or non-fibrillar intermediate-sized particles 
that initially consist of 25-50 monomers that grow up to 2000-6000 monomers [87]. The 
cytotoxic species of IAPP have been suggested to permeabilize cell membranes via a channel- 
or pore-like mechanism, or simply by causing small membrane defects [87, 106, 260, 270, 271]. 
 
  
1.6.5 Inhibition of IAPP amyloid formation and cytotoxicity 
Serveral inhibitors of IAPP amyloidogenicity and related cytotoxicity have been developed 
and tested in vitro. Such inhibitors include aromatic organic compounds such as the amyloid-
specific dye CR, tetracycline, rifampicin and rifampicin analogues, and others that bind to 
amyloid fibrils and/or suppress amyloid fibril formation [106, 267, 272-274]. CR has been 
reported to completely inhibit cytotoxicity of IAPP in β-cells but the presence of CR did not 
inhibit the conversion of soluble IAPP into insoluble amyloid fibrils [106]. However, recent 
studies suggested that CR stabilizes the oligomers of IAPP, blocking both their lateral and 
longitudinal growth into mature fibrils [260]. This observation that CR stabilizes IAPP at the 
                                                                                              Introduction 
 39
oligomer level is particularly interesting in light of the current view that distinct amyloid 
oligomers rather than the polymorphic fibrils are the toxic agent. Rifampicin has been shown 
to prevent fibril formation of IAPP but not formation of toxic oligomers [267, 272, 275]. 
Other inhibitors which consist of short synthetic peptides have been derived from sequences 
of IAPP that contain IAPP self-recognition domains. These inhibitors are short partial IAPP 
sequences in a non-modified form, i.e. IAPP(20-25) and IAPP(24-29) [276], while, very 
recently short IAPP self-recognition sequences carrying α-aminoisobutyric acid (Aib) have 
been also reported to inhibit amyloid formation of IAPP [277]. However, although some of 
the above peptides have been shown to be able to inhibit IAPP amyloidogenesis, up to date 
only one of them, IAPP(20-25), has been reported to be capable of reducing both amyloid 
formation and cytotoxicity of IAPP. Therefore, rationally designed compounds that may be 
able to interfere with the amyloid fibril formation pathway of IAPP and affect both fibril 
formation and related cytotoxicity are important tools for developing novel molecular 
strategies for the treatment of T2D. Toward this and, selectively N-methylated short IAPP 
amyloid core containing peptide sequences have been developed [245]. The double N-
methylated IAPP amyloid core peptide [(N-Me)G24, (N-Me)I26]-IAPP(22-27) (IAPP(22-27)-
GI or NFGAIL-GI) has been found to inhibit both amyloidogenicity and cytotoxicity of IAPP 
[255]. These results showed that the cytotoxic effect of IAPP is associated with its amyloid-
forming ability and that inhibiting its amyloid-forming propensity will inhibit cytotoxicity.  
 
 
1.7 Aim of the study 
Folding, misfolding, and the aggregation and fibrillogenesis propensities of proteins or 
polypeptides appear to be intrinsic properties of the amino acid sequence [69]. An increasing 
body of evidence suggests that aggregates that form during in vivo protein self-assembly and 
amyloidogenesis are cytotoxic. This offers a link between protein/polypeptide aggregation, 
cell degeneration, and the pathogenesis of a number of diseases which are called protein 
aggregation disease [9, 69]. Several lines of evidence suggest that common mechanisms may 
underlie self-assembly, cell degeneration, and pathogenesis of different protein aggregation 
diseases. Two prominent representatives of these diseases are AD and T2D [4, 9, 69].  
The major component of AD brain amyloid is Aβ, an ubiquitary expressed 40- to 42-residue 
polypeptide of yet unknown physiological function [131]. The pancreatic amyloid plaques in 
T2D consist mainly of IAPP, a 37-residue polypeptide which is secreted by the pancreas and 
acts as a neuroendokrine regulator of glucose homeostasis [4, 226]. Thus, in both AD and 
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T2D, two medium-sized linear polypeptides are the key amyloidogenic molecules. Amyloid 
fibril formation by both Aβ and IAPP follows nucleation dependent kinetics and occurs via 
misfolding and self-association of a natively non-toxic ensemble of conformations into toxic 
oligomeric structures and fibrillar aggregates [4, 9, 85, 234, 278]. Although the molecular 
mechanism of misfolding and the structures of the cytotoxic species have not yet been 
elucidated, increasing evidence suggests that early prefibrillar oligomers might be major 
mediators of cell toxicity by both Aβ and IAPP [4, 9] 
Devising molecular strategies to inhibit IAPP self-assembly, amyloid formation, and related 
cytotoxicity is an important task of biomedical research to both understanding the molecular 
basis of T2D and developing novel drugs for the treatment of this disease. Soluble IAPP 
analogues that combine bioactivity with the ability to inhibit cytotoxic self-assembly of native 
IAPP are therefore of high biomedical interest. Such “bifunctional” analogues would be 
promising candidates for therapeutic application in diabetes and tools for understanding the 
molecular basis of IAPP self-recognition and its relationship to cytotoxic self-assembly. 
Using a minimalistic conformational restriction strategy, three double N-methylated IAPP 
analogues have been recently designed and synthesized [279]. The approach has been based 
on the hypothesis that the sequence IAPP(22-27) or NFGAIL is a crucial amyloid core and 
self-recognition sequence of IAPP and consisted of the introduction of two N-methyl residues 
into selected amide bonds within the NFGAIL region of the full length IAPP molecule. 
Interstrand amide H-bond formation, a process necessary for β-sheet-mediated self- or hetero-
association events, was thus only possible via one side of the NFGAIL β-strand in the 
designed IAPP analogues [(N-Me)G24, (N-Me)I26]-IAPP (IAPP-GI), [(N-Me)A25, (N-
Me)L27]-IAPP (IAPP-LA), and [(N-Me)F23, (N-Me)A25]-IAPP (IAPP-AF) (Scheme 2). To 
study the role of H-bond versus hydrophobic interactions in self-association of IAPP, a fourth 
analogue, [(N-Me)I26, (N-Me)L27]-IAPP (IAPP-LI) has been designed and synthesized 
(Scheme 2).  
The initial aims of the here presented studies were: 
1) to examine the solubility, amyloidogenic propensity, the β-sheet-forming potential, the 
cytotoxic properties, and the biological activity of the N-methylated IAPP analogues as 
compared to natively occuring IAPP and 
2) to investigate the interaction of these analogues with IAPP and their effect on IAPP self-
assembly and cytotoxicity. 
In the course of these studies however, a paper appeared which reported that Aβ(1-40) fibrils 
can seed in vitro fibrillization of IAPP [278]. This intriguing finding indicated that Aβ(1-40) 
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and IAPP might populate conformations or assembly states that might be able to cross-interact. 
In addition, clinical studies have suggested that persons suffering from T2D might be at the 
risk of AD and vice versa, but a molecular link between the diseases has not been known [280, 
281]. Interestingly, the Aβ(1-40) and IAPP sequences exhibit a 25% identity and a 50% 
similarity  [278] (Scheme 3).  
 
Scheme 2.  The primary structure of IAPP and the designed N-methylated IAPP analogues studied in this work. 
The residues of the IAPP amyloid core region IAPP(22-27) or NFGAIL are shown in pink. The N-methylated 
residues in the analogues are shown in blue. The one-letter code is used for the amino acids.  
 
Based on the above observations and the results of the studies on the initial aim of the thesis, 
in the second part of the work, the interaction of IAPP analogues with Aβ(1-40) and their 
effects on Aβ(1-40) amyloid-fibril formation and cytotoxicity were studied. Parallel to this, 
the interaction of IAPP with Aβ(1-40) and its interference with the cytotoxic self-assembly 
pathways of both polypeptides were also investigated in detail. 
Thus, the aims of the second part of this thesis were: 
1) to address the question whether specific IAPP and Aβ(1-40) conformeric states might be 
able to interact with each other by using the synthesized conformationally constrained IAPP 
analogues IAPP-GI, IAPP-LA, IAPP-AF, and IAPP-LI as molecular tools and  
2) to examine whether the above synthetic analogues might be effective inhibitors of Aβ(1-40) 
self-assembly and cytotoxicity. 
 
Scheme 3. Primary structures of IAPP and Aβ(1-40). Identical residues between sequences are indicated in red, 
and similar residues are indicated in blue [278]. 
                              1                          10                            20              29                       37 
IAPP               KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 
                            1                         10                           20                      29                    37 
        IAPP          KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 
                             1                         10                           20                  23                 25       29                    37 
   IAPP-FA      KCNTATCATQRLANFLVHSSNN(N-Me)FG(N-Me)AILSSTNVGSNTY 
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   IAPP-LI       KCNTATCATQRLANFLVHSSNNFGA(N-Me)I(N-Me)LSSTNVGSNTY 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Protein and other chemicals 
Protein/Peptide Company (city or country) 
calcitonin gene-related peptide (CGRP) Bachem (Switzerland) 
Nα-[digoxigenin-Aca0]IAPP (Dig-IAPP-GI) product of SPPS synthesis in Prof. 
Kapurniotu´s group 
Nα-[biotinyl-Aca0]IAPP (Biotin-IAPP)  product of SPPS synthesis in Prof. 
Kapurniotu´s group 
Nα-[biotinyl-Aca0]IAPP-GI (Biotin-IAPP-GI) product of SPPS synthesis in Prof. 
Kapurniotu´s group 
gel filtration standard for calibration Bio-Rad (USA) 
synthetic human IAPP Calbiochem-Novabiochem (Bad Soden) 
IAPP peptidyl-resin Peptide Specialty Laboratories (Heidelberg) 
IAPP-GI product of SPPS synthesis in Prof. 
Kapurniotu´s group 
IAPP-LA product of SPPS synthesis in Prof. 
Kapurniotu´s group 
IAPP-FA product of SPPS synthesis in Prof. 
Kapurniotu´s group 
IAPP-LI product of SPPS synthesis in Prof. 
Kapurniotu´s group 
IAPP(22-27)-GI product of SPPS synthesis in Prof. 
Kapurniotu´s group 
synthetic Aβ(1-40) (TFA salt)                Bachem (Switzerland) 
synthetic glucagon               Calbiochem-Novabiochem (Bad Soden) 
rat IAPP (rIAPP)                 Calbiochem-Novabiochem (Bad Soden) 
human parathormon (1-34) Bachem (Switzerland) 
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2.1.2 Chemicals 
Chemical Company (city or country) 
acetic acid (100% ACS) Merck (Darmstadt)  
acetonitrile (HPLC-R)  Biosolve (Netherland) 
biotinamidocaproate N-hydroxysuccinimide  
ester Sigma (Steinheim) 
bovine serum albumin (BSA) Roth (Darmstadt) 
ammonium acetate Fluka (Steinheim) 
digoxigenin-3-O-methylcarbonyl-ε-aminocaproic 
acid-N-hydroxysuccinimide ester 
Roche Diagnostics (Switzerland) 
dimethylsulfoxid Sigma (München)  
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) 
Aldrich (Steinheim) 
dimethysulfide Fluka (neu-Ulm) 
dimethylformamid Biosolve (Netherland) 
1,2-ethandithiol (>98% GC) Fluka (Steinheim) 
ether (p.a. Grade) Hedinger (Stuttgat)  
fetal bovine serum GIBCOTM (UK) 
glutamine GIBCOTM (UK) 
glycin Fluka (Steinheim) 
guanidinium-HCl Roth (Darmstadt) 
HCl Sigma-Aldrich (Steinheim) 
HEPES Merck (Darmstadt) 
1,1,1,3,3,3-hexafluoro-2-propanol 
(grade 99+% ) (HFIP) 
Sigma-Aldrich (Steinheim) 
H2SO4 Merck (Darmstadt) 
horse serum GIBCOTM (UK) 
KCl Merck (Darmstadt) 
L-glutamine Invitrogen (Karlsruhe) 
methanol (p.a.) Roth (Karlsruhe) 
milk powder (nonfat dried) AppliChem (Darmstadt)  
NuPage-LDS-sample buffer Invitrogen (Karlsruhe) 
NuPage-SDS-running buffer Invitrogen (Karlsruhe) 
NuPage-transfer buffer Invitrogen (Karlsruhe) 
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NaCl KMF (Lohmar) 
NaOH Merck  (Darmstadt) 
NaH2PO4 Merck (Darmstadt) 
Na2HPO4 Merck (Darmstadt) 
NH4HCO3 Fluka (Steinheim) 
penicillin GIBCOTM (UK) 
phenol (99% A.C.S reagent) Sigma-Aldrich (Steinheim) 
polylysine Sigma-Aldrich (Steinheim) 
2-propanol  (p.a grade) Merck (Darmstadt) 
proteinmarker-Muti Mark TM Invitrogen (Karlsruhe)  
sodium acetate Merck (Darmstadt) 
sodium dodecyl sulfate (SDS) Merck (Darmstadt) 
sodium pyruvate GIBCOTM (UK) 
streptavidin-coupled magnetic beads  
(dynabeads M-280 streptavidin) 
Dynal Biotec ASA (Norway) 
streptomycin GIBCOTM (UK) 
super signal duration ECL staining solution  Pierce (USA)/KMF (Lohmar) 
thioanisole (>99% GC) Fluka (Steinheim) 
thioflavin T Sigma (Steinheim) 
trifluoroacetic acid  
(>99.5% for protein sequence analysis) 
Fluka (Steinheim) 
Tris Roth (Darmstadt)  
Triton-100 Sigma (München)  
Trypsin/EDTA Invitrogen (Eggenstein) 
Tween 20 Fluka (Switzerland) 
uranyl acetate Merck (Darmstadt) 
 
 
2.1.3 Assay kits 
Assay Kit Company (city or country) 
 micro bicinchoninic acid (BCA) protein assay kit Pierce (USA) 
cAMP Enzyme Immunoassay BiotractTM (EIA) 
system (dual range) 
Amersham Biosciences (UK) 
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2.1.4 Materials  
Material Company (city or country) 
Black microwell-plate (96-well) NUNC (Denmark) 
carbon-coated copper grids (300 mesh) Electron Microscopy Sciences (USA) 
cylindrical quartz CD cells  
(pathlength 10 mm, volume 800 ul) 
Jasco (Gross-Umstadt) 
 
eppendorf tube (1.5 ml, 0.5 ml) Sarstedt (Nümbrecht) 
syringe needle 20G 1½ ″ - Nr.1 (0.9X40 mm, 
sterile) 
DB Microlance TM  (Ireland) 
 
syringe needle 27G ¾ ″- Nr.20 (0.4X19 mm, 
sterile) 
DB Microlance TM  (Ireland) 
 
single-use syringe 1 ml (sterile) B|BRAUN (Melsungen) 
syringe 20 ml (sterile) DB Discardit 
TM  (Spain) 
Filter Millex-FG (0.2 µm pore size, 4 mm)       Millipore (Japan) 
Filter Millex-FG (0.2 µm pore size, 25 mm)     Millipore (Japan) 
Filter  (0.2 µm pore size, unsterile)           Schleicher & Schuell MicroScience (Dassel) 
Filter  (0.2 µm pore size, sterile)           Schleicher & Schuell MicroScience (Dassel) 
nitrocellulose membran Schleicher & Schuell MicroScience (Dassel) 
NuPAGE 4-12% Bis-Tris-Gel Invitrogen (Karlsruhe) 
tissue culture flask (75 cm2, 250 ml, PS, filter 
cap, sterile) 
Greiner Bio-One (Frickenhausen)  
 
 
 
2.1.5 Cell culture media 
cell culture medium Company (city or country) 
RPMI-1640 GIBCOTM  (UK) 
Dulbecco´s modified Eagle´s medium (DMEM) GIBCOTM  (UK) 
HAM´s nurient mixture F-12 (HAM medium) GIBCOTM  (UK) 
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2.1.6 Antibodies 
Antibody Antigen Company (city or country) 
1-antibody anti-digoxigenin antibody (sheep) Roche Diagnostics (Switzerland) 
1-antibody rabbit anti-amylin (human) IgG Bachem (Switzerland) 
1-antibody anti-amyloid β-protein (1-40) (Rabbit) Sigma (Steinheim) 
2-antibody donkey anti-goat IgG-POD Dianova (Hamburg) 
2-antibody donkey anti- rabbit IgG-POD Amersham (UK) 
Anti-biotin streptavidin-POD conjugate Roche (Switzerland) 
 
 
2.2 Methods 
2.2.1 Peptide synthesis  
Synthetic human IAPP was obtained from Calbiochem-Novabiochem or synthesized in our 
laboratory by Fmoc-solid phase peptide synthesis (SPPS). Crude IAPP in reduced form was 
then obtained following deprotection and cleavage of the peptidyl-resin [256]. 
For SPPS, protected amino acids (4-fold excess) were coupled using O-benzotriazole-
N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) (4-fold excess) and 
diisopropylethylamine (DIEA) (6-fold excess) except for the cysteines that were coupled via 
1-hydroxybenzotriazole (HOBt) and diisopropylcarbodiimide (DIC). All amino acids were 
coupled twice with the exception of (N-Me)I26 (3 times) and A25 (5 times). 
Following deprotection and cleavage from the resin, disulfide bridge formation between the 
cysteines at positions 2 and 7 was performed by air oxidation (1 mg crude material / ml 
solution) in aqueous 0.1 M NH4HCO3 containing 3 M (for IAPP-analogues) or 6 M (for IAPP) 
guanidinium-HCl. Oxidations for “non-toxic" IAPP were performed in aqueous 10 mM 
CH3COONH4 containing 10% dimethyl sulfoxide (DMSO) and 40% acetonitrile (ACN) 
overnight at room temperature. For the completion of the oxidations of IAPP and the IAPP 
analogues, 2-4 h were usually required.  
Purification of IAPP and the IAPP-analogues were carried out by reverse-phase high 
performance liquid chromatography (RP-HPLC) on a C18 Nucleosil column with a length of 
25 cm, internal diameter of 8 mm and 7 µm particle size. The device consisted of a Jasco PU-
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2089 HPLC pump and integrator and a Jasco UV-2075 detector. The flow rate was 2 ml/min 
and eluting buffers were: A, 0.058% (v/v) trifluoroacetic acid (TFA) in water and B, 0.05% 
(v/v) TFA in 90% ACN/water. Peptides were detected at 214 nm and the gradients that were 
applied are shown in table 2. Eluates containing peptide peaks were immediately frozen in dry 
ice and lyophilised. Peptides were characterized by matrix-assisted laser desorption ionization 
mass spectrometry (MALDI-MS). 
Nα-biotinyl labels were introduced as follows: following assembly of fully protected peptide 
chains and Nα-Fmoc-cleavage, Fmoc-protected ε-aminocaproic acid was coupled followed by 
Fmoc-cleavage and coupling of biotin using the same coupling protocols as used for the SPPS. 
Deprotection and cleavage of the peptides from the resin, disulfide bridge formation, 
purification and characterization of the peptides were performed as described above.  
The N-terminal digoxigenin-ε-aminocaproic acid moiety was introduced into IAPP-GI by  
coupling digoxigenin-3-O-methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester 
to synthetic, oxidized and HPLC-purified IAPP-GI in dimethylformamid (DMF) followed by 
RP-HPLC purification of the crude product. 
 
Table 2. HPLC gradient  
HPLC gradient 1 HPLC gradient 2 Step 
 Time (min) Buffer A (%) Buffer B (%) Time (min) Buffer A (%) Buffer B (%) 
1 0 70 30 0 90 10 
2 7 70 30 1 90 10 
3 37 40 60 31 10 90 
 
 
2.2.2 Peptide stock solutions 
2.2.2-1 IAPP and IAPP analogues stock solutions 
HPLC purified peptides were stored in lyophilised form at -20 °C. Peptide stock solutions 
were made by dissolving the peptide in HFIP to final concentrations of 200–500 µM on ice 
and filtering through a filter (Millex-FG, 0.2 µm pore size; single-use syringe 1 ml). The exact 
concentration of the stock solutions was determined by using UV-spectroscopy (Varian, Cary 
1 Bio UV-visible spectrophotometer). UV-absorbance of the peptide solution was measured 
between 200 and 400 nm and the absorbance at 274.5 nm was used to determine the exact 
peptide concentration. At this wavelength, the extinction coefficient of the Tyr residue 
(ε=1370 M-1cm-1) and the disulfide bridge of Cys1
 
and Cys7(ε=70 M-1cm-1) was 1440 M-1cm-1. 
Peptide concentrations were calculated according to the formula:     
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                               [C] = Ab274.5nm / (ε x l)  
               where ε= molecular extinction coefficient of peptides at 274.5 nm  
                          l= the length of the cuvette (1 cm)  
Peptide concentrations were confirmed by the BCA assay. 
IAPP stock solutions were stored at 4 oC and used within 1 week.  Stock solutions of the 
IAPP analogues were stored at -20 oC. 
 
 
2.2.2-2 Aβ(1-40)  stock solution 
Synthetic Aβ(1-40) (TFA salt, Bachem) was dissolved at 1 mg/ml in a mixture of 72% ACN 
in water containing 0.04% TFA, aliquoted, and lyophilized. Aβ stocks were freshly made by 
reconstituting freshly lyophilized Aβ(1-40) aliquots with HFIP (1 mg/ml) on ice. 
Concentrations of the Aβ(1-40) stocks were determined using the BCA protein assay. Stock 
solutions of Aβ(1-40) were stored at 4 oC and used within 1 day. 
 
 
2.2.2-3 Stock solutions of other peptides 
Peptides were stored in lyophilised form at –20 °C. Peptide stock solutions were made by 
dissolving the peptides in HFIP to a final concentration of about 200–500 µM on ice. Peptide 
concentrations were determined then by the BCA protein assay. Stock solutions of the 
peptides were stored at -20 oC. 
 
 
2.2.3 Bicinchoninic acid (BCA) protein assay  
Aliquots (0.5–5 µg) of peptide solution in HFIP were added to a 96-well plate (in triplicates). 
Following evaporation of HFIP via a nitrogen stream, 50 µl of a solution containing 10 mM 
sodium phosphate buffer, pH 7.4 was added. Thereafter, 150 µl freshly made working reagent 
solution (BCA protein assay Kit, A:B:C = 25:24:1) were added to each sample. Following 
mixing, the wells were covered with lids and incubated for 2 h at 37 °C. Samples were cooled 
on ice to room temperature and absorbance at 570 nm was measured with a Microplate reader 
(Bio-RAD, model 550). The amounts of the peptides were determined from a standard curve 
of absorbance versus protein amount. The method was able to detect IAPP and Aβ(1-40) for 
between 0.5-5 µg and 1-5 µg, respectively. 
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2.2.4 Sedimentation assay 
Peptide incubations in 10 mM sodium phosphate buffer, pH 7.4 (with 1% HFIP for the 1 µM 
assay), were performed at room temperature. At various time points, aliquots (12.8 µl for the 
100 µM assay, 100 µl for the 10 µM assay, and 1ml for the 1 µM assay) were centrifuged 
(20200 g for 20 min) with a 5417R Eppendorf microcentrifuge, and pellets and supernatants 
were separated and quantified by the BCA protein quantification assay. 
 
 
2.2.5 Size Exclusion Chromatography (SEC) 
The elution buffer was 10 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl 
and the flow rate was 0.25 ml/min. Detection of the peptides was performed at 214 nm. The 
column was calibrated with proteins and peptides of known molecular weights (Table 3). 
Incubations of IAPP or IAPP-GI (6.25 µM) were made in elution buffer at room temperature 
and 800 µl (20 µg) aliquots were applied onto the column at various time points. All samples 
were centrifuged (17000 g for 10 min) using a 5417R Eppendorf microcentrifuge before 
application to the TSK-Gel column (G2000SWXL, internal diameter of 7.8 mm, length of 30 
cm, and 5 µm particle size) (Biotech Support Group). The device consisted of a Hewlett 
Packard 1050 Series HPLC Systems (pump, integrator, and detector). 
 
Table 3. Gel filtration standard proteins used for calibration (Bio-Rad) 
protein content (mg) molecular weight isoelectric point elution time (min) 
thyroglobulin 5 670,000 4,5 22.85  
bovine gamma globulin 5 158,000 5,1 26.89  
chicken ovalbumin 5 44,000 4,6 29.99  
equine myoglobin 2.5 17,000 6,9 39.35  
vitamin B-12 0.5 1,350 4,5 47.22  
 
 
2.2.6 Far-UV CD spectroscopy 
Peptide incubations were performed in 10 mM sodium phosphate buffer, pH 7.4, with 1% 
HFIP in quartz cells at room temperature. CD spectra were collected at various time points 
using an AVIV 202SF spectropolarimeter. Spectra were collected between 195 or 200 and 
250 nm at 1 nm intervals, a response time of 8 seconds and at room temperature. CD spectra 
(mean residue ellipticities [θ]) are presented after subtracting the spectra of buffer alone. The 
5 µM IAPP, Aβ(1-40), and all other peptide solutions were always made freshly and handled 
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according to the following procedure:  8 µl of the 500 µM peptide stock solution in HFIP (on 
ice) was diluted directly into the buffer-containing (a mixture of 784 µl 10 mM sodium 
phosphate pH 7.4 and 8 µl 20 mM sodium phosphate buffer pH 7.4) cell (on ice) to give a 
peptide final concentration of 5 µM in 10 mM sodium phosphate buffer (pH 7.4), containing 
1% HFIP. Mixing was performed by gentle pipetting and the CD spectrum was then measured 
at 4 °C. Thereafter, the solutions were allowed to reach room temperature (a rate of 2 °C per 
minute), and CD spectra were measured again. No changes in the CD spectrum of IAPP or the 
other peptides between 4 oC and 25 oC were found. Of note, IAPP and Aβ(1-40) were in the 
lag-time of its fibrillization according to ThT and TEM (not shown). The mixtures of IAPP 
with IAPP analogues and Aβ(1-40) with IAPP analogues were always made by freshly 
mixing 500 µM stock solutions of two peptides and then handled according to the above 
procedure. 
millidegrees [θ]= # amino acid x peptide concentration (M) x cell length (cm) x 10 
where # = number of amino acids of the peptide 
 
 
2.2.7 Transmission Electron Microscopy (TEM)  
10 µl aliquots of peptide incubations in 10 mM sodium phosphate buffer (pH 7.4) or of 
incubations of peptides for ThT binding assay or CD Spectroscopy studies were applied on 
carbon-coated copper grids for 3 minutes, dried, and stained with a drop (10 µl) of 2% (w/v) 
uranyl acetate in water (for 1 minute). In the case of peptide incubations in 50 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP, grids were washed with 
10 µl destilled water for 1 minute to remove salts before staining. Samples were air-dried and 
examined with a Philips EM 400 T electron microscope at 60 kV.  
 
 
2.2.8 Adenylate Cyclase Activation Assay 
Human breast adenocarcinoma MCF-7 cells were a kind gift from Dr. R. Lilischkis, 
University Hospital of the RWTH Aachen. Cells were grown in an 1/1 mixture of Dulbecco’s 
modified Eagle’s medium containing 4.5 g/l glucose and HAM’s F12 nutrient mixture 
supplemented with 2 mM L-glutamine, 0.1 mg/ml penicillin/streptomycin, and 10% fetal calf 
serum (FCS). Cells were subcultured in 96-well plates at a density of 5 x 105 cells/ml (100 
µl/well). Following incubation for 24 h (37oC, humidified atmosphere with 5% CO2), the 
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medium was gently aspirated. Cells were then washed with PBS (200 µl) and 100 µl of 
RPMI-1640 containing 0.1% (w/v) BSA (assay medium, kept on ice) was added and then 100 
µl of the solutions (freshly made and kept on ice) containing the peptides at various 
concentrations or vehicle alone in assay medium were added to the cells. Incubations were 
performed for 15 min at 37oC (humidified atmosphere with 5% CO2). Intracellular cyclic 
adenosine monophosphate (cAMP) was quantified following cell lysis by ELISA using the 
“cAMP Biotract Enzyme Immunoassay System” (Amersham Biosciences). Components of 
the adenylate cyclase activation assays are shown in Table 4. 
 
Table 4. Components of the cAMP Biotrak enzymeimmunoassay (EIA) system 
Solution  Solution content 
assay buffer 0.05 M acetate buffer with 0.02% w/v BSA and 0.01% w/v preservative, pH 5.8 
lysis reagent 1 dodecyltrimethylammonium bromide  
lysis reagent 2 sequestration component 
lysis buffer 1A 2.5% dodecyltrimethylammonium bromide in assay buffer 
lysis buffer 1B 0.25% dodecyltrimethylammonium bromide in assay buffer 
lysis buffer 2A 5% lysis reagent 2 in assay buffer 
lysis buffer 2B 0.5% lysis reagent 2 in assay buffer 
Standard 
(for non-acetylation assay) 
Solution contains cAMP at a concentration of 32 pmol/ml in lysis 
buffer 1B. cAMP standard for non-acetylation assays in the range 
12.5–3200 fmol/well. 
antibody rabbit anti-cAMP antibody in lysis buffer 2B  
peroxidase conjugate: cAMP horseradish peroxidase in assay buffer  
wash buffer 0.01 M phosphate buffer containing 0.05% (w/v) Tween 20, pH 7.5 
TMB substrate: enzyme substrate containing 3,3,5,5-Tetramethylbenzidine (TMB) <1% Hydrogen Peroxide. Ready for use 
 
The cAMP Biotrak™ competitive enzymeimmunoassay system is specifically designed, non-
radioactive, rapid method for cAMP quantification [282]. Lysis reagent 1 hydrolyses cell 
membranes to release intra-cellular cAMP. Lysis reagent 2 sequesters the key component in 
lysis reagent 1 and ensures cAMP is free for subsequent analysis. The detergent/sequestrant 
complex does not interfere with antigen-antibody binding. Lysis reagent 1 is simply added to 
cultured cells, followed by some minutes of incubation before the assay (Fig. 24 A) [282]. 
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The antiserum is reconstituted with lysis reagent 2. The assay is based on competition 
between unlabelled cAMP and a fixed quantity of peroxidase-labelled cAMP for a limited 
number of binding sites on a cAMP specific antibody (Fig. 24 B) [282]. 
Fig. 24 Principle of the cAMP Biotrak™ competitive enzymeimmunoassay system [282] 
 
cAMP was quantified according to the following procedure: 
Solutions were gently aspirated from the cells and 200 µl of cell lysis buffer 1B were added to 
each well. An aliquot of the cell lysate containing solution was then diluted 25-fold with lysis 
buffer 1B and then 100 µl of this sample were transferred to the ELISA plate. Serial dilutions 
of a cAMP standard solution were prepared in lysis buffer 1B and 100 µl aliquots from each 
of the serial dilutions (12.5, 25, 50, 100, 200, 400, 800 and 1600 fmol/well) were added into 
the wells. 100 µl of lysis buffer 1B were added into the zero standard wells. For non-specific 
binding (NSB) wells, 100 µl lysis buffer 1B and 100 µl lysis buffer 2B were pipetted. 100 µl 
of the rabbit antiserum solution were then added into all wells except for the NSB wells. The 
ELISA plate was covered with the lid provided, gently mixed, and then incubated for 2 h at 4 
°C. Thereafter, 50 µl of the cAMP horseradish peroxidase conjugate in assay buffer were 
added to each well and the plate was incubated for 1 h at 4 °C. The solutions were then 
decanted from the wells, and the plate was thoroughly washed with wash buffer. Residual 
liquid was removed by blotting the plate on tissue paper. Immediately thereafter, 150 µl of the 
solution containing the enzyme substrate (TMB substrate) were added to all wells (a blue 
colour started to develop). The plate was gently mixed on a microplate shaker (LTF 
Labortechnik, Wasserburg) for ~20 min at room temperature and the reaction was then 
stopped by adding 100 µl of 1 M sulphuric acid to all wells. Absorbance (Abs) was measured 
by a 1420 Multilabel Counter Victor2 (PerkinElmer Life Sciences, Germany) at 450 nm. 
A
B
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Results are expressed as percent of maximum adenylate cyclase activation above the basal 
level and maximum stimulation was the stimulation caused by 1 µM IAPP.  
Adenylate cyclase (AC) activation (%maximum) for each standard and sample were calculated 
using the following relationship: 
Standard: AC activation = 
(Absstandard -AbsNSB) x 100 
    (Abszero standard-AbsNSB) 
Sample: AC activation = 
(Abssample -AbsNSB) x 100 
    (Absmaximum -AbsNSB) 
 
 
 
2.2.9 Thioflavin T (ThT) Binding Assay 
ThT binding was measured on aliquots of incubations of peptide alone or mixtures of peptides 
made in ThT assay buffer 1 or assay buffer 2. Peptide solutions were incubated in eppendorf 
tubes at room temperature and stirring kinetics of fibrillogenesis were followed for up to 7 or 
14 days. At the specific time points, the solutions were mixed by briefly vortexing and 
aliquots were transferred in a black 96-well plate (NUNC) and aliquots of a ThT solution (see 
table. 6) were added to each of the wells. Mixing ratios were: peptide concentration between 
625 nM and 2 µM, ThT concentration between 4 and 5 µM. ThT binding was determined then 
after gentle mixing by measuring fluorescence emission at 485 nm (triplicate determination) 
following excitation at 450 nm using a 1420 Multilabel Counter Victor2 (PerkinElmer Life 
Sciences, Germany). An increase in fluorescence emission indicated increased amyloid 
formation. Solutions used in the ThT binding assays are shown in Table 5. 
 
Table 5. ThT assay buffer and ThT solutions for the ThT binding assay 
Solution  Solution content Used for 
ThT assay 
buffer 1 
10 mM Tris buffer, pH 7.4, containing 2% 
HFIP 
for the peptide concentrations of 
625 nM, 6.25 µM, and 62.5 µM 
ThT assay 
buffer 2 
50 mM sodium phosphate buffer, pH 7.4, 
containing 100 mM NaCl and 0.5% HFIP 
for the peptide concentration 16.5 
µM 
ThT solution A 5 µM ThT in 100 mM glycine/NaOH, pH 8.5 
for peptide concentrations of 6.25 
and 62.5 µM using ThT assay 
buffer 1  
ThT solution B 200 µM ThT in 100 mM glycine/NaOH, pH 8.5 
for the peptide concentration 625 
nM using ThT assay buffer 1 
ThT solution C 5 µM ThT in 50 mM glycine/NaOH, pH 8.5 for the peptide concentration 16.5 µM using ThT assay buffer 2 
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Peptide incubations were made according to the following procedures: 
For the studies of the properties of IAPP and the IAPP analogues, aliquots of a stock solution 
of IAPP or IAPP analogues in HFIP (on ice) were placed in eppendorf tubes and HFIP was 
evaporated via a nitrogen stream. Then ThT assay buffer (see table. 6) was added and the 
solutions were mixed thoroughly by vortexing and allowed to incubate at room temperature.  
For the studies on the effects of IAPP analogues on IAPP fibrillogenesis (peptide 
concentrations of 6.25 µM and 16.5 µM), a stock solution of the IAPP analogue in HFIP was 
mixed with a stock solution of IAPP in HFIP (on ice) and, following evaporation of HFIP via 
nitrogen stream, ThT assay buffer (see table. 6) was added. The solutions were mixed 
thoroughly by vortexing and allowed to incubate at room temperature. Incubations of IAPP 
analogues or IAPP were performed under the same conditions and were included in each 
experimental set.  
For the studies of the inhibitory effect of different concentrations of IAPP-GI on formation of 
IAPP fibrils, aliquots of a serial dilution of IAPP-GI in HFIP (prepared on ice) were placed in 
eppendorf tubes and HFIP was evaporated via a nitrogen stream. Aliquots of a freshly made 
IAPP solution (16.5 µM in assay buffer 2) were added to the eppendorf tubes containing 
different amounts of IAPP-GI and the solutions were mixed thoroughly by vortexing and 
incubated at room temperature.  
For the fibril dissolution assays, aliquots of an IAPP incubation (16.5 µM in ThT assay buffer 
2) were withdrawn at various time points of the fibrillization process and added to eppendorf 
tubes containing an equimolar amount of IAPP-analogues (in dry form, obtained by 
evaporation of HFIP stocks). To assess the effect of IAPP-GI on aged and fibrillar IAPP, 
fibrillar IAPP was prepared from a 3 days aged 16.5 µM IAPP solution in ThT assay buffer 2 
and the amount of fibrillar IAPP was quantified by the BCA assay. Different amounts of 
IAPP-GI aliquots (in HFIP, prepared on ice) for IAPP-GI/IAPP molar ratios of 1/1, 10/1, and 
50/1 were placed in eppendorf tubes and HFIP was evaporated via a nitrogen stream. Aliquots 
of the fibrillar IAPP solution were added to eppendorf tubes and were mixed thoroughly by 
vortexing. The solutions, including a control fibrillar IAPP alone solution, were then 
incubated at room temperature for 3 days and fibrils were quantified by the ThT assay. 
For the seeding experiments with preformed IAPP fibrils, ThT assay buffer 1 without HFIP 
was used where IAPP (at 6.25 µM) fibrillization exhibited a lag-time of about 48 h. IAPP 
fibrils were prepared from 100 µM IAPP in 10 mM phosphate buffer, pH 7.4. This solution 
was incubated at room temperature for 24 h, and completeness of amyloid fibril formation 
was confirmed by the ThT assay and TEM.  Following centrifugation (20200 g for 20 min) 
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using centrifuge (5417R, Eppendorf) and fibril quantification by BCA, pellets (IAPP fibrils) 
were dissolved in ThT assay buffer 1 (without HFIP) at final concentration of 6.25 µM. IAPP 
fibrils (10% on a monomer basis) were added to freshly made solutions containing IAPP with 
or without IAPP-GI.  
For the studies of the effects of IAPP analogues on Aβ(1-40) fibrillogenesis, an aliquot of a 
freshly made stock solution of Aβ(1-40) in HFIP (on ice) was placed in an eppendorf tube and 
HFIP was evaporated via a nitrogen stream. Then ThT assay buffer 2 was added and the 
solution was mixed thoroughly. One aliquot of the freshly made Aβ(1-40) solution (16.5 µM 
in ThT assay buffer 2) was mixed with IAPP analogues (in dry form, obtained by evaporation 
of HFIP stocks). Incubations of Aβ(1-40) alone were performed in each experimental set. Of 
note, same inhibitory effects on Aβ(1-40) fibrillogenesis were found when a stock solution of 
IAPP-GI in HFIP was mixed with a stock solution of Aβ(1-40) in HFIP (on ice), and, 
following evaporation of HFIP via a nitrogen stream, ThT assay buffer 2 was added.  
For the studies on the effect of IAPP analogues on Aβ(1-40) fibrillogenesis at different time 
points, Aβ(1-40) solutions (16.5 µM in ThT assay buffer) were made and aged at room 
temperature. At specific time points, one aliquot was added to the eppendorf tubes containing 
IAPP analogues (in dry form, obtained by evaporation of HFIP stocks).  
For the dissolution assay of fibrillar Aβ(1-40), fibrillar Aβ(1-40) was prepared from a 7 days 
aged Aβ(1-40) solution (16.5 µM in ThT assay buffer 2) and, following quantification of 
fibrillar Aβ(1-40) by the BCA assay, the solution was mixed with IAPP-GI (in dry form, 
obtained by evaporation of HFIP stock) at IAPP-GI/Aβ(1-40) molar ratios of 1/1, 10/1, 50/1 
and 100/1. The solutions, including a control fibrillar Aβ(1-40) alone solution, were then 
incubated at room temperature for 3 days and and fibrils were quantified by the ThT assay. 
For the studies on the effect of prefibrillar or fibrillar IAPP on prefibrillar Aβ(1-40) species 
and vice versa, incubations were made by adding aliquots of freshly made or aged IAPP 
solutions (16.5 µM, made by dissolving an appropriate amount of IAPP (in dry form, obtained 
by evaporation of HFIP stocks) into ThT assay buffer 2) to the appropriate amounts of Aβ(1-
40) (dry aliquot from evaporation of a freshly made HFIP stock).  
For studying the effect of fibrillar IAPP on prefibrillar Aβ(1-40) fibrillization, IAPP fibrils were 
prepared by incubating 100 µM IAPP (in 10 mM phosphate buffer, pH 7.4) at room temperature 
for 24 h. Completeness of amyloid fibril formation was confirmed by the ThT assay and TEM.  
Following centrifugation (20200 g, 20 min) and fibril quantification by BCA, pellets were 
dissolved in ThT assay buffer 2 to a final concentration of 16.5 µM and solutions were then 
added (1/1 on a monomer basis) to Aβ(1-40) (in dry form, for final concentration of 16.5 µM ).  
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For studying the effect of fibrillar Aβ(1-40) on prefibrillar IAPP fibrillization, a 16.5 µM 
Aβ(1-40) solution (in ThT assay buffer 2) was incubated at room temperature for 6 days and 
fibrillization was followed by the ThT assay. Following completeness of fibrillization (based 
on ThT, TEM, and BCA quantification of pellets following centrifugation (20200 g, 20 min) 
of small aliquots), this fibrillar Aβ(1-40) solution was added (1/1 on a monomer basis) to 
IAPP (in dry form, for final concentration of 16.5 µM).  
For seeding experiments of Aβ(1-40) or of mixtures of Aβ with inhibitors with preformed 
Aβ(1-40) fibrils, solutions containing Aβ(1-40), in the absence or presence of inhibitor were 
made as for Aβ(1-40) fibrillogenesis studies (see above). Aβ(1-40) fibrils were prepared from 
a 7 days aged Aβ(1-40) solution (16.5 µM in ThT assay buffer 2). Following centrifugation 
(20200 g, 20 min) and fibril quantification by BCA, pellets were dissolved in ThT assay 
buffer 2 to a final concentration of 16.5 µM and added (10% on a monomer basis) to the 
freshly made mixture solutions. 
For seeding experiments of mixtures of IAPP with Aβ(1-40) with preformed IAPP fibrils, 
IAPP fibrils were prepared as described for studying the effect of fibrillar IAPP on prefibrillar 
Aβ(1-40) fibrillization and were added (10% on a monomer basis) to freshly made solutions 
of IAPP/Aβ(1-40) mixture which were made for Aβ(1-40) fibrillogenesis studies (as 
described for the studies on the effect of prefibrillar IAPP on prefibrillar Aβ(1-40) species). 
 
2.2.10 Assessment of Cytotoxicity via the MTT Reduction Assay 
The rat insulinoma cell line RIN5fm and the rat pheochromocytoma cell line PC-12 were used. 
The rat insulinoma cell line RIN5fm was obtained by T. E. Rucinsky from the Washington 
University Tissue Culture Support Center and was cultured in RPMI 1640 containing 10% 
heat-inactivated fetal bovine serum, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 
mM sodium pyruvate, 1 mg/ml glucose, and 0.1 mg/ ml penicillin/streptomycin. RIN5fm cells 
were plated in 96-well plates at a density of 5x10
5 
cells/ml (100 µl/well). The rat 
pheochromocytoma cell line PC-12 was cultured in RPMI 1640 medium containing 10% 
horse serum, 5% fetal calf serum, 25 units/ml penicillin, and 25 µg/ml strepromycin. PC-12 
cells were plated at a density of 1x10
5 
cells/ml (100 µl/well) in polylysine-coated 96-well 
plates.  Following incubation for 24 h, serial dilutions of the peptide solutions were made in 
cell culture medium and 11 µl added to the wells at different final concentrations. The term 
“peptide concentration” in figures presenting viability of cells treated with peptide mixtures 
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refers to the molar concentration of one of the mixture components as indicated in the figure 
or its legend. Incubations were performed for about 20 hours (37 oC, humidified atmosphere 
with 5% CO2). Thereafter, 25 µl of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT) solution (5 mg/ml in PBS) were added into the cells. Following incubation 
for 2 h at 37 oC, cell viabilities were then assessed by measuring the cellular reduction of 
MTT, whereas for the PC-12 cells a slightly modified protocol was applied. Accordingly, PC-
12 cells were first incubated with MTT (1 mg/ml) for 2-4 h at 37 oC. Thereafter, 90 µl of cell 
lysis buffer (10% SDS in 20 mM HCl, pH 4.5) was added and cellular MTT reduction was 
measured after overnight incubation at room temperature. MTT reduction was determined by 
measuring the absorbance at 570 nm with a Microplate reader (Bio-RAD, model 550).  
Complete inhibition of cell function (0% viability) was defined as the absorbance value 
obtained in wells containing 0.1% Triton X-100. 100% MTT reduction was defined as the 
absorbance value obtained in wells containing vehicle alone. For the calculation of cell 
viability (% of control) the following formula was used:  
 
% MTT reduction = [(Abssample- Abs0.1 % Triton) / (Absmedium- Abs0.1 % Triton) x 100  
 
Peptide incubations for the MTT reduction assays were made as follows: 
For studies on the effects of IAPP and the analogues on β-cell cell viability, peptides (16.5 
µM) were first incubated in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM 
NaCl and 0.5% HFIP at room temperature for 7 days. In another experimental set up 
(incubation under strongly amyloidogenic conditions) peptides (2 mM) were incubated in 
10% acetic acid at room temperature for 4 days and neutralised then with aqueous ammonia 
(10%). Thereafter, aliquots of the solutions were diluted with cell culture medium and added 
to the RIN 5fm cells at final concentrations between 500 nM and 100 pM for the 16.5 µM 
peptide incubations and between 10 µM and 10 nM for 2 mM peptide incubations.  
All other studies were performed in combination with the ThT binding assay. The incubations 
were prepared in ThT assay buffer 1 (peptide concentration of 6.25 µM) or in ThT assay 
buffer 2 (peptide concentration of 16.5 µM) as described under “ThT Binding Assays” 
(chapter 2.2.9).  
Briefly, for the studies of the effects of IAPP analogues on IAPP cytotoxicity (peptide 
concentrations of 6.25 µM and 16.5 µM), incubations of mixture of IAPP with IAPP-
analogues were made as described under “ThT Binding Assays” (chapter 2.2.9). An 
incubation of IAPP alone was performed under the same conditions and was included in each 
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experimental set. At specific time points, aliquots of incubations were diluted with cell culture 
medium and added to the RIN5fm cells at final concentrations between 150 nM and 100 pM 
for peptide incubations using ThT assay buffer 1 and between 500 nM and 100 pM for 
peptide incubations using ThT assay buffer 2.  
For the fibril dissolution assays, incubations of mixtures of IAPP with IAPP-GI were made as 
described under “ThT Binding Assays” (chapter 2.2.9). Fibrillar IAPP solution (16.5 µM in 
ThT assay buffer 2) was mixed with IAPP-GI at IAPP-GI/IAPP molar ratios of 1/1, 10/1, and 
50/1. The solutions, including a control fibrillar IAPP alone solution, were then incubated at 
room temperature for up to 3 days and added to the RIN5fm cells at final concentrations 
between 500 nM and 100 pM.  
For seeding experiments with preformed IAPP fibrils, incubations of mixture of IAPP with 
IAPP-GI and of mixture of IAPP with Aβ were made as described under “ThT Binding 
Assays” (chapter 2.2.9). Seeded mixtures of IAPP with IAPP-GI were incubated for 72 h at 
room temperature then added to the RIN5fm cells at final concentrations between 500 nM and 
100 pM, while seeded mixture of IAPP with Aβ were incubated for 24 h at room temperature 
then added to the RIN5fm cells.  
To assess the effect of fibrillar Aβ(1-40) on IAPP cytotoxicity, solutions (made as described 
under “ThT Binding Assays” (chapter 2.2.9)) including IAPP alone and fibrillar Aβ(1-40) 
alone were incubated at room temperature for 24 h then added to RIN5fm cells at final 
concentrations between 500 nM and 100 pM. 
For the studies on the effect of the IAPP analogues on Aβ(1-40) cytotoxicity, aliquots of the 
freshly dissolved or aged Aβ(1-40) solutions were added to the corresponding peptides (as 
described under “ThT Binding Assays” (chapter 2.2.9)) and solutions were incubated at room 
temperature and added to PC-12 (at final concentrations between 1 µM and 1 nM ) at the 
various time points.  
For determination of the IC50 of the inhibitory effect of IAPP-GI on toxicity of Aβ(1-40, an 
aliquot of stock solution of Aβ(1-40) in HFIP was mixed with a stock solution of IAPP-GI in 
HFIP (on ice) at peptide ratios between 1/0.05 and 1/2 (Aβ(1-40)/IAPP-GI), and, following 
evaporation of HFIP via a nitrogen stream, ThT assay buffer 2 was added (the final 
concentration of Aβ(1-40) was 16.5 µM). The solutions, including a control Aβ(1-40) alone 
solution were incubated at room temperature for 3 days and thereafter were added to the PC-
12 cells (the final concentration of Aβ(1-40) on cells was 500 nM). 
To assess the effect of IAPP-GI on cytotoxicity of aged and fibrillar Aβ(1-40), solutions 
(made as described under “ThT Binding Assays” (chapter 2.2.9)) including a control fibrillar 
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Aβ(1-40) alone, were incubated at room temperature for up to 7 days and added to PC-12 (at 
final concentrations between 1 µM and 1 nM ) at the various time points.  
To assess the effect of preformed IAPP fibrils on Aβ(1-40) cytotoxicity, solutions (prepared 
as described under “ThT Binding Assays” (chapter 2.2.9)) including fibrillar IAPP and Aβ(1-
40) alone were incubated for 72 h and added then to PC-12 cells at final concentrations 
between 1 µM and 1 nM.  
For the Aβ(1-40) seeding experiments with preformed Aβ(1-40) fibrils, solutions (made as 
described under “ThT Binding Assays” (chapter 2.2.9)) including a control Aβ(1-40) alone, 
were incubated at room temperature for up to 7 days and added then to PC-12 (at final 
concentrations between 1 µM and 1 nM ) at the various time points.  
 
 
2.2.11 Pull-down Assay 
For the studies of Interaction of IAPP-GI with IAPP, Nα-[digoxigenin-Aca0]IAPP (Dig-IAPP-
GI) (2.5 µM) was incubated (1 h) alone or in a mixture with Nα-[biotinyl-Aca0]IAPP (Biotin-
IAPP) (2.5 µM) in 1 ml of 10 mM sodium phosphate buffer, pH 7.4, (assay buffer) at room 
temperature. Streptavidin-coupled magnetic beads (Dynal Biotec ASA) were washed with 
PBS and a solution of 20 mM Tris, pH 7.3, containing 150 mM NaCl and 0.05% Tween 20 
(TBSn) and then blocked with 0.25% bovine serum albumin in TBSn for 90 min. Beads were 
washed with TBSn, PBS, and assay buffer and then the preincubated peptide solutions were 
incubated with the beads for 1 h. Bead-bound complexes were isolated by magnetic affinity 
and beads were washed with 25 mM HEPES, pH 7.7, containing 0.1 M NaCl and 0.5% Triton 
X100. Reducing NuPAGE sample loading buffer (Invitrogen) was added, the beads were 
boiled (5 min), and supernatants containing complexes or peptides alone were subjected to 
NuPAGE electrophoresis in 4-12% Bis-Tris gels with MES running buffer according to the 
manufacturer’s recommendations (Invitrogen). Equal amounts of peptide (100% input: 4 µg) 
were loaded. Peptides were blotted onto nitrocellulose using a XCell II Blot Module blotting 
system (Invitrogen). Dig-IAPP-GI bound to biotin-IAPP was revealed by Western blot (WB) 
using a polyclonal sheep anti-digoxigenin antibody (Roche Diagnostics) in combination with 
peroxidase (POD)-coupled secondary antibody (Dianova) and the Super Signal Duration ECL 
staining solution (Pierce/KMF). Control blots performed to stain Biotin-IAPP were developed 
with streptavidin-POD (Roche). A molecular weight marker (Invitrogen) ranging from 3-185 
kDa was electrophoresed in the same gels. 
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For the studies of interaction of IAPP-GI or IAPP with Aβ(1-40), synthetic Nα-[biotinyl-
Aca0]IAPP-GI (Biotin-IAPP-GI) or Biotin-IAPP (2.5 µM) were incubated (1 h) alone or in a 
mixture with Aβ(1-40) (2.5 or 5 µM) in 1 ml of 10 mM sodium phosphate buffer, pH 7.4, 
(assay buffer) at room temperature. Aβ(1-40) alone (2.5 or 5 µM) was also included to the 
incubations to control for nonspecific binding (NSB) to the beads. ThT assay and CD studies 
had previously shown that Aβ(1-40) was in the lag-phase of its fibrilization process (not 
shown). The pull-down assays using streptavidin-coated magnetic beads were then performed 
essentially as described above. Briefly, beads were washed, blocked, incubated with assay 
buffer, and preincubated peptide solutions (see above) were then added to the beads. After 
incubation for 1 h, bead-bound complexes were isolated by magnetic affinity and beads were 
washed. Reducing NuPAGE sample loading buffer was added, the beads were boiled (5 min), 
and supernatants containing complexes or peptides alone were subjected to NuPAGE 
electrophoresis in 4-12 % Bis-Tris gels with MES running buffer according to the 
manufacturer’s recommendations. Equal amounts of peptides (100% input of biotinyl peptide: 
4 µg; 50% of input of Aβ(1-40): 4 µg) were loaded. Peptides were blotted onto nitrocellulose 
using a XCell II Blot Module blotting system. Aβ(1-40) bound to Biotin-IAPP-GI or Biotin-
IAPP was revealed by WB using a polyclonal rabbit anti-Aβ(1-40) antibody (Sigma) in 
combination with peroxidase (POD)-coupled secondary antibody and the Super Signal 
Duration ECL staining solution. Control blots were performed to stain Biotin-IAPP-GI or 
Biotin-IAPP and were developed with streptavidin-POD. No NSB was found for Aβ(1-40) 
under the applied conditions. A molecular weight marker ranging from 3-185 kDa was 
electrophoresed in the same gels. 
 
 
2.2.12 Oligomerization assay and NuPAGE analysis 
Peptides (50 µM, 8 µl) were incubated in 10 mM sodium phosphate buffer, pH 7.4, at room 
temperature for 24 h. Freshly dissolved peptides (0 h) and peptide incubations were mixed 
with NuPAGE buffer without reducing agent at room temperature and then subjected to 
NuPAGE electrophoresis without any boiling procedure using 4-12 % Bis-Tris gels with MES 
running buffer according to the manufacturer’s recommendations (Invitrogen). Equal amounts 
of peptides (1,5 µg) were loaded throughout all lanes. Peptides were blotted onto 
nitrocellulose using a XCell II Blot Module blotting system (Invitrogen). Peptides were 
visualized by WB which was performed as described above under pull-down assays. Peptides 
were revealed by WB using a polyclonal rabbit anti-IAPP antibody (Bachem).  
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3. Results 
3.1 Biophysical properties of the IAPP analogues 
3.1.1 Solubilities 
The solubilities of the IAPP analogues were determined by using sedimentation assay and 
compared to the solubility of IAPP. IAPP and its analogues were incubated in aqueous buffer 
(pH 7.4) at room temperature. At various time points, aliquots were centrifuged and the 
amount of the peptides in both the pellets and the supernatants (except for the concentration of 
1 µM where only pellets were measured) was quantified by the BCA protein assay. As shown 
in Fig. 25, IAPP was insoluble even at a concentration of 1 µM. 1 µM IAPP precipitated 
nearly completely within 5 days while, at 10 and 100 µM aggregates, precipitated 
immediately and fibrillogenesis was accomplished at 24 h, respectively, 2 h (Fig. 25). 
These aggregates were shown by TEM to consist mainly of fibrils (Fig. 26C). By contrast, all 
IAPP analogues were soluble even at a 100-fold higher concentration than IAPP (100 µM) 
(Fig. 25) and TEM indicated the absence of fibrillar aggregates (data not shown). These 
results demonstrated that the IAPP analogues were at least 100 times more soluble than IAPP.  
 
Fig. 25. Solubilities of IAPP and IAPP analogues at concentrations between 100 and 1 µM as followed by a 
sedimentation assay and TEM.  Incubations of the peptides were performed in 10 mM sodium phosphate buffer, 
pH 7.4 (containing 1% HFIP for the 1 µM peptide concentrations). At various time points solutions were 
centrifuged (20200 g, 20 min) and the amounts of the peptides in pellets and supernatants were determined by 
the BCA assay. Results are means (±SEM) from three to five experiments.  
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3.1.2 Amyloidogenicities 
To quantify the amyloidogenicity of IAPP and the IAPP analogues, the ThT binding assay 
was next employed. Amyloid fibrils of polypeptides and proteins, including IAPP, bind the 
fluorescent dye ThT and the increase in ThT fluorescence emission is broadly used as a 
specific and quantitative assay for fibril formation [283, 284]. IAPP and the analogues were 
incubated at various concentrations (pH 7.4) and the fibril formation process was followed via 
the ThT binding assay. In good agreement to the results of the sedimentation assay (Fig. 25), 
IAPP aggregated into fibrils even at submicromolar concentrations (625 nM) (Fig. 26A). 
 
Fig. 26. Fibrillogenesis of IAPP and IAPP analogues as assessed by the ThT assay and TEM. (A)-(B) ThT 
fluorescence versus time of IAPP and IAPP analogues. (A) Incubations of IAPP and IAPP-GI at 625 nM, 
and (B) incubations of IAPP and IAPP analogues at 62.5 µM in 10 mM Tris buffer, pH 7.4, containing 2% 
HFIP. At the indicated time points, aliquots of the solutions were mixed with a ThT solution and ThT 
binding was determined. Results are means (±SEM) from 3 experiments (performed in triplicates). (C) 
TEM (bars, 100 nm) of aged incubations of 1 µM IAPP (4 days, left) and 100 µM IAPP (2 h, middle) and 
100 µM IAPP-GI (14 days, right).  Incubations of the peptides were performed in 10 mM sodium phosphate 
buffer, pH 7.4 (containing 1% HFIP for the 1 µM peptide concentrations) at room temperature [256].   
 
By contrast, IAPP-GI did not bind ThT at that concentration. Moreover, all IAPP analogues 
did not bind ThT even when a 100-fold higher concentration than IAPP was applied (62.5 µM; 
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incubation for 14 days) (Fig. 26B). Thus, all IAPP analogues were at least 100-fold less 
amyloidogenic than IAPP at physiological pH. The formation of insoluble fibrillar precipitates 
by IAPP was also confirmed by transmission electron microscopy (TEM). IAPP and the IAPP 
analogues were incubated in aqueous buffer (pH 7.4) for up to 14 days. A solution of 1 µM 
IAPP was found mainly to consist of mature fibrils at the time-point of 4 days (Fig. 26C, left) 
while a 100 µM IAPP solution consisted mainly of fibrils following only 2 h of incubation (Fig. 
26C, middle). By contrast, no fibrillar aggregates were present in solutions of 100 µM IAPP-GI 
and the other analogues (data not shown) even after 14 days (Fig. 26C, right). These results 
were in good agreement with the results of the ThT assay (Fig.  26A and 26B).   
 
 
3.1.3 Conformation and amyloidogenicities 
Next, the conformation of IAPP and the IAPP analogues were determined by far-UV CD 
spectroscopy. For these measurements, peptides were dissolved in aqueous buffer (5 µM, pH 
7.4) and CD spectra were obtained at time 0 following preparation of the solution and at 
several time points thereafter. As shown in Figure 27A, the spectrum of IAPP immediately 
following solution preparation had a pronounced minimum at 204 nm. This indicated the 
presence of significant amounts of unordered structure (minimum at 195～200 nm). By 
contrast, the spectra of the analogues IAPP-GI, IAPP-LA, and IAPP-FA were characterized 
by two minima at 225 nm and 205 nm which was indicative of more ordered, most likely β-
sheet- and/or β-turn-containing, conformations. The spectrum of IAPP-LI had a minimum at 
225 nm and differed thus from the spectra of the other analogues. The shape of the spectrum 
of IAPP-LI also indicated the presence of significant amounts of ordered structure. CD 
concentration dependence studies with IAPP-GI (Fig. 27B) indicated that the peptide 
populated similarly ordered conformational states between 500 nM～15 µM. However, at 
higher concentrations (25 µM and 50 µM) a pronounced increase of the minimum at ~200 nm 
was observed which suggested a concentration-dependent change of its conformation. The 
CD spectrum of IAPP-GI at higher concentrations might reflect an oligomerization induced 
increase of the contribution of specific conformations such as β-turn and/or the Poly-Prolin-II 
helix. Interestingly, the magnitudes of the CD spectra of all IAPP analogues were weak 
suggesting the presence of oligomers. Time-dependence CD studies showed that IAPP (5 µM) 
was initially in a predominantly unordered state and aggregated after ~3.5 h into soluble β-
sheets (minimum at 217 nm) and insoluble fibrils (Fig. 27C). TEM examination of the IAPP 
solution at that time-point confirmed that it consisted mainly of amyloid fibrils (Fig. 27C, insets). 
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By contrast, the CD spectrum of IAPP-GI (5 µM) did not change over a 14-day period (Fig. 
27D) suggesting that the peptide was constrained in a stable non-amyloidogenic conformation. 
In fact, TEM examination of the IAPP-GI solution confirmed the complete absence of 
amyloid fibrils (Fig. 27D, insets) which was consistent with IAPP-GI being in a soluble and 
non-fibrillar state over 14 days. 
 
Fig. 27. Far-UV CD and TEM studies (A) CD spectra of IAPP and IAPP analogues (5 µM in 10 mM sodium 
phosphate buffer, pH 7.4 containing 1% HFIP) at time 0 min following the begin of incubation. (B) IAPP-GI far-
UV CD concentration dependence studies, the concentration of IAPP-GI solutions (10 mM sodium phosphate 
buffer, pH 7.4 containing 1% HFIP) were between 500 nM and 50 µM. (C) Time dependence Far-UV CD studies of 
IAPP. CD spectra of IAPP incubation (5 µM in 10 mM sodium phosphate buffer, pH 7.4 containing 1% HFIP) were 
measured at various time points. Insets: TEM of IAPP incubation at 3.5 h (bars, 100 nm) [256]. (D) Time 
dependence Far-UV CD studies of IAPP-GI. CD spectra of IAPP-GI incubation (5 µM in 10 mM sodium 
phosphate buffer, pH 7.4 containing 1% HFIP) were measured at various time points. Insets: TEM of IAPP-GI at 14 
days (bars, 100 nm) [256]. Spectra shown in (A) - (D) are representative of 2-3 independent experiments. 
 
3.1.4 Self-assembly states  
To obtain more information about the self-assembly state of IAPP and the IAPP analogues in 
aqueous solution, SEC assay was performed. IAPP and the IAPP analogues (6.25 µM) were  
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Fig. 28. Self-assembly states of IAPP and the IAPP analogues as determined by SEC. IAPP (A), IAPP-GI (B), 
IAPP-LA (C), IAPP-FA (D), IAPP-LI (E) were incubated in elution buffer (6.25 µM in 10 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl) at room temperature and 800 µl (20 µg) aliquots were 
applied to the column (after centrifugation) at the indicated time points. The column was calibrated with proteins 
and peptides of known molecular weight as described in Materials and Methods. Results shown in (A)-(E) are 
representative of 2-3 assays. 
 
incubated in the elution buffer (pH 7.4) and 800 µl aliquots were applied onto the column 
after centrifugation at various time points. The column was calibrated with proteins and 
peptides of known molecular weights (MW). As shown in Fig. 28, IAPP formed monomers, 
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dimers and tetramers directly following its dissolution in aqueous buffer (Fig. 28A). Kinetic 
follow up of its association indicated that 90% of the amount of IAPP further aggregated into 
large and pertly insoluble aggregates which were separated during centrifugation or could not 
pass through the column (Fig. 28A). Freshly dissolved IAPP-GI formed monomers and 
dimmers and then further associated into tetramers and a few other soluble oligomers. 
Importantly no insoluble aggregates were found by IAPP-GI (Fig. 28B). Freshly dissolved 
IAPP-LA formed mainly dimers, few monomers, tetramers and octamers and no significant 
changes were obtained up to 48 h (Fig. 28C).  IAPP-FA formed monomers, dimers and 
tetramers directly after dissolution while 24 h later it further associated into octamers, other 
low MW oligomers, and high MW aggregates (Fig. 28D). IAPP-LI formed monomers, dimers 
and tetramers when freshly dissolved in buffer and thereafter, it associated into octamers and 
various different oligo- and high MW multimers which were either insoluble or could not pass 
through the column (Fig.  28E). This data indicated that the IAPP analogues had pronounced 
self-association propensities.  
 
Fig. 29. Formation of oligomers of IAPP and the IAPP analogues as assessed by oligomerization assay (peptides 
50 µM in 10 mM sodium phosphate buffer, pH 7.4) with NuPAGE, and Western blot analysis with anti-IAPP 
antibodies. Lanes (from left to right), MW (kDa), IAPP-LI (24 h, 0 h), IAPP-FA (24 h, 0 h), IAPP-LA (24 h, 0 h), 
IAPP-GI (24 h, 0 h), and IAPP (24 h, 0 h). Equal amounts of IAPP and the IAPP analogues were loaded 
throughout all lanes. Blots shown are representative of 2 assays.  
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NuPAGE electrophoresis without any boiling procedure. Species containing IAPP and the 
IAPP analogues were then visualized by WB with anti-IAPP antibody (Fig. 29). The WB 
results showed the presence of monomers and various oligomeric assemblies including di- to 
decamers in freshly dissolved IAPP and IAPP further aggregated into multimers with MWs 
higher than 40 kD after 24 h while only monomers were observed in freshly dissolved and 24 
h incubated IAPP-GI (Fig. 29). Freshly dissolved IAPP-LA and IAPP-FA consisted 
monomers and dimers while IAPP-LI only monomers, and after 24 h incubation all the three 
peptides formed tri- to octamers and other low MW oligomers (Fig. 29). According to the 
oligomerization assay, IAPP-GI had a reduced oligomerization propensity as compared to 
IAPP and the other analogues. 
 
 
3.1.5 Effects on β-cell cell viability  
Next, the effects of IAPP and the IAPP analogues on β-cell cell viability were studied by the 
MTT reduction assay. Peptides (16.5 µM each) were first incubated in aqueous buffer (pH 7.4) 
for 7 days for the studies shown in Fig. 30A. Aliquots of the solutions were then diluted with 
cell culture medium and added to the RIN 5fm cells at the indicated final concentrations and 
cell viabilities were assessed by measuring the cellular reduction of MTT. This assay showed  
 
Fig. 30. Effects of IAPP versus the analogues on viability of RIN 5fm cell. (A) Peptides (16.5 µM in 50 mM 
sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) were incubated for 7 days. Aliquots 
were then diluted with cell culture medium and added to the RIN 5fm cells at the indicated final concentrations. 
Cell viabilities were assessed via the MTT reduction assay.  (B) Peptides (2 mM in water containing 10% acetic 
acid) were incubated for 4 days. Following neutralization with ammonia solution, aliquots were diluted with cell 
culture medium and then added to RIN 5fm cells. Cell viabilities were assessed via the MTT reduction assay. 
Data in (A) and (B) are means (±SEM) of 3 assays (performed in triplicates). 
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that while IAPP was strongly cytotoxic to ß-cells, the analogues were completely devoid of 
any cytotoxicity. The peptides were then incubated under conditions which were previously 
found to be strongly amyloidogenic for IAPP at (peptide concentration 2 mM in 10% acetic 
acid for 4 days). After neutralization with ammonia solution, aliquots of the solutions were 
diluted with cell culture medium and added to the RIN 5fm cells at the indicated final 
concentrations (Fig. 30B). As expected, the MTT reduction assay showed that fibrillated IAPP 
solution was strongly cytotoxic. Interestingly, when applied to the cells at a 10 µM 
concentration, the 4 days aged solutions of IAPP-GI, IAPP-LA, and IAPP-FA were found to 
contain few cytotoxic species too while 4 days aged IAPP-LI was still devoid of any cytotoxic 
properties (Fig. 30B). These results demonstrated that even under these extreme 
amyloidogenesis inducing conditions, the analogues were much less cytotoxic than IAPP (Fig. 
30B). The reduced ability of the N-methylated analogues to misfold and self-assemble into 
cytotoxic species correlated thus with their low amyloidogenic potentials. 
 
 
3.1.6 Studies on their abilities to stimulate adenylate cyclase 
IAPP exhibits several of its biological actions via binding to G protein-coupled receptors and  
activation of adenylate cyclase. Such high affinity receptors are expressed in the human breast 
carcinoma cell line MCF-7. To evaluate the receptor agonistic potency of the IAPP analogues, 
the adenylate cyclase activation potency of the analogues vesus IAPP was next studied using 
the MCF-7 cell line. Peptides were dissolved in assay medium and were applied to the cells 
immediately thereafter. Following incubation for 15 minutes at 37 °C, generated cAMP was 
quantified following cell lysis by ELISA. The analogues were found to exhibit the same 
maximum effect on adenylate cyclase stimulation as IAPP which suggested that they are full 
agonists of the human IAPP receptor (Fig. 31). The adenylate cyclase activation isotherms 
showed that IAPP-LA was the most potent agonist (2.5-fold more potent than IAPP) 
whereas IAPP-GI was the least potent one (7-fold less potent than IAPP). The EC50 of IAPP 
and the analogues are shown in Table 6. Their adenylate cyclase activation potencies follow 
the order IAPP-LA > IAPP > IAPP-LI > IAPP-AF > IAPP-GI. rIAPP which is a natively non-
amyloidogenic IAPP analog that differs from IAPP (human) in 6 residues was also studied 
and its adenylate cyclase activation potency (EC50 265 pM) was found to be very similar to 
the potency of IAPP-LA (Fig. 31). Together, these results showed that all IAPP analogues are 
full IAPP receptor agonists and indicated that there are specific structural features within the 
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IAPP region 24-27 which are closely associated with receptor activation. These results 
suggested that it might be possible to tailor IAPP bioactivity by relocating the N-methyl 
residues. 
 
Table 6.  Adenylate cyclase activation potency (EC50) of IAPP, rIAPP and the analogues 
peptide IAPP IAPP-GI IAPP-LA IAPP-AF IAPP-LI rIAPP 
EC50 631 pM 4.4 nM 249 pM 1.6 nM 1.4 nM 265pM 
 
 
Fig. 31. Adenylate cyclase activation potentials of IAPP, rIAPP, and the analogues in MCF-7 cells. Following 
dissolution in assay medium (RPMI 1640 containing 0.1% (W/V) BSA), peptides were incubated for 15 min at 37 
°C with MCF-7 cells. Following cell lysis generated cAMP was quantified via a cAMP ELISA assay. Results are 
expressed as percent of maximum adenylate cyclase activation above the basal level and maximum stimulation was 
the stimulation caused by 1 µM IAPP. Results are means (±SEM) of 3-4 assays (performed in duplicates). 
 
 
3.1.7 Effects of storage time on agonistic potency  
Due to the high aggregation propensity of IAPP, aqueous IAPP solutions are expected to lose 
their biological activity when standing for longer time periods. To assess whether solutions 
containing the IAPP analogues are able to keep their bioactivities for longer time periods, the 
adenylate cyclase activation potencies of such solutions were next studied. The analogues 
IAPP-GI (the weakest agonist) and IAPP-LA (the strongest agonist) were selected for these 
studies. Their adenylate cyclase activation potencies following incubation of highly 
concentrated solutions in neutral pH for 4 days were compared with the adenylate cyclase 
activation potency of an IAPP solution which has been aged under the same conditions. 250 
µM solutions of IAPP, IAPP-GI, and IAPP-LA in aqueous buffer (pH 7.4) were incubated for 
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4 days at room temperature. At the indicated time points, aliquots were mixed with assay 
medium and added to the human breast carcinoma cell line MCF-7. Following incubation for 
15 minutes at 37 °C, generated cAMP was quantified. In fact, the maximum effect of IAPP 
was found to decrease by about 50% within 48 h. By contrast, the effects of IAPP-GI and 
IAPP-LA did not change for up to 96 h (Fig. 32). This data demonstrated that storage of 
highly concentrated solutions of IAPP-GI and IAPP-LA did not affect their biological activity 
for at least 4 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32. IAPP-analogues keep their receptor agonistic potency. 250 µM solutions of IAPP, IAPP-GI, and IAPP-LA 
were incubated in aqueous buffer (10 mM sodium phosphate buffer, pH 7.4) at room temperature. At the indicated 
time points, aliquots were mixed with assay medium and added to MCF-7 cells at a final concentration of 1 µM. 
Generated cAMP was then quantified via ELISA. Results are means (±SEM) of 3 assays (performed in duplicates). 
 
 
3.2 Inhibition of IAPP amyloidogenesis and cytotoxicity by the IAPP analogues 
3.2.1 Interaction of IAPP-GI with IAPP as studied by CD and a pull-down assay 
To address the question whether IAPP-GI interacts with IAPP, far-UV CD spectroscopy was 
first performed. For the far-UV CD experiments a 5 µM IAPP solution (pH 7.4) was used 
which corresponds to a kinetically soluble but supersaturated IAPP solution. CD spectra of 
the following solutions were measured: IAPP alone, a mixture of IAPP with IAPP-GI (1:1), 
and IAPP-GI alone (5 µM).  All measurements were performed in the same buffer system (pH 
7.4). The CD spectrum of the mixture in the presence of IAPP-GI at time 0 following the 
begin of incubation differed markedly from the sum of the spectra of IAPP and IAPP-GI (at 
time 0 h) which indicated that IAPP-GI interacted with IAPP (Fig. 33A). The spectrum of the 
mixture exhibited minima at 208 nm and 222 nM which indicated increased α-helical contents 
as compared to IAPP alone.   
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Fig. 33. Binding of IAPP-GI to IAPP as studied by far-UV CD and a pull-down assay. (A) Far-UV CD spectra of 
IAPP (5 µM), IAPP-GI (5 µM), the mixture of IAPP with IAPP-GI (1/1) and the spectrum corresponding to the 
sum of the CD spectra of IAPP alone and IAPP-GI alone are shown. CD measurements were performed in 10 
mM sodium phosphate buffer, pH 7.4, 1% HFIP. (B) Binding of Dig-IAPP-GI to Biotin-IAPP as assessed by a 
biotin pull-down assay: Upper panel, anti-digoxigenin western blot analysis of a mixture of Dig-IAPP-GI with 
Biotin-IAPP (2.5 µM each in 10 mM sodium phosphate buffer, pH 7.4) and suitable controls following biotin 
pull-down and peptide dissociation. Lane,” Dig-IAPP-GI input”: input (100%) (freshly dissolved peptide (4 µg) 
not incubated with beads); lane, “Biotin-IAPP”: Biotin-IAPP alone; lane “Dig-IAPP-GI”: Dig-IAPP-GI alone 
(nonspecific binding (NSB) of Dig-IAPP-GI for lane “mixture”); lane, “mixture”: mixture of Dig-IAPP-GI and 
Biotin-IAPP-GI; lane “Biotin-IAPP input”: Biotin-IAPP input (100%, 4 µg). Lower panel, anti-biotin western 
blot analysis of the same mixture as in upper panel. Lanes are as in upper panel. The band densities of the anti-
digoxigenin western are also shown. NSB of Dig-IAPP-GI was 4% of input. Results shown in (A) and (B) are 
representative of 3 independent experiments. The figure (B) shown is from ref. [256]. 
 
The ability of IAPP-GI to bind IAPP was then further confirmed by a pull-down assay in 
combination with NuPAGE gel electrophoresis and WB (Fig. 33B). N-terminally 
digoxigenin-labeled IAPP-GI (Dig-IAPP-GI) (2.5 µM, pH 7.4) was incubated (1 h at room 
temperature) with N-terminally biotinylated IAPP (Biotin-IAPP) (2.5 µM) and complexes 
were isolated by binding Biotin-IAPP on streptavidin-coated magnetic beads. Following 
dissociation, components were revealed by NuPAGE in combination with WB with anti-
biotin and anti-digoxigenin antibodies. The anti-digoxigenin WB showed the presence of 
significant amounts of Dig-IAPP-GI demonstrating that IAPP-GI binds IAPP. 
 
3.2.2 IAPP-GI inhibits IAPP misfolding into cytotoxic β-sheets and fibrils 
To examine whether interaction of IAPP-GI with IAPP could inhibit IAPP misfolding und 
self-assembly into β-sheet oligomers and fibrils, far-UV CD spectroscopy and TEM were 
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used. IAPP (5 µM, pH 7.4) was incubated alone or in the presence of IAPP-GI (5 µM) and 
CD spectra were measured at various time points. At indicated time points, aliquots were 
subjected to TEM while UV spectra were measured to control for peptide loss due to 
insolubilization. IAPP aggregated into soluble β-sheets and insoluble aggregates precipitated 
within 2.5 h (Fig. 34A). TEM at this time point showed that these aggregates consisted mainly 
of fibrils (Fig. 34A, inset). In the presence of IAPP-GI, however, no insolubilization occured 
(14 days) and the spectrum did not change over 14 days (Fig. 34B). TEM between 24 h - 14 
days showed soluble round oligomers and chain-like assemblies of spherical oligomers and no 
fibrillar aggregates were detected even at 14 days (Fig. 34B, inset). 
To obtain a quantitative estimation of the effect of IAPP-GI on IAPP fibrillogenesis, IAPP 
fibrillization in the absence or presence of IAPP-GI was next followed by the ThT binding 
assay. IAPP alone (16.5 µM) and the mixture of IAPP with IAPP-GI (16.5 µM each) were first 
incubated in aqueous buffer (pH 7.4) for 14 days for the studies shown in Fig. 34C. 
Fibrillization of IAPP exhibits about 30 min lag-time and conversion of IAPP into fibrils was 
accomplished within 8 - 24 h. In the presence of IAPP-GI (at 1/1), however, fibril formation 
was completely suppressed (14 days). The ThT binding assay was then also performed in the 
presence of 2% HFIP (IAPP fibrillogenesis accelerating condition). IAPP (6.25 µM) was 
incubated alone or in the presence of IAPP-GI (6.25 µM) in aqueous buffer (pH 7.4) containing 
2% HFIP. As shown in Fig. 34D, IAPP fibrillization had no lag-time and aggregated into fibrils 
within 2-8 h, while no ThT binding was found in the mixture of IAPP with IAPP-GI.  
To investigate if interaction of IAPP-GI with IAPP could also inhibit formation of cytotoxic 
IAPP aggregats, aliquots of 1/1 mixtures of IAPP with IAPP-GI (from (C) and (D)) and of 
incubations of IAPP alone (from (C) and (D)) were added to RIN 5fm cells at various time 
points and cytotoxicities were assessed by MTT reduction (Fig. 34E and 34F). IAPP was 
non-cytotoxic at time 0 under the experimental conditions with lag-time, while it was strongly 
cytotoxic under the conditions without lag-time at time 0 h. At time 24 h, IAPP under both 
conditions had already reached a maximum of cytotoxicity. However, when IAPP-GI was 
present formation of cytotoxic IAPP species was completely blocked for at least 2 weeks (Fig. 
34E). Even under fibrillogenesis accelerating conditions, formation of cytotoxic IAPP species 
was nearly completely suppressed (Fig. 34F). Together, the above studies showed that IAPP-
GI completely blocked formation of cytotoxic IAPP assemblies and fibrils at a ratio of 1:1 
(IAPP/IAPP-GI), suggesting that IAPP-GI binds early prefibrillar IAPP species and blocks 
their further conversion into cytotoxic oligomers and fibrils. 
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Fig. 34. Inhibition of IAPP misfolding, fibrillogenesis and cytotoxicity by IAPP-GI as studied by far-UV CD, 
ThT binding and cytotoxicity assays and TEM studies. (A) and (B) Far-UV CD and TEM studies: The 
conformation of (A) IAPP alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4, 1% HFIP ) versus (B) a 
mixture of IAPP and IAPP-GI (5 µM each) was followed by CD over 14 days. CD spectra at various time points 
up to 14 days are shown. Insets: TEM of the incubations at 2.5 h (IAPP) and 14 days (mixture of IAPP and 
IAPP-GI) (bars, 100 nm). Spectra shown in (A) and (B) are representative of 3 independent experiments. (C) 
Fibrillogenesis of IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 
0.5% HFIP) and of a mixture of IAPP with IAPP-GI (1/1, 16.5 µM each) as assessed by ThT binding assay. (D) 
Fibrillogenesis of IAPP (6.25 µM in 10 mM Tris buffer, pH 7.4, containing 2% HFIP) and of a mixture of IAPP 
with IAPP-GI (1/1, 6.25 µM each) as assessed by ThT binding assay. (E) and (F) Effects of IAPP versus a 
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mixture of IAPP and IAPP-GI (solutions from (C) and (D) respectively) on the RIN 5fm cells viability as 
assessed by MTT reduction assay.  Data  in (C)-(F) are means (±SEM) from 3-4 assays (performed in triplicates). 
The TEM 0f IAPP and the mixture of IAPP and IAPP-GI shown are from ref. [256]. 
 
 
Fig. 35. Titration of IAPP with various amounts of IAPP-GI (A) Fibrillogenesis of IAPP (16.5 µM in 50 mM 
sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) and of a mixture of IAPP and 
IAPP-GI (1/1 to 1/10-5) as assessed by ThT binding assay. (B) Effects of IAPP versus a mixture of IAPP and 
IAPP-GI (solutions from (A) at 24 h) on β-cell viability as assessed by MTT reduction assay. (C) Determination 
of the affinity of the IC50 of the inhibitory effect of IAPP-GI on IAPP fibrillogenesis via titration of IAPP with 
IAPP-GI using the ThT binding assay. Data are from (A) at 24 h.   (D) Determination of the IC50 of the inhibitory 
effect of IAPP-GI on formation of cytotoxic IAPP species (at 500 nM) via titration of IAPP with IAPP-GI using 
the MTT reduction assay. Data in (A)- (D) are means (±SEM) from 4-5 assays (performed in triplicates). 
 
The inhibitory effect of IAPP-GI on formation of fibrils of IAPP (16.5 µM) following 
addition of various amounts of IAPP-GI was next followed by the ThT binding assay (Fig. 
35A). In addition, these solutions were also added to RIN 5fm cells (following of incubation 
24 h) and cell viabilities were assessed by the MTT reduction assay (Fig. 35B). IAPP-GI 
significantly inhibited IAPP fibril formation and cytotoxicity even when applied at a 10-fold 
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lower concentration (1/0.1) than IAPP (Fig. 35A and 35B), while it still affected both IAPP 
amyloidogenicity and cytotoxicity even at a 1000-fold lower concentration than IAPP. Two 
sigmoidal titration curves were obtained as shown in Fig. 35A and Fig. 35B and app. affinities 
of 70 nM and 28 nM were determined by curve fitting for the inhibitory effects of IAPP-GI on 
IAPP fibrillogenesis and cytotoxicity, respectively. Of note, a 1/1 molar ratio of IAPP-GI to 
IAPP caused maximal inhibition of cytotoxicity (Fig. 35C and 35D). These results showed 
that IAPP-GI is a low nanomolar activity inhibitor of both IAPP fibrillogenesis and 
cytotoxicity. 
 
 
3.2.3 IAPP-GI redissolves cytotoxic IAPP aggregates and fibrils and reverses their 
cytotoxic effects 
To test whether IAPP-GI could block or reverse already started IAPP fibrillogenesis processes, 
fibrillization of a solution of IAPP alone (16.5 µM, pH 7.4) versus the same solution 
following addition of IAPP-GI (16.5 µM) at various time points of the fibrillization process 
were followed using the ThT binding assay. IAPP-GI (at 1/1) was able to completely block 
IAPP fibrillization regardless of the stage of the process, i.e. both when added before and after 
the begin of fibrillogenesis (Fig. 36A). Most importantly, IAPP-GI was found to be able to 
redissolve IAPP fibrils and, thus, to reverse an already started IAPP fibrillogenesis process 
(Fig. 36A). To address the issue if IAPP-GI mediated dissolution of IAPP fibrils and possibly 
of non-fibrillar aggregates would also result in a reversement of cytotoxicity, solutions of the 
above ThT binding assays were applied to RIN 5fm cells (at 24 h) and cell viabilities were 
assessed via the MTT reduction assay. In parallel, the cytotoxicity of IAPP at the same time-
points but before addition of IAPP-GI was also determined. In fact, IAPP-GI (at 1/1) was 
found to be able to nearly quantitatively reverse the cytotoxic effects of already formed IAPP 
aggregates and fibrils (Fig. 36B). Of note, the cytotoxicity of IAPP alone already reached a 
maximum at 4 h (Fig. 36C). To see whether IAPP-GI could also redissolve mature IAPP 
fibrils, IAPP fibrils were made by incubating IAPP for 3 days, quantified via BCA analysis 
and, thereafter, IAPP-GI was added at various different molar amounts including 1/1, 1/10, 
and 1/50. The solutions were incubated for 3 days and, thereafter, the fibrils were quantified 
by the ThT binding assay and cytotoxicities were determined by the MTT reduction assay. In 
fact, IAPP-GI at a 10-50-fold excess with regard to IAPP (monomers) completely dissolved 
mature IAPP fibrils (Fig. 36D), while at a 50-fold excess it was found to be able to completely  
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Fig. 36. Dissolution of preformed IAPP fibrils and cytotoxic IAPP aggregates by IAPP-GI as studied by ThT 
binding and MTT reduction assays. (A) Dissociation of IAPP fibrils by IAPP-GI (1/1) as followed by ThT binding 
assay. IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) was 
allowed to aggregate. At the indicated time points aliquots were mixed with IAPP-GI (1/1) and fibrillogenesis of 
IAPP alone versus the mixtures was quantified by the ThT binding assay. (B) Reversal of cytotoxicity of IAPP 
oligomers and fibrils by IAPP-GI. Solutions of (A) were added to RIN 5fm cells (at 24 h) at the indicated final 
concentrations. Cell viability was assessed via the MTT assay. (C) Assessment of cytotoxicity of IAPP following 
aging for the indicated time-points (0-24 h) via the MTT reduction assay. (D) Dissociation of mature IAPP fibrils 
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by IAPP-GI. Fibrillar IAPP was prepared from a 3 days aged IAPP solution (16.5 µM in 50 mM sodium phosphate 
buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP). The IAPP fibrils were first quantified by the BCA assay 
and then they were mixed with various amounts of IAPP-GI (IAPP/IAPP-GI molar ratio as indicated). The 
solutions, including a control fibrillar “IAPP alone” solution, were then incubated for 3 days and fibrils were 
quantified by the ThT binding assay. (E) Assessment of cytotoxicities of solutions of (D) by the MTT reduction 
assay. (F) Cytotoxicity of fibrillar IAPP versus IAPP/IAPP-GI (molar ratio 1/50) at the indicated time-points was 
determined via the MTT reduction assay. Data in (A)-(F) are means (±SEM) from 3 assays (performed in 
triplicates). 
 
redissolve cytotoxic IAPP species (Fig. 36E). The cytotoxicity of a mixture of IAPP fibrils 
containing a 50-fold molar excess of IAPP-GI was then assessed at various time-points 
following solution preparation. A strongly reduced cytotoxicity was found already 24 h after 
addition of IAPP-GI while IAPP cytotoxicity was completely abolished after 72 h. These data 
clearly showed that IAPP-GI was able to redissociate already formed mature IAPP fibrils. 
 
 
3.2.4 IAPP-GI inhibits the nucleating effect of IAPP fibrillar seeds on IAPP fibrillogenesis 
To test if IAPP-GI would be able to inhibit the nucleating effect of exogeneously added 
fibrillar seeds on IAPP fibrillogenesis, the effect of seeding an IAPP-IAPP-GI mixture with 
IAPP fibrils was next studied. An aliquot of an aged and fibrillar IAPP solution was added 
(0.1 molar equivalent) to an IAPP solution and to a mixture of IAPP with IAPP-GI (1/1).   
 
Fig. 37. Inhibition of the nucleation effect of IAPP fibrillar seeds on IAPP fibrillogenesis and cytotoxicity by 
IAPP-GI (A) IAPP (6.25 µM in 10 mM Tris buffer, pH=7.4) in the absence or presence of IAPP-GI (1/1) was 
seeded with IAPP fibrils.  Fibrillogenesis was followed by the ThT binding assay. (B) Cytotoxicities of solutions 
of (A) at 72 h were assessed by the MTT reduction assay. Results in (A) and (B) are means (±SEM) from 3-4 
assays (performed in triplicates). 
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Fibrillogenesis and cytotoxicities were then assessed by ThT binding and MTT reduction 
assays. Incubations were made with 6.25 µM IAPP (pH=7.4, without HFIP) which are 
condition leading to a 48 h lag-time in the fibrillogenesis process of IAPP (Fig. 37A). As 
expected, seeding with preformed IAPP fibrils resulted in an immediate begin of 
fibrillogenesis and accelerated formation of cytotoxic assemblies (Fig. 37A and 37B). In the 
presence of IAPP-GI (1/1), however, the seeding effect of IAPP fibrils was completely 
blocked and formation of new cytotoxic assemblies and fibrils was completly suppressed (Fig. 
37A and 37B). These results further supported the suggestion that IAPP-GI binds IAPP 
prefibrillar monomers and/or other early species of the fibrillogenesis pathway inhibiting thus 
their conversion into cytotoxic oligomers and fibrils. 
 
 
3.2.5 Interaction of the IAPP analogues IAPP-LA, IAPP-FA, and IAPP-LI with IAPP as 
studied by far-UV CD 
Far-UV CD was used to examine the interaction of IAPP with the IAPP-analogues IAPP-LA, 
IAPP-FA, and IAPP-LI. Therefore, spectra of IAPP alone (5 µM , pH 7.4) or in the presence 
of IAPP-LA (5 µM), IAPP-FA (5 µM), or IAPP-LI (5 µM) and also spectra of each of the 
analogues alone (5 µM) were measured. The spectra of the mixtures at time 0 h following begin 
of incubation strongly differed from the sum of the spectra of IAPP with each of the analogues 
which indicated that IAPP-LA, IAPP-FA, and IAPP-LI had interacted with IAPP (Fig. 38A-
38C). Of note, the shapes of the spectra of the mixtures were very similar to the spectra of the 
analogues alone indicating a strong effect of the IAPP analogues on IAPP conformation. Also, 
while the shapes of the spectra of the mixtures of IAPP with IAPP-LA, and IAPP-FA were very 
similar to each other, the spectra of the IAPP-GI-IAPP and IAPP-LI-IAPP mixtures strongly 
differed from the spectra of other mixtures (Fig. 38D). This indicated a different conformation 
of the IAPP-IAPP-LI and IAPP-IAPP-GI complexes as compared to the other complexes.  
 
 
3.2.6 IAPP-LA, IAPP-FA and IAPP-LI cannot block IAPP misfolding into β-sheets 
The effect of the interaction of IAPP-analogues with IAPP on the conformational transition of 
IAPP into β-sheets was next examined by CD. Solutions of IAPP alone (5 µM, pH 7.4) or of 
mixture of IAPP with IAPP-LA, IAPP-FA, and IAPP-LI (1/1) were allowed to age and CD 
spectra were measured at various time points (Fig. 39). IAPP alone misfolded into β-sheets 
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and formed insoluble aggregates within 4 h (Fig. 39A).  The mixtures of IAPP with IAPP-LA 
and IAPP with IAPP-FA also aggregated into soluble β-sheets while insoluble amyloid 
fibrils precipitated out of solution at 6 and 8 h, respectively (Fig. 39B and 39C). The mixture 
of IAPP with IAPP-LI was also characterized by a strong increase of the magnitude of the 
existing red shifted β-sheet minimum at 225 nm indicating an aggregation dependent 
conformational transition process. Insoluble aggregates precipitated after 6 h (Fig. 39D). Thus, 
in contrast to IAPP-GI, the analogues IAPP-LA, IAPP-FA, and IAPP-LI were unable to block 
IAPP misfolding into β-sheets. 
 
Fig. 38. Interaction of IAPP-LA, IAPP-FA, IAPP-LI with IAPP as assessed by far-UV CD spectroscopy  (A) CD 
spectrum of IAPP alone (5 µM) and CD spectrum of the mixture of IAPP with IAPP-LA (1/1) at time 0 h 
following begin of incubation. For comparison, the sum of the CD spectra of IAPP and IAPP-LA is also shown. 
(B) Far-UV CD spectra of IAPP (5 µM), IAPP-FA (5 µM), and the mixture of IAPP with IAPP-FA (1/1) as also 
the spectrum corresponding to the sum of the CD spectra of IAPP and IAPP-FA as well are shown. (C) Far-UV 
CD spectra of IAPP (5 µM), IAPP-LI (5 µM), and the mixture of IAPP with IAPP-LI (1/1) as also the spectrum 
corresponding to the sum of the CD spectra of IAPP and IAPP-LI are shown. (D) CD spectrum of IAPP alone (5 
µM) and of the mixtures of IAPP with IAPP-GI, IAPP-LA, IAPP-FA, and IAPP-LI (1/1) at time 0 h following begin of 
the incubations. Experiments were performed in 10 mM sodium phosphate buffer, pH 7.4, containing 1% HFIP. 
Spectra shown in (A)-(D) are representative of 2-3 independent experiments. 
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Fig. 39. Inhibitory effect of IAPP-LA, IAPP-FA and IAPP-LI on IAPP aggregation into β-sheets as studied by far-UV 
CD. (A) CD spectrum of IAPP alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4, 1% HFIP) at various time 
points  (B) - (D) CD spectra of the mixture of IAPP with IAPP-LA (1/1) (B); with IAPP-FA (1/1) (C); with IAPP-LI 
(1/1) (D) recorded between 0 and 6 h or 0 and 8 h following the begin of the incubations and up to the appearance of 
insoluble aggregates are shown. Spectra shown in (A)-(D) are representative of 2-3 independent experiments. 
 
 
3.2.7 IAPP-LA, IAPP-FA, and IAPP-LI partially suppress IAPP fibrillogenesis and 
cytotoxicity  
To investigate if the interaction of the IAPP analogues IAPP-LA, IAPP-FA, and IAPP-LI 
with IAPP could inhibit IAPP fibrillogenesis and cytotoxicity, incubations of IAPP in the 
absence or presence of the analogues (at 1/1) were performed and fibrillogenesis and 
cytotoxicity were assessed by ThT binding and MTT reduction assays. For these studies IAPP 
(16.5 µM, pH 7.4) and the mixtures of IAPP with the analogues (16.5 µM each) were first 
incubated for 14 days. As shown in Fig. 40A, ThT fluorescence of IAPP alone strongly 
increased within 8 h. This steep increase was followed by a plateau which indicated the end of 
the fibrillization process. In the presence of the analogues (at 1/1) the ThT fluorescence also  
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Fig. 40. Effects of IAPP-LA, IAPP-FA and IAPP-LI on IAPP fibrillogenesis and cytotoxicity as assessed by the 
ThT binding assay and the MTT reduction assay. (A) ThT fluorescence versus time of IAPP (16.5 µM in 50 mM 
sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) solutions or mixtures of IAPP (16.5 
µM) with the peptides IAPP-LA, IAPP-FA, and IAPP-LI (16.5 µM).  (B), (C) and (D) Effects of the mixtures of 
IAPP with IAPP-LA (B) or IAPP-FA (C) and IAPP-LI (D) on RIN 5fm viability at different time points as 
indicated. (E) ThT fluorescence versus time of IAPP (6.25 µM in 10 mM sodium phosphate buffer, pH 7.4, 2% 
HFIP) solutions or mixtures of IAPP (6.25 µM) with the peptides IAPP-LA, IAPP-FA, and IAPP-LI (6.25 µM). 
(F) Effects of the mixtures (from (E)) of IAPP with IAPP-LA, IAPP-FA, and IAPP-LI on RIN 5fm viability at 
24 h. Data in (A)-(F) are means (+SEM) of 3 independent experiments (performed in triplicates). 
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increased. Its plateau, however, was reduced as compared to the IAPP solution. Even after 14 
days of incubation, the ThT fluorescence of the mixtures was significantly lower than in the 
IAPP alone incubation suggesting that the analogues inhibited IAPP fibrillization. The kinetic 
profiles of the ThT binding assays suggested that the IAPP analogues caused a reduction of 
the amount of the IAPP fibrils but could not completely suppress IAPP fibril formation. To 
examine if the interaction of the analogues with IAPP could also inhibit formation of 
cytotoxic IAPP aggregates, aliquots of the incubations of the ThT binding assays were added 
to RIN 5fm cells at various time-points and cytotoxicities were assessed by MTT reduction 
assay (Fig. 40B-40D). The cytotoxicity of IAPP alone reached a maximum following aging 
for 24 h. The mixtures of IAPP with the analogues were not toxic when added to the cells 
immediately after solution preparation. However, cytotoxicity increased within 24 h aging and 
it did not change upon further aging up to 14 days (Fig. 40B-40D). Incubation for the ThT 
binding and the MTT reduction assays were then performed in the presence of 2% HFIP (Fig. 
40E and 40F). IAPP (6.25 µM, pH 7.4 containing 2% HFIP) was incubated alone or in the 
presence of the analogues (at 1/1) and applied to RIN5fm cells following aging for 24 h. Cell 
viabilities were assessed via the MTT reduction assay. As shown in Fig. 40E, IAPP 
aggregated into fibrils within 2-8 h, while the amount of IAPP fibrils in the presence of 
the analogues was significantly reduced as compared to IAPP alone. The effect of the 
analogues on IAPP cytotoxicity was similar to the effect of under the 0.5% HFIP containing 
buffers incubation condition (Fig. 40B-40D and 40F). The above results indicated that IAPP-
LA, IAPP-FA, and IAPP-LI (at 1:1) were able to suppress up to a big extend formation of 
cytotoxic IAPP assemblies and fibrils. However, the potencies of the three analogues with 
regard to the incubation of fibrillogenesis were significantly less than the potency of IAPP-GI.  
 
 
3.2.8 Studies on the effects of IAPP-LA, IAPP-FA, and IAPP-LI on already formed 
IAPP fibrils and cytotoxic aggregates  
To study whether IAPP-LA, IAPP-FA and IAPP-LI can reverse already started IAPP 
fibrillogenesis, fibrillization of IAPP (16.5 µM, pH 7.4) with or without the analogues (at 1/1) 
at various time points of the fibrillization process was followed using the ThT binding assay. 
In addition, to study whether these analogues might be able to dissociate already formed 
cytotoxic IAPP aggregates, solutions of the ThT binding assays (at 24 h) were applied to RIN5fm 
cells. Cell viabilities were then assessed via the MTT reduction assay. In parallel, the cytotoxicity 
of IAPP at various time points but before addition of the analogues was also determined.  
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Fig. 41. Studies on the ability of IAPP-LA, IAPP-
FA, and IAPP-LI to redissociate already formed 
IAPP fibrils and cytotoxic aggregates as assessed 
by ThT binding and MTT reduction assays. 
(A)-(C) IAPP (16.5 µM in 50 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM 
NaCl and 0.5% HFIP) was allowed to aggregate. 
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At the indicated time points aliquots were mixed (at 1/1) with IAPP-LA (A), IAPP-FA (B), or IAPP-LI (C) and 
fibrillogenesis of IAPP alone versus the mixtures were quantified by the ThT binding assay. (D) The 
cytotoxicity of IAPP alone at various time points as assessed by the MTT reduction assay. (E)-(F) The 
cytotoxicity of the mixtures from the ThT binding assay at 24 h as assessed by the MTT reduction assay. (E) 
Solutions of the ThT binding assays A, (F) Solutions of the ThT binding assays B, (G) Solutions of the ThT 
binding assays C were added to RIN 5fm cells (at 24 h). Cell viability was assessed via the MTT reduction assay. 
Data in (A)-(G) are means (+SEM) of 3 independent experiments (performed in triplicates). 
 
As shown in Fig. 41A-41C, IAPP-LA, and IAPP-FA (at 1/1) were unable to stop an already 
ongoing IAPP fibrillization process or redissociate fibrils. However, the plateau of ThT 
fluorescence of the mixtures was significantly reduced as compared to IAPP alone (Fig. 41A 
and 41B). This result was consistent with the previous findings (Fig. 40A and 40E) and 
indicated that addition of the analogues caused a decrease in the amount of mature IAPP 
fibrils. However, these two analogues were, in contrast to IAPP-GI, unable to redissociate 
already formed IAPP fibrils. Interestingly, addition of IAPP-LI at the time-point of 30 min. 
nearly completely blocked formation of IAPP fibrils while addition at later time-points (4 h 
and 8 h) resulted in partial fibril redissociation (Fig. 41C). According to the MTT reduction 
assay, IAPP alone was not toxic when added to the cells immediately after solution preparation 
however some cytotoxic species appeared in the 30 min aged solution. Thereafter, 
cytotoxicity increased and reached a maximum between 4 and 8 h (Fig. 41D). All three 
analogues were found to be unable to dissociate cytotoxic IAPP species (Fig. 41E-41G).  
 
 
3.3 Effects of other peptides on IAPP fibrillogenesis and cytotoxicity 
3.3.1 Effect of NFGAIL-GI on IAPP fibrillogenesis and cytotoxicity 
Introduction of two N-methyl rests in the β-sheet- and amyloid core-containing sequence 
IAPP(22-27) or NFGAIL converted this amyloidogenic and cytotoxic sequence into non-
amyloidogenic and non-cytotoxic NF(N-Me)GA(N-Me)IL (IAPP(22-27)-GI or NFGAIL-GI). 
NFGAIL-GI has been previously found to be able to suppress IAPP fibrillogenesis and 
cytotoxicity at a IAPP/NFGAIL-GI ratio of 1/0.1 or 1/10 in the assay system where IAPP 
fibrillization had a lag-time of 48 h (Fig. 42A and 42B) [255]. To directly compare the potency 
of the inhibitory effect of IAPP-GI on IAPP fibrillogenesis with the effect of NFGAIL-GI, 
NFGAIL-GI was mixed with IAPP under the ThT assay conditions used for IAPP-GI studies. 
The fibrillogenesis of IAPP/NFGAIL-GI mixtures were followed by the ThT binding assay 
and their cytotoxicities were then assessed by the MTT reduction assay toward RIN 5fm cells. 
                                                                                                     Results 
 85
 
Fig. 42. Effect of NFGAIL-GI on IAPP fibrillogenesis and cytotoxicity towards RIN 5fm cells as studied by the 
ThT binding and MTT reduction assays. (A) Fibrillogenesis of IAPP (6.25 µM in 10 mM Tris buffer, pH 7.4) and 
of a mixture of IAPP and NFGAIL-GI (1/0.1, 1/10) as assessed by ThT binding. (B) Effects of IAPP versus a 
mixture of IAPP and NFGAIL-GI on cell viability. Solutions of IAPP (5 µM in 10 mM sodium phosphate buffer, 
pH 7.4) and of a mixture of IAPP and NFGAIL-GI (1/0.1, 1/10) were added to the RIN 5fm cells. Cell viability was 
assessed following 20 h incubation of the above solutions with the cells via the MTT reduction assay. (C) 
Fibrillogenesis of IAPP (6.25 µM in 10 mM Tris buffer, pH 7.4, containing 2% HFIP) and of a mixture of IAPP 
and NFGAIL-GI (1/1, 6.25 µM each) as assessed by ThT binding. (D) Effects of IAPP versus a mixture of IAPP 
and NFGAIL-GI on cell viability. Solutions from (C) were added to the RIN 5fm cells at 24 h, cell viability as 
assessed by MTT reduction. (E) Fibrillogenesis of IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, 
containing 100 mM NaCl and 0.5% HFIP) and a mixture of IAPP and NFGAIL-GI (1/1, 16.5 µM each) as assessed 
by ThT binding.  (F) Effects of IAPP versus a mixture of IAPP and NFGAIL-GI on cell viability. Solutions from 
(E) were added to the RIN 5fm cells at 24 h, and cell viability was assessed by the MTT reduction assay. Data in 
(A)-(E) are means (±SEM) from 3 assays (performed in triplicates). 
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Interestingly, NFGAIL-GI was found to be unable to inhibit IAPP fibrillogenesis (Fig. 42C 
and 42E). and cytotoxicity (Fig. 42D and 42F) under these conditions. Thus, NFGAIL-GI was 
in contrast to IAPP-GI unable to inhibit IAPP fibrillogenesis and cytotoxicity at 1/1, which 
might be related to the fact that IAPP solutions were very close to their nucleation points in 
the applied assay system. 
 
 
3.3.2 Effect of CGRP on IAPP fibrillogenesis and cytotoxicity 
Calcitonin gene-related peptide (CGRP) is a 37 amino acid residue neuropeptide that is 
widely distributed in central and peripheral nervous systems in mammals. Here, CGRP was 
mixed with IAPP (1/1) to test its effect on the fibrillization and cytotoxicity of IAPP. In fact, 
CGRP was found to be unable to affect both IAPP fibrillogenesis and cytotoxicity (at 1/1) 
(Fig. 43A and 43B).  
 
Fig. 43. Effect of CGRP on IAPP fibrillogenesis and cytotoxicity as studied by the ThT binding and the MTT 
reduction assays. (A) Fibrillogenesis of IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 
100 mM NaCl and 0.5% HFIP), the mixture of IAPP with CGRP (1/1), and CGRP (16.5 µM) alone as assessed 
by the ThT binding assay. (B) Effects of IAPP versus a mixture of IAPP with CGRP (1/1) on the RIN 5fm cell 
viability as assessed by the MTT reduction assay. Data in (A) and (B) are means (±SEM) from 3-4 assays 
(performed in triplicates). 
 
 
3.3.3 Effect of rIAPP on IAPP fibrillogenesis and cytotoxicity 
rIAPP is a natively non-amyloidogenic and non-cytotoxic IAPP analog that differs from 
(human) IAPP in 6 residues. Here, IAPP fibrillization in the absence or presence of rIAPP, 
and under two different assay conditions systems, was followed by the ThT binding assay. 
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rIAPP (at 1/1) was able to effect  IAPP fibrillization only in the assay system where IAPP 
fibrillization had a lag-time of 0.5 h (Fig. 44A and 44B). In addition, rIAPP was unable to 
block IAPP cytotoxicity in both assay systems (Fig. 44C and 44D).   
 
Fig. 44. Effect of rIAPP on IAPP fibrillogenesis and cytotoxicity as studied by the ThT binding and the MTT 
reduction assays. (A) Fibrillogenesis of IAPP (6.25 µM in 10 mM Tris buffer, pH 7.4, containing 2% HFIP) and 
a mixture of IAPP and rIAPP (1/1, 6.25 µM each) as assessed by the ThT binding assay. (B) Fibrillogenesis of 
IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) and a 
mixture of IAPP and rIAPP (1/1, 16.5 µM each) as assessed by the ThT binding assay. (C) Effects of IAPP 
versus a mixture of IAPP and rIAPP. Solutions from (A) were added to the RIN 5fm cells at 24 h, and cell 
viabilities were assessed by the MTT reduction assay.  (D) Effects of IAPP versus a mixture of IAPP and rIAPP. 
Solutions from (B) were added to the RIN 5fm cells at 24 h, and cell viabilities were assessed by the MTT 
reduction assay.  Data in (A) and (C) are means (±SEM) from 1 assay (performed in triplicates). Data in (B) and 
(D) are means (±SEM) from 3 assays (performed in triplicates). 
 
 
3.3.4 Effect of NFGAIL-GI on preformed IAPP fibrils 
In another experimental set the question whether NFGAIL-GI was able to dissociate already 
formed IAPP fibrils and whethe it was able to stop an already ongoing IAPP fibril formation 
process were addressed. In fact, NFGAIL-GI was found to be unable to stop already started 
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IAPP cytotoxic self-assembly. It was unable to dissociate IAPP fibrils even at a 100-fold 
higher molar excess than IAPP (Fig. 45A and 45B). These results indicated that the effects of 
IAPP-GI on IAPP cytotoxic seif-assembly and fibrillogenesis are specific. 
 
Fig. 45. Effect of  NFGAIL-GI on preformed IAPP oligomers and fibrils as studied by the ThT binding assays. 
(A) IAPP (6.25µM in 10 mM sodium phosphate buffer, pH 7.4, containing 2% HFIP) was allowed to aggregate. 
At the indicated time points aliquots were mixed with NFGAIL-GI (1/1) and fibrillogenesis of IAPP alone 
versus the mixtures was quantified by the ThT assay. (B) Fibrillar IAPP was prepared from a 3 days aged IAPP 
solution (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP). 
Aliquots were then mixed with NFGAIL-GI at the indicated molar ratios. The solutions, including a control 
fibrillar "IAPP alone" solution, were then incubated and fibrils were quantified at 72 h by the ThT binding assay. 
Data in (A) and (B) are means (±SEM) from 2 assays (performed in triplicates). 
 
 
3.4 Inhibition of Aβ(1-40) amyloidogenesis and cytotoxicity by the IAPP-analogues 
3.4.1 Interaction of IAPP-GI with Aβ(1-40) and effect of IAPP-GI on Aβ(1-40) misfolding 
into β-sheets 
To investigate whether IAPP-GI was able to bind Aβ(1-40), far-UV CD spectroscopy and pull 
down assays were used. For the far-UV CD studies, solutions of Aβ(1-40) alone (5 µM), 
IAPP-GI alone (5 µM), and the mixture of Aβ(1-40) with IAPP-GI (5 µM each, pH 7.4) were 
prepared and CD spectra were measured immediately thereafter (time 0 h) (Fig. 46A). The 
spectrum of the mixture differed markedly from the spectrum corresponding to the sum of the 
spectra which indicated that IAPP-GI interacted with Aβ(1-40). In addition, the presence of 
minima at ~225 and ~202 nm indicated the presence of significant amounts of α-helical, β-
sheet and/or β-turn structural contents suggesting that interaction resulted in formation of 
ordered, soluble Aβ(1-40)-IAPP-GI hetero-complexes.  Of note, Aβ(1-40) was in the lag-
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phase of fibrillogenesis under these conditions according to CD (Fig. 46D).  To obtain direct 
evidence for Aβ(1-40)-IAPP-GI hetero-complex formation, an Aβ(1-40) pull-down assay in 
combination with NuPAGE gel electrophoresis and WB was next used (Fig. 46B). Synthetic, 
Nα-terminally biotinylated IAPP-GI (Biotin-IAPP-GI) (2.5 µM) was incubated with freshly 
dissolved Aβ(1-40) (2.5 or 5 µM) for 1 h (pH 7.4). Of note, Aβ(1-40) was in the lag-phase of 
fibrillogenesis according to the ThT binding assay (data not shown).  
 
Fig. 46. Binding of IAPP-GI to Aβ(1-40) and inhibition of IAPP-GI on Aβ(1-40) misfolding into β-sheet as studied 
by far-UV CD and a pull-down assay. (A) Interaction of Aβ(1-40) with IAPP-GI as assessed by far-UV CD: CD 
spectra of Aβ(1-40) alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4 containing 1% HFIP), IAPP-GI alone 
(5 µM), a mixture of Aβ(1-40) and IAPP-GI (1/1), and the mathematical sum of the spectra of Aβ(1-40) and IAPP-
GI are shown. (B) Binding of Aβ(1-40) to Biotin-IAPP-GI as assessed by a biotin pull-down assay: Upper panel, 
anti-Aβ(1-40) western blot analysis of a mixture of Aβ(1-40) (5 µM) and Biotin-IAPP-GI (2.5 µM) versus Aβ(1-40) 
alone (5 µM) following biotin pull-down and peptide dissociation. Lane, “Aβ input”: input (50%) (freshly dissolved 
peptide (4  µg) not incubated with beads); lane, “Biotin-IAPP-GI input”: input (100%, 4  µg); lane, “Biotin-IAPP-
GI”: Biotin-IAPP-GI alone; lane, “mixture”: mixture of Biotin-IAPP-GI and Aβ(1-40); lane, “Aβ NSB”: Aβ(1-40) 
alone (nonspecific binding (NSB) for lane “mixture”). Lower panel, anti-biotin western blot analysis of the same 
mixture as in upper panel. Lanes are as in upper panel. Solutions were prepared in 10 mM sodium phosphate buffer, 
pH 7.4. Blots shown are representative of 3 independent experiments. (C) The conformation of a mixture of Aβ(1-
40) and IAPP-GI (5 µM each, in 10 mM sodium phosphate buffer, pH 7.4 containing 1% HFIP) was followed by 
CD over 14 days. (D) CD spectra of Aβ(1-40) alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4 containing 
1% HFIP) at various time points (in parallel to the experiment shown in (C)). Spectra shown are representative of 2 
independent experiments. The figure (B) shown is from ref. [285]. 
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Biotin-IAPP-GI-Aβ(1-40) complexes were isolated by binding to streptavidin-coated 
magnetic beads. Following complex dissociation and NuPAGE, WB with anti-Aβ(1-40) 
antibodies revealed significant amounts of Aβ(1-40) monomers and dimers in the mixture 
(Fig. 46B). These results demonstrated that Biotin-IAPP-GI bound Aβ(1-40).  
To examine whether interaction of IAPP-GI with Aβ(1-40) could inhibit Aβ(1-40) misfolding 
into β-sheets, the conformation of a mixture of Aβ(1-40) and IAPP-GI (5 µM each, pH 7.4) 
was followed by CD over 14 days (Fig. 46C).  In comparison, CD spectra of Aβ(1-40) alone 
(5 µM, pH 7.4) at various time points up to 14 days were also measured by CD and are shown 
in Fig. 46D. Aβ(1-40) alone was in the lag-phase for about 8 h, and aggregated into soluble β-
sheets as indicated by the increase of the minimum at 217 nm within the next 17 h. At that 
time point (time point of 25 h), formation of insoluble fibrillar aggregates occurred as also 
comfirmed by TEM (data not shown). By contrast, the CD spectra of the Aβ(1-40)-IAPP-GI 
mixture indicated formation of ordered heterocomplexes which did not further aggregate into 
β-sheets and fibrils. Notably, no insolubilization was observed in the Aβ(1-40)-IAPP-GI 
mixture even 14 days after the begin of the incubation.  
 
 
3.4.2 Inhibitory effect of IAPP-GI on Aβ(1-40) cytotoxic self-assembly and fibrillogenesis 
Next, the question was addressed whether IAPP-GI could intervene with Aβ(1-40) self-
assembly into fibrils and affect formation of cytotoxic Aβ(1-40) aggregates. Aβ(1-40) alone 
(16.5 µM, pH 7.4) and the mixture of Aβ(1-40) with IAPP-GI (16.5 µM each, pH 7.4) were 
incubated for 7 days and fibrillogenesis and cytotoxicity were followed by the ThT binding 
and the MTT reduction assay (Fig. 47). According to the ThT binding assay, Aβ(1-40) 
fibrillogenesis (16.5 µM) exhibited a lag-time of ~48 h and reached completion between 72 
and 96 h (Fig. 47A). These results were confirmed by TEM which showed that long mature 
fibrils were the main species present at 72 h (Fig. 47C). In the presence of IAPP-GI (1/1), 
however, Aβ(1-40) fibrillogenesis was nearly completely suppressed (Fig. 47A). TEM 
confirmed that main species in the Aβ-IAPP-GI incubations were (a) spherical or slightly 
elliptical oligomers with diameters between 20-50 nm (Fig. 47C, inset) and (b) fibril-like, 
strongly beaded oligomeric assemblies (Fig. 47C). TEM analysis revealed that the fibril-like 
assemblies consisted of chains of spherical oligomers and exhibited a very different 
morphology from Aβ(1-40) fibrils (Fig. 47C, right panels) which was consistent with their 
inability to bind ThT. To evaluate the potency of the inhibitory effect of IAPP-GI on formation 
of cytotoxic Aβ(1-40) aggregates, aliquots of the mixture of Aβ(1-40) with IAPP-GI (16.5 µM 
                                                                                                     Results 
 91
each, pH 7.4) and the incubation of Aβ(1-40) alone (16.5 µM) (solutions used for the ThT binding 
assay, Fig. 47A) were added to cultured rat pheochromocytoma PC-12 cells at various time 
 
Fig. 47. Inhibition of Aβ(1-40) cytotoxic self-assembly and fibrillogenesis by IAPP-GI as studied by the ThT 
binding assay, cytotoxicity assays, and TEM. (A) Fibrillogenesis of Aβ(1-40) alone (16.5 µM in 50 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) versus a mixture of Aβ(1-40) and IAPP-GI 
(1/1) as assessed by the ThT binding assay. Data are means (+SEM) from 6 independent assays. (B) A strong 
and lasting inhibitory effect of IAPP-GI on Aβ(1-40) cytotoxicity: Incubations of Aβ(1-40) alone (16.5 µM in 50 
mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP), IAPP-GI alone, and mixture 
of Aβ(1-40) with IAPP-GI were allowed to age for 7 days (aging was followed by the ThT binding assay as 
shown in Fig. 4.2 A). At various time points (0 h, 24 h, 72 h, and 7 days) solutions were added to PC-12 cells at 
the indicated final concentrations and cytotoxicities were assessed by the MTT reduction assay. Data are means 
(+SEM) from 3-6 independent assays (performed in triplicates). (C) Fibril formation in a solution of Aβ(1-40) 
alone (16.5 µM) (upper) versus a mixture of Aβ(1-40) and IAPP-GI (1/1) (lower) as assessed by TEM. Aliquots 
of the incubations studied by the ThT binding assay (Fig. 4.2 A) were examined by TEM 72 h following the 
begin of incubation (bars, 100 nm). The inset shows spherical oligomeric assemblies. (D) Determination of the 
IC50 of the inhibitory effect of IAPP-GI on PC-12 cell toxicity of Aβ(1-40) via titration of Aβ(1-40) (16.5 µM in 
50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP was incubated, 500nM was 
added to the cells) with IAPP-GI and determination of cell viability via the MTT reduction assay. Data are 
means (+SEM) from 1 assay (performed in triplicates). The figure (C) shown is from ref. [285]. 
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points of the fibrillogenesis process (between 0 h and 7 days) and cell viability was assessed 
by the MTT reduction assay. Aβ(1-40) alone was not toxic when added to the cells 
immediately after solution preparation. Aβ(1-40) cytotoxicity increased within 24 h and 
reached a maximum after 72 h of incubation (Fig. 47B). In the presence of IAPP-GI, 
however, a complete suppression of Aβ(1-40) cytotoxicity was observed for at least 7 days 
(Fig. 47B) which correlated very well with the observed strong inhibitory effect on Aβ(1-40) 
fibrillogenesis. Of note, IAPP-GI alone was not toxic (Fig. 47B). Titrations of cytotoxic 
Aβ(1-40) species (formed at a concentration of 500 nM) with IAPP-GI yielded an IC50 of 269 
nM consistent with IAPP-GI being a nanomolar activity inhibitor of Aβ(1-40) cytotoxicity 
(Fig. 47D). These findings showed that IAPP-GI was a potent inhibitor of Aβ(1-40) 
fibrillogenesis and suggested that the IAPP-GI-Aβ(1-40) interaction might result in formation 
of soluble, non-fibrillar, and non-toxic hetero-oligomeric assemblies. 
 
 
3.4.3 Effects of IAPP-GI on already formed Aβ(1-40) fibrils and cytotoxic aggregates 
The questions “what stages of the Aβ(1-40) self-assembly pathway IAPP-GI interferes with 
and what is the effect of such interference on Aβ cytotoxicity towards PC-12 cells” were next 
addressed. Aβ(1-40) (16.5 µM, pH 7.4) was aged for 7 days and aliquots were mixed with 
IAPP-GI (1/1) at various time points of the fibrillization pathway (Fig. 48A). Fibrillization of 
the mixtures and of Aβ(1-40) alone was followed via the ThT binding assay and cytotoxicities 
were assessed by MTT reduction assay (Fig. 48A and 48B). According to the ThT binding 
assay, IAPP-GI competely blocked Aβ(1-40) fibrillogenesis when added to Aβ(1-40) both at 
the begin of the incubation (0 h) and during the lag-time (24 h) (Fig. 48A). When added to 
Aβ(1-40) (at 1/1) after nucleation (72 h), IAPP-GI also completely blocked further 
fibrillogenesis and, in addition, it redissociated already formed Aβ(1-40) fibrils. However, 
fibrils slowly reassociated within the next 48 h (Fig. 48A). Aliquots of the Aβ(1-40) 
incubations before or after addition of IAPP-GI (at pre- (0, 24 h) and post-nucleation time 
points (72 h)) were then added to the cells at 72 h and cytotoxicities were assessed (Fig. 48B). 
As expected, non-aged Aβ(1-40) (0 h) was non-toxic. Cytotoxic non-fibrillar oligomers (Fig. 
48A and 48B) formed during the fibrillization lag time (24 h) and cytotoxicity reached a 
maximum at 72 h (Fig. 48B). When IAPP-GI was added to toxic Aβ(1-40) oligomers present 
during the fibrillization lag time (at 24 h), it caused a strong reduction of their cytotoxic effects. 
When IAPP-GI was added to cytotoxic Aβ(1-40) species present after nucleation of 
fibrillization (at 72 h), it also caused a reduction of their cytotoxicity. However, in contrast to its  
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Fig. 48. Inhibitory effects of IAPP-GI on different stages of Aβ(1-40) cytotoxic self-assembly and fibrillogenesis as 
studied by ThT binding and MTT cell viability assays. (A) Suppression of Aβ(1-40) fibrillogenesis at different 
stages by IAPP-GI. Aβ(1-40) alone (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM 
NaCl and 0.5% HFIP) was allowed to aggregate. At the indicated time points (before nucleation: 0 and 24 h; after 
nucleation: 72 h) aliquots were mixed with IAPP-GI (1/1) and fibrillogenesis of Aβ(1-40) alone versus the mixtures 
was quantified by the ThT binding assay. (B) Inhibition and reversal of Aβ(1-40) cytotoxicity by IAPP-GI before 
and after nucleation of Aβ(1-40) fibrillogenesis: Solutions of (A) were added to PC-12 cells at 72 h and at the 
indicated final concentrations. Cell viability was assessed via the MTT reduction assay. (C) Dissociation of mature 
Aβ(1-40) fibrils by IAPP-GI. Fibrillar Aβ(1-40) was prepared from a 7 days aged, 16.5 µM of Aβ(1-40) solution in 
50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP. The fibrillar Aβ(1-40) solution 
was then mixed with various amounts of IAPP-GI (Aβ(1-40)/ IAPP-GI molar ratio as indicated). The solutions, 
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including a control fibrillar Aβ(1-40) alone solution, were then incubated for 3 days and fibrils were quantified by 
the ThT binding assay. (D) Reversal of cytotoxicity of Aβ(1-40) fibrils by IAPP-GI. 7 days aged 16.5 µM fibrillar 
Aβ(1-40) solution was first diluted to 1.65 µM with buffer (50 mM sodium phosphate buffer, pH 7.4, containing 
100 mM NaCl and 0.5% HFIP) and then mixed with various amounts of IAPP-GI (Aβ(1-40)/IAPP-GI molar ratio 
as indicated). The solutions, including a control fibrillar Aβ(1-40) alone solution, were incubated for 3 days and 
added to PC-12 cells at the indicated final concentrations. Cell viability was assessed via the MTT reduction assay. 
(E) Time dependence of the effects of IAPP-GI (1/1) on fibrillar Aβ(1-40) cytotoxicity. (F) Time dependence of the 
effects of 100–fold IAPP-GI on fibrillar Aβ(1-40) cytotoxicity. Data in (A)-(F) are means (+SEM) from 3 
independent assays (performed in triplicates). 
 
effect on 24 h aged Aβ(1-40), IAPP-GI (1/1) was unable to completely reverse the cytotoxic 
effect of 72 h aged Aβ(1-40) (Fig. 48B). Thus, IAPP-GI (at 1/1 to Aβ(1-40)) not only blocked 
further progress of Aβ(1-40) cytotoxic self-assembly but it also reversed cytotoxic effects of 
already formed cytotoxic assemblies. To study in more detail the effect of IAPP-GI on already 
formed fibrillar and cytotoxic Aβ(1-40) assemblies, the 7 days aged Aβ(1-40) solution, which 
consisted mainly of mature Aβ(1-40) fibrils (Fig. 48B), was then used. IAPP-GI was added to 
7 days aged and fibrillar Aβ(1-40) (16.5 µM) at different IAPP-GI/Aβ(1-40) molar ratios, 
ranging from 1/1 to 100/1, and the ThT fluorescence of the mixtures versus Aβ(1-40) alone 
was determined 3 days later. As shown in Fig. 48C, IAPP-GI at a 10-100-fold excess with 
regard to Aβ(1-40) (concentration of Aβ(1-40) monomers) completely dissolved mature 
Aβ(1-40) fibrils (Fig. 48C). IAPP-GI was then added to aged and cytotoxic Aβ(1-40) fibrils 
(1.65 µM, concentration of Aβ(1-40) monomers) at different IAPP-GI/Aβ(1-40) molar ratios, 
ranging from 1/1 to 100/1, and cytotoxicities were assessed at various time points following 
solution preparation (data from the assay at the time point of 72 h are shown). No changes in 
Aβ(1-40) cytotoxicity in mixtures containing a 1- or 10-fold molar excess of IAPP-GI were 
observed whereas the cytotoxicity of Aβ(1-40) in mixtures containing a 50- and 100-fold 
molar excess of IAPP-GI was completely abolished at the time point of 3 days (Fig. 48D). 
For the time dependence studies of the effect of IAPP-GI on fibrillar Aβ(1-40) 
cytotoxicity, the cytotoxicity of the 1/1 and 1/100 (Aβ(1-40)/IAPP-GI) mixtures of Aβ(1-40) 
with IAPP-GI were followed at several time points. No changes in cytotoxicity of Aβ(1-
40) in mixture containing a 1-fold molar of IAPP-GI were observed over 7 days whereas a 
strong reduction of cytotoxicity was observed already one day after addition of 100-fold 
IAPP-GI while cytotoxicity was completely abolished three days later (Fig. 48E and 48F). 
Similar results to 1-fold were obtained with 10-fold excess of IAPP-GI and very similar 
results to 100-fold were obtained with 50-fold excess of IAPP-GI (data not shown). Of note, 
no changes in cytotoxicity of aged Aβ(1-40) alone were observed within the additional 7 days 
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(Fig. 48E and 48F). These data demonstrated that IAPP-GI was able to dissociate already 
built-up, non-fibrillar and fibrillar cytotoxic Aβ(1-40) assemblies.  
 
 
3.4.4 Aβ(1-40)-IAPP-GI hetero-complexes are ‘‘protected’’ from seeding effects of Aβ(1-
40) fibrils on Aβ(1-40) 
 
Fig. 49. Effect of Aβ(140) seeds on cytotoxicity and fibrillogenesis of Aβ(140) versus Aβ(140)-IAPP-GI 
complexes as studied by the ThT binding and the MTT reduction assays. (A) The Aβ(140)-IAPP-GI complex was 
made by mixing freshly dissolved Aβ(140) (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 
mM NaCl and 0.5% HFIP) with IAPP-GI (1/1 or 1/10) and fibrillogenesis and cytotoxicity following seeding with 
preformed Aβ(140) fibrils (0.1 equivalent) were followed over time by the ThT binding and the MTT reduction 
assays. Aβ fibrils were prepared from a 7 days aged incubation of 16.5 µM Aβ(140) in 50 mM sodium phosphate 
buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP. (B) - (D) At the indicated time points (0 h, 24 h, 72 h, 
and 7 days): solutions of the ThT binding assay were added to PC-12 cells and cell viabilities were assessed by the 
MTT reduction assay. (B) Time-dependence of formation of cytotoxic species by Aβ(140) alone with or without 
seeds. (C) Time-dependence of formation of cytotoxic species in the mixture of Aβ(140) and IAPP-GI (1/1) with 
Aβ(140) seeds. (D) Time-dependence of the cytotoxicity of the mixture of Aβ(140) and IAPP-GI (1/10) with 
Aβ(140) seeds. Data in (A)-(D) are means (±SEM) from 3 independent assays (performed in triplicates). 
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To test if IAPP-GI would be able to inhibit the nucleating effect of exogeneously added Aβ(1-
40) fibrillar seeds on Aβ(1-40) fibrillogenesis, the effect of seeding of Aβ(1-40)-IAPP-GI 
hetero-complexes with Aβ(1-40) fibrils as compared to seeding Aβ(1-40) alone was studied. 
An aged and fibrillar Aβ(1-40) solution was added (at 0.1 molar equivalent) to a mixture of 
freshly dissolved Aβ(1-40) (16.5 µM, pH 7.4) with IAPP-GI (1/1 or 1/10) or to Aβ(1-40) 
alone (16.5 µM) and fibrillogenesis and cytotoxicities were assessed at various time points by 
ThT binding and MTT reduction assays. As expected, seeding of Aβ(1-40) with Aβ(1-40) 
fibrils strongly accelerated the formation of fibrils and cytotoxic assemblies (Fig. 49A and 
49B). Importantly, the seeding effect of Aβ fibrils in the Aβ(1-40)-IAPP-GI mixtures (1/1 or 
1/10) was completely blocked and formation of new cytotoxic assemblies and fibrils was 
strongly suppressed (Fig. 49A, 49C and 49D) suggesting that Aβ(1-40)-IAPP-GI complexes 
were “protected” from the seeding effect of Aβ(1-40) fibrils. Moreover, the presence of a 10-
fold molar excess of IAPP-GI with regard to Aβ(1-40) (which corresponds to a 100- fold excess 
with regard to the added Aβ(1-40) seeds) not only blocked formation of new cytotoxic 
assemblies and fibrils but it also nearly completely reversed the cytotoxicity of the added 
Aβ(1-40) seeds (Fig. 49D). These results were in good agreement with the finding that IAPP-
GI at a 100-fold molar excess was able to redissociate cytotoxic Aβ(1-40) assemblies and 
fibrils (Fig. 48F). 
 
 
3.4.5 Interaction of the IAPP analogues IAPP-LA, IAPP-FA, and IAPP-LI with Aβ(1-40)  
Far-UV CD was used to examine the interaction of Aβ(1-40) with the IAPP analogues IAPP-
LA, IAPP-FA, and IAPP-LI. The spectra of Aβ(1-40) alone (5 µM, pH 7.4) or in the presence 
of IAPP-LA (5 µM), IAPP-FA (5 µM), or IAPP-LI (5 µM) as also the spectra of each of the 
analogue alone (5 µM) as well were measured. The spectra of the mixtures at time 0 h following 
begin of incubation strongly differed from the sum of the spectra of Aβ(1-40) with each of the 
analogues which indicated that IAPP-LA, IAPP-FA and IAPP-LI had interacted with IAPP (Fig. 
50A-50C). Of note, the shapes of the spectra of the mixtures were very similar to the spectra of 
the analogues alone indicating a strong effect of the conformation of the IAPP analogues on 
Aβ(1-40) conformation. Also, while the shapes of the spectra of the mixtures of Aβ(1-40) with 
IAPP-GI, and IAPP-LA were similar to each other, the IAPP-FA-Aβ(1-40) and IAPP-LI-Aβ(1-
40) mixture spectra were very similar to each other and strongly differed from the spectra of 
other mixtures (Fig. 50D). This indicated that the structures of the IAPP analogues-Aβ(1-40) 
hetero-complexes were depended on the involved IAPP analogue.  
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Fig. 50. Interaction of IAPP-LA, IAPP-FA, IAPP-LI with Aβ(1-40) as assessed by far-UV CD spectroscopy  (A) 
CD spectrum of Aβ(1-40) alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4, 1% HFIP) and CD spectrum 
of the mixture of Aβ(1-40) with IAPP-LA (1/1) at time 0 h following begin of incubation. For comparison, the 
mathematical addition of the CD spectra of Aβ(1-40) and IAPP-LA is also shown. (B) CD spectra of Aβ(1-40) 
(5 µM in 10 mM sodium phosphate buffer, pH 7.4, containing 1% HFIP), IAPP-FA (5 µM), and the mixture of 
Aβ(1-40) with IAPP-FA (1/1) as also the spectrum corresponding to the mathematic addition of the CD spectra 
of Aβ(1-40) and IAPP-FA as well are shown. (C) CD spectra of Aβ(1-40) (5 µM in 10 mM sodium phosphate 
buffer, pH 7.4, 1% HFIP), IAPP-LI (5 µM), and the mixture of Aβ(1-40) with IAPP-LI (1/1) as also the 
spectrum corresponding to the mathematic addition of the CD spectra of Aβ(1-40) and IAPP-LI are shown. (D) 
CD spectrum of Aβ(1-40) alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4, 1% HFIP) and of the 
mixtures of Aβ(1-40) with IAPP-GI, IAPP-LA, IAPP-FA, and IAPP-LI (1/1) at time 0 h following begin of the 
incubations. Spectra shown in (A)-(D) are representative of 2-3 independent experiments. 
 
 
3.4.6 Inhibitory effects of IAPP-LA, IAPP-FA, and IAPP-LI on Aβ(1-40) misfolding into 
β-sheets  
The effect of the interaction of the IAPP-analogues with Aβ(1-40) on the conformational 
transition of Aβ(1-40) into β-sheets was next examined by CD. Solutions of Aβ(1-40) alone 
(5 µM, pH 7.4) or of a mixture of Aβ(1-40) with IAPP-LA, IAPP-FA, and IAPP-LI (1/1) were 
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allowed to age and CD spectra were measured at various time points (Fig. 51). Aβ(1-40) 
alone misfolded into β-sheets and formed insoluble aggregates at about 25 h (Fig. 51A).  By 
contrast, the kinetic follow-up of the changes of the CD spectra of the IAPP-LA-Aβ(1-40) and 
IAPP-FA-Aβ(1-40) mixtures indicated formation of ordered heterocomplexes which did not 
further aggregate into β-sheets and no insolubilization was observed in the mixture even 14 
days after the begin of the incubation (Fig. 51B and 51C). However, the mixture of Aβ(1-40) 
with IAPP-LI exhibited a red shifted β-sheet minimum at 227 nm and insoluble aggregates 
precipitated after 48 h (Fig. 51D). The spectra of the IAPP-LA-Aβ(1-40)  and IAPP-FA-
Aβ(1-40) mixtures exhibited pronounced minima at ～204-206 nm which indicated significant  
 
Fig. 51. Inhibitory effect of IAPP-LA, IAPP-FA and IAPP-LI on Aβ(1-40) aggregation into β-sheets as studied 
by far-UV CD (A) CD spectrum of Aβ(1-40) alone (5 µM in 10 mM sodium phosphate buffer, pH 7.4, 1% HFIP) 
at various time points  (B) CD spectra of the mixture of Aβ(1-40) (5 µM ) with IAPP-LA (1/1 in 10 mM sodium 
phosphate buffer, pH 7.4, 1% HFIP) recorded between 0 and 14 days following the beginning of the incubations 
(C) CD spectra of the mixture of Aβ(1-40) (5 µM ) with IAPP-FA (1/1 in 10 mM sodium phosphate buffer, pH 
7.4, 1% HFIP) recorded between 0 and 14 days following the beginning of the incubations with (D) CD spectra 
of the mixture of Aβ(1-40) (5 µM ) with IAPP-LI (1/1 in 10 mM sodium phosphate buffer, pH 7.4, 1% HFIP) 
recorded between 0 and 48 h following the beginning of the incubations and up to the appearance of  insoluble 
aggregates are shown. Spectra shown in (A)-(D) are representative of 2-3 independent experiments. 
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contents of non-β-sheet structure in these heterocomplexes. Of note, the 204 nm minima 
became stronger in both the IAPP-LA-Aβ(1-40) and the IAPP-FA-Aβ(1-40) mixtures 
between 0 to 14 days (Fig. 51B and 51C).  These data suggested that, the analogues IAPP-LA 
and IAPP-FA were able to attenuate Aβ(1-40) misfolding into β-sheet aggregates while IAPP-
LI was a weak inhibitor of Aβ(1-40) aggregation.  
 
 
3.4.7 Inhibitory effects of IAPP-LA, IAPP-FA, and IAPP-LI on Aβ(1-40) cytotoxic self-
assembly and fibrillogenesis 
 
Fig. 52. Effects of IAPP-LA, IAPP-FA, and IAPP-LI on Aβ(1-40) fibrillogenesis and cytotoxicity as assessed by 
ThT binding assay and MTT reduction assay. (A) ThT fluorescence of an Aβ(1-40) solution (16.5 µM in 50 mM 
sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) or of mixtures of Aβ(1-40) with the 
peptides IAPP-LA, IAPP-FA, and IAPP-LI (16.5 µM each).  (B), (C), and (D) Effects of the mixtures of Aβ(1-
40) with (B) IAPP-LA, (C) IAPP-FA, and (D) IAPP-LI on PC-12 cell viability at different time points as 
indicated. Data in (A)-(D) are means (+SEM) of three independent experiments (performed in triplicates). 
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 Next, the effects of the IAPP analogues IAPP-LA, IAPP-FA, and IAPP-LI on Aβ(1-40) 
cytotoxic assembly and fibrillogenesis were studied. Aβ(1-40) alone (16.5 µM) and the 
mixtures of Aβ(1-40) with the analogues (at 1/1) were incubated in aqueous solution (pH 7.4) 
for 7 days and fibrillogenesis and cytotoxicity over time were followed by the ThT binding 
and the MTT reduction assays. As shown in Fig. 52A, Aβ(1-40) alone formed fibrils after a 
lag-time of ~48 h. However, in the presence of the analogues (at 1/1) Aβ(1-40) 
fibrillogenesis was strongly suppressed as was also observed with IAPP-GI. When Aβ(1-40)  
was added to the cells immediately after solution preparation, mixtures were not toxic at 0 h 
whereas cytotoxicity gradually increased in the following 24 h to 7 days (Fig. 52B-52D).  
Nevertheless, in the presence of the analogues, Aβ(1-40) cytotoxicity was markedly reduced 
as compared to Aβ(1-40) alone at 72 h and 7 days (the cytotoxicity of Aβ(1-40) alone reached 
a maximum at 72 h (Fig. 52B-52D)). Of note, the analogues alone were found to be non-toxic 
for at least 7 days (Fig. 52B-52D). The above results indicated that IAPP-LA, IAPP-FA, and 
IAPP-LI (at 1:1) were able to nearly completely suppress Aβ(1-40) fibrillogenesis and to 
suppress but not completely block formation of cytotoxic Aβ(1-40) assemblies. Thus, the 
IAPP analogues IAPP-LA, IAPP-FA, and IAPP-LI exhibit similar but weaker inhibitory 
effects on formation of cytotoxic Aβ(1-40) aggregates assemblies as compared to IAPP-GI 
whereas their effects on Aβ(1-40) fibrillogenesis were similar to the ones of IAPP-GI. 
 
 
3.4.8 Studies on the effects of IAPP-LA, IAPP-FA, and IAPP-LI on already formed 
Aβ(1-40) fibrils and cytotoxic aggregates  
Next, the effects of the analogues IAPP-LA, IAPP-FA, and IAPP-LI at different stages of 
the Aβ(1-40) self-assembly pathway were examined by the ThT binding and the MTT 
reduction assay. Aβ(1-40) (16.5 µM, pH 7.4) was incubated for 7 days and aliquots were 
mixed (at 1/1) with IAPP- LA, IAPP-FA, or IAPP-LI at various time points. Fibrillization 
of the mixtures versus Aβ(1-40) was followed via the ThT binding assay and 
cytotoxicities were assessed by the MTT reduction assay (Fig. 53). According to the ThT 
binding assay, IAPP-LA and IAPP-FA affected strongly but did not completely block 
Aβ(1-40) fibrillogenesis when added to Aβ(1-40) during the lag-time (0-24 h) (Fig. 53A 
and 53B). When added to Aβ(1-40) after nucleation of Aβ(1-40) fibrillogenesis (72 h), 
IAPP-LA and IAPP-FA blocked further fibrillogenesis and dissociated a part of the Aβ(1-
40) fibrils. However, their effects on fibril dissociation were not as strong as fibrils slowly  
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Fig. 53. Inhibitory effects of the IAPP analogues on different stages of Aβ(1-40) cytotoxic self-assembly and 
fibrillogenesis as studied by ThT binding assays and cell viability assays on PC-12 cells. (A) - (C) Effects of the 
IAPP analogues IAPP-LA, IAPP-FA, and IAPP-LI on Aβ(1-40) fibrillogenesis. Aβ(1-40) alone (16.5 µM in 50 
mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) was allowed to aggregate. At 
the indicated time points (before nucleation: 0 and 24 h; after nucleation: 72 h) aliquots were mixed with IAPP-
LA (A), IAPP-FA (B), and IAPP-LI (C) (at 1/1) and fibrillogenesis of Aβ(1-40) alone versus the mixtures was 
quantified by the ThT binding assay. (D) – (F) Studies on the effects of IAPP analogues IAPP-LA (D), IAPP-FA 
(E), and  IAPP-LI (F) on cytotoxic Aβ(1-40) species formed before and after nucleation of Aβ(1-40) 
fibrillogenesis. Solutions of ThT binding assays (from (A) – (C)) were added to PC-12 cells at 72 h and at the 
indicated final concentrations. Cell viabilities were assessed via the MTT assay. Date in (A)-(F) are means 
(+SEM) of three independent experiments (performed in triplicates). 
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reassociated within the next 24- 48 h (Fig. 53A and 53B). IAPP-LI nearly completely 
blocked Aβ(1-40) fibrillogenesis when added to the Aβ(1-40) incubation during the 
fibrillization lag-time (0-24 h) (Fig. 53C). When added after nucleation of Aβ(1-40) 
fibrillogenesis (72 h), IAPP-LI was unable to redissociate already formed fibrils but it 
blocked further fibrillogenesis (Fig. 53C). Aliquots of the Aβ(1-40) incubations before 
and after addition of the analogues (used for the ThT binding assays) were added to PC-12 
cells and cell viabilities were assessed (Fig. 53D-53F). As expected, non-aged Aβ(1-40) 
(0 h) was non-toxic while cytotoxic Aβ(1-40) oligomers formed during the fibrillization 
lag-time (24 h) and their cytotoxic effects reached a maximum at 72 h (Fig. 53D-53F). 
When the analogues were added to non-aged and non-toxic Aβ(1-40) (0 h), the solutions 
of the mixtures were markedly less cytotoxic (at 72 h) than the Aβ(1-40) alone incubation. 
When the analogues were added to the cytotoxic Aβ(1-40) species that were present 
during the lag time (24 h) or after nucleation of Aβ(1-40) fibrillogenesis (72 h), similar 
cytotoxicities as in the Aβ(1-40) alone solution at these time points, respectively, were 
observed (Fig. 53D-53F). These results indicated that the IAPP analogues blocked further 
progress of Aβ(1-40) cytotoxic self-assembly when they were added during the lag time 
(0-24 h) but in contrast to IAPP-GI, they were unable to reverse cytotoxic effects of 
already formed Aβ(1-40) cytotoxic assemblies.  
 
 
3.5 Inhibition of Aβ(1-40) amyloidogenesis and cytotoxicity by prefibrilar IAPP species 
and vice versa 
 
3.5.1 Interaction of prefibrillar IAPP with Aβ(1-40) as studied by far-UV CD 
spectroscopy and pull-down assays 
As IAPP-GI analogue a non-amyloidogenic and non-toxic conformation which IAPP might 
populate, at least partially, when it is in a prefibrillar state, the above results raised the 
question whether prefibrillar IAPP species might also interact with Aβ(1-40) and affect Aβ(1-
40) fibrillogenesis and cytotoxicity. To address this issue, far-UV CD spectroscopy and Aβ(1-
40) pull-down assays with NuPAGE gel electrophoresis and WB were used. CD spectroscopy 
was performed as for the IAPP-GI-Aβ(1-40) interaction (Fig. 54A). CD spectra of freshly 
dissolved Aβ(1-40) alone (5 µM, pH 7.4), IAPP alone (5 µM, pH 7.4), and the mixture of 
freshly dissolved Aβ(1-40) with IAPP (1/1) were measured (Fig. 54A). The sum of the CD 
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spectra of IAPP (5 µM) and Aβ(1-40) (5 µM) differed from the spectrum of the IAPP-Aβ(1-40) 
mixture (1/1) indicating that IAPP interacted with Aβ(1-40) (Fig. 54A). Of note, the CD 
spectrum of the Aβ(1-40)-IAPP mixture was similar to spectrum of the Aβ(1-40)-IAPP-GI 
mixture (Fig. 54A).  The presence of minima at 222 nm and 202 nm indicated the presence of 
significant amounts of secondary structure suggesting that interaction resulted in formation of 
ordered, soluble Aβ(1-40)-IAPP hetero-complexes. To confirm that Aβ(1-40) binds IAPP, pull-
down assays were then used. Synthetic N
α
-amino-terminal Biotin-IAPP (2.5 µM) was incubated 
with freshly dissolved Aβ(1-40) (2.5 or 5 µM, pH 7.4) for 1 h; as performed for the IAPP-GI-
Aβ(1-40) solutions. Of note, IAPP and Aβ(1-40) were in the lag-phase of fibrillogenesis 
according to the ThT binding assay (not shown). Biotin-IAPP-Aβ(1-40) complexes were 
isolated by binding to streptavidin-coated beads and, following dissociation and NuPAGE, WB 
with anti-Aβ(1-40) antibodies showed significant amounts of Aβ(1-40) monomers and dimers 
in the mixture demonstrating that Biotin-IAPP bound Aβ(1-40) (Fig. 54B). 
 
 
Fig. 54. Bindng of IAPP to Aβ(1-40) as studied by far-UV CD and a pull-down assay. (A) Interaction of Aβ(1-40) 
with IAPP as assessed by far-UV CD: CD spectra of freshly dissolved Aβ(1-40) alone (5 µM), IAPP alone (5 µM), 
and the mixture of Aβ(1-40) with IAPP (1/1) were measured immediately after solution preparation. The sum of the 
spectra of Aβ(1-40) and IAPP is also shown. CD spectra were measured in 10 mM sodium phosphate buffer, pH 
7.4 containing 1% HFIP. Spectra shown are representative of 2-3 independent experiments (B) Binding of Aβ(1-40) 
to Biotin-IAPP as assessed by a pull-down assay: Top: anti-Aβ(1-40) western blot analysis of a mixture of Aβ(1-40) 
(5 µM) and Biotin-IAPP (2.5 µM) versus Aβ(1-40) alone (5 µM) following biotin pull-down and peptide 
dissociation. Lane, “Aβ input”: input (50%, freshly dissolved peptide (4 µg) not incubated with beads); lane, 
“Biotin-IAPP input”: input (100%, 4 µg); lane, “Biotin-IAPP”: Biotin-IAPP alone; lane, “mixture”: 1:2 mixture of 
Biotin-IAPP and Aβ(1-40); lane, “Aβ NSB”: Aβ(1-40) alone (NSB for lane “mixture”). Bottom: anti-biotin western 
blot analysis of the same mixture as in upper panel. Lanes are as in upper panel. Incubations were performed for 1 h 
in 10 mM sodium phosphate buffer, pH 7.4. Blots shown are representative of three independent experiments. The 
figure (B) shown is from ref. [285]. 
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3.5.2 Effect of the interaction of prefibrillar IAPP and Aβ(1-40) species on misfolding 
into β-sheets and fibrillogenesis of both Aβ(1-40) and IAPP 
 To examine whether the interaction of IAPP with Aβ(1-40) could inhibit Aβ(1-40) misfolding 
into β-sheets and affect Aβ(1-40) or IAPP fibrillogenesis, far-UV CD spectroscopy and ThT 
binding assays combined with TEM were used. The conformation of a mixture of Aβ(1-40) 
and IAPP (5 µM each, solution from Fig. 54A) was followed by CD over 7 days. In 
comparison, CD spectra of Aβ(1-40) (5 µM) and IAPP (5 µM) alone incubations at various 
time points were also measured. As shown in Fig. 55A, the minimum at 202 nm was unstable 
and red shifted to 207 nm and back during the 7 days of incubation. The CD spectrum of the 
mixture fluctuated thus between spectrum with minima at 202 nm and 222 nm and one with 
minima at 207 nm and 222 nm.  However, no insoluble aggregates formed within the 7 days. 
In contrast, Aβ(1-40) alone aggregated into soluble β-sheets after 8 h (increase of the 
minimum in the 217 nm region) and fibrillar aggregates precipitated after 25 h (Fig. 55B). 
IAPP alone was in the lag-phase of fibrillization for about 2 h and aggregated thereafter first 
into soluble β-sheets (increase of the minimum in the 217 nm region) and then into insoluble 
fibrils at the time point of 7 h (Fig. 55C). These results indicated that the Aβ(1-40)-IAPP 
interaction resulted in formation of ordered, soluble Aβ(1-40)-IAPP hetero-complexes which 
attenuated aggregation of both Aβ(1-40) and IAPP into β-sheet oligomers and fibrills.  
Next, freshly dissolved Aβ(1-40) alone (16.5 µM), IAPP alone (16.5 µM), and a 1/1 mixture 
of freshly dissolved Aβ(1-40) with IAPP were incubated in aqueous buffer (pH 7.4) and 
fibrillization was followed by using the ThT binding assay (Fig. 55D). Aβ(1-40) 
fibrillogenesis exhibited a lag-time of ~48 h and reached completion between 72 and 96 h 
while IAPP had a lag-time of ~0.5 h (Fig. 55D, inset) and maximum fibrillization was 
observed at ~24 h. Importantly, fibrillization of the IAPP-Aβ(1-40) mixture was found to be 
delayed by ~24 h as compared to Aβ(1-40) and by ~72 h as compared to IAPP (Fig. 55D). 
Thus, interaction of prefibrillar IAPP and Aβ(1-40) species attenuated the onset of 
fibrillization of both Aβ(1-40) and IAPP. TEM was then used to characterize the species 
formed during the self-assembly process of the incubations of Aβ(1-40), IAPP, and the 
mixture of Aβ(1-40) with IAPP. At the 24 h time-point, pre- or protofibrillar oligomers were 
the main species in the Aβ(1-40) solution whereas the IAPP solution consisted mainly of 
mature IAPP fibrils. These findings were consistent with the results of the ThT binding assays. 
The Aβ(1-40)-IAPP mixture, however, consisted mainly of two species: (a) round or elliptical 
oligomers of various diameters ranging mostly between 20 and 50 nm and (b) fibrils (Fig. 55E). 
Notably, the round oligomers were not present in the Aβ(1-40) or IAPP alone incubations  
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Fig. 55.  Effects of IAPP on Aβ(1-40) misfolding into β-sheets and Aβ(1-40) fibrillogenesis and vice verse as 
studied by far-UV CD, the ThT binding assay, and TEM. (A) CD spectra of an Aβ(1-40) incubation (5 µM) at 
various time points are shown. (B) In parallel, CD spectra of an IAPP incubation (5 µM) at various time points are 
shown. (C) The conformation of a mixture of Aβ(1-40) and IAPP (5 µM each) was followed by CD over 7 days. 
CD spectra at various time points up to 7 days are shown.  CD spectra shown in (A)-(C) were measured in 10 mM 
sodium phosphate buffer, pH 7.4 containing 1% HFIP. Spectra shown are representative of 2-3 independent 
experiments. (D) IAPP delays Aβ(1-40) fibrillogenesis and IAPP fibrillogenesis is delayed by Aβ(1-40): 
Fibrillogenesis of a mixture of freshly dissolved IAPP (16.5 µM) with Aβ(1-40) (16.5 µM), and Aβ(1-40) alone 
(16.5 µM), IAPP alone (16.5 µM) in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% 
HFIP were assessed by the ThT binding assay. Inset: The first 30 min of the plot of IAPP ThT fluorescence versus 
time are shown. Data of the ThT binding assay are means (±SEM) from 8 independent assays. (E) TEM analysis of 
the assemblies present in the incubations of Aβ(1-40), IAPP, and the Aβ(1-40)-IAPP mixture at 24 h and at the end 
200 210 220 230 240 250
-8000
-6000
-4000
-2000
0
M
ea
n 
re
si
du
e 
el
lip
tic
ity
(d
eg
.c
m
2 .
dm
ol
-1
)
wavelength (nm)
 0 h
 2 h
 8 h
 22 h
 24 h
 25 h
B
200 210 220 230 240 250
-8000
-6000
-4000
-2000
0
2000
M
ea
n 
re
si
du
e 
el
lip
tic
ity
(d
eg
.c
m
2 .
dm
ol
-1
)
wavelength (nm)
 0 h
 2 h
 4 h
 5 h
 6 h
 7 h
C 
E 
0 24 48 72 96 120 144 168
0
5000
10000
15000
20000
Th
T 
flu
or
es
ce
nc
e 
(a
.u
.)
Time (h)
 Aß
 IAPP
 Aß + IAPP 
D
0
5000
Time (h)T
hT
 fl
uo
re
sc
en
ce
 (a
.u
.)
0 h 0,5 h
200 210 220 230 240 250
-5000
-4000
-3000
-2000
-1000
0
1000
2000
 0 h
 1 h
 24 h
 2 and 6 days
 3, 5 and 7days
M
ea
n 
re
si
du
e 
el
lip
tic
ity
(d
eg
.c
m
2 .
dm
ol
-1
)
wavelength (nm)
A 
                                                                                                     Results 
 106
point of fibrillogenesis (7 days) (bars, 100 nm). Arrows in the Aβ(1-40)-IAPP mixture (24 h) depict round 
oligomers of similar appearance to the ones in the Aβ(1-40)-IAPP-GI mixture (Fig. 55E, inset). TEM was 
performed on the incubations used in the ThT binding assays (Fig.55D). TEM shown is from ref. [285]. 
 
and had a similar appearance to the oligomers found in the Aβ(1-40)-IAPP-GI incubations 
(Fig. 55E and Fig. 47C). The fibrillar assemblies, however, did not exhibit the beaded 
structure of the fibril-like Aβ(1-40)-IAPP-GI assemblies (Fig. 47C) and appeared to be very 
similar to mature IAPP or Aβ(1-40) fibrils. TEM at 7 days showed that fibrils 
indinstinguishable from mature Aβ(1-40) or IAPP fibrils were the main species in the Aβ(1-
40)-IAPP incubation (Fig. 55E). The round oligomeric species were absent from the 7 days 
aged Aβ(1-40)-IAPP incubation which suggested that these assemblies formed transiently and 
converted subsequently into fibrils. Thus, in contrast to IAPP-GI, IAPP attenuated but was 
unable to block Aβ(1-40) fibrillogenesis (Fig. 55D and 55E). 
 
 
3.5.3 Inhibitory effects of prefibrillar IAPP on different stages of Aβ(1-40) cytotoxic self-
assembly and fibrillogenesis  
Next, it was examined what stage of the Aβ(1-40) fibrillogenesis and cytotoxicity pathway 
prefibrillar IAPP interferes with and what is the effect of such interference on Aβ(1-40) 
cytotoxicity towards PC-12 cells. Freshly dissolved IAPP (16.5 µM, pH 7.4) was mixed with 
Aβ(1-40) (16.5 µM) before (0 h and 24 h) and after nucleation (72 h) of Aβ(1-40) 
fibrillogenesis and kinetics of fibrillogenesis were followed by the ThT binding assay (Fig. 
56A). While IAPP delayed Aβ(1-40) fibrillogenesis and had a similar inhibitory effect when 
added to prefibrillar Aβ(1-40) (0 h and 24 h), it did not affect further fibrillogenesis of a 72 h 
aged and already fibrillar Aβ solution (Fig. 56A). To investigate whether the IAPP-Aβ(1-40) 
interaction also affected Aβ cytotoxicity, aliquots of the 72 h aged incubations were then 
added to PC-12 cells and cytotoxicities were assessed by the MTT reduction assay (Fig. 56B). 
To be able to compare the effects on cell viability with the effect of Aβ(1-40) alone just before 
mixing, the cytotoxicities of the Aβ(1-40) incubations before addition of IAPP (at pre- (0, 24 h) 
and post-nucleation time points (72 h)) were also assessed (Fig. 56B). Non- aged Aβ(1-40) (0 h) 
was non-toxic. Cytotoxic non-fibrillar oligomers formed, however, during the fibrillization 
lag-time (24 h) and cytotoxicity reached a maximum at 72 h (Fig. 56B). The MTT reduction 
assay showed that IAPP attenuated formation of cytotoxic Aβ(1-40) species when added to 
prefibrillar Aβ(1-40) (0 h and 24 h) but did not affect cytotoxicity of a 72 h aged, already 
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fibrillized, and strongly cytotoxic Aβ(1-40) solution (Fig. 56B). Of note, IAPP attenuated 
formation of cytotoxic Aβ(1-40) species when added to 0 h aged Aβ(1-40) stronger than when 
added to 24 h aged Aβ(1-40) which was most likely due to the fact that IAPP was unable to 
reverse cytotoxic effects of already formed cytotoxic Aβ(1-40) species. These results showed 
that IAPP attenuates further fibrillization and cytotoxic self-assembly of prefibrillar Aβ(1-40) 
species whereas it has no effects on already formed fibrillar Aβ(1-40) assemblies.  
 
Fig. 56. Effects of prefibrillar IAPP on different stages of Aβ(1-40) cytotoxic self-assembly and fibrillogenesis 
as studied by the ThT binding assay and the MTT reduction assays. (A) Suppression of Aβ(1-40) fibrillogenesis 
at different stages by prefibrillar IAPP. Aβ(1-40) alone (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, 
containing 100 mM NaCl and 0.5% HFIP) was allowed to aggregate. At the indicated time points (before 
nucleation: 0 and 24 h; after nucleation: 72 h) aliquots were mixed with IAPP (1/1) and fibrillogenesis of Aβ(1-
40) alone versus the mixtures was quantified by the ThT binding assay. (B) Effects of prefibrillar IAPP on Aβ(1-
40) cytotoxicity: Solutions of the ThT binding assays were added to PC-12 cells at 72 h (as indicated by the grey 
bars in Fig. 5.3 A) and cytotoxicities of Aβ(1-40) alone before addition of IAPP (at pre- (0, 24 h) and post-
nucleation time points (72 h)) at the indicated final concentrations. Cell viability was assessed via the MTT 
reduction assay. Data in (A) and (B) are means (+SEM) from 4-8 independent assays (performed in triplicates). 
 
 
3.5.4 Effects of prefibrillar Aβ(1-40) on different stages of IAPP cytotoxic self-assembly 
and fibrillogenesis  
Next, the effects of prefibrillar Aβ(1-40) on different stages of the pathway of IAPP 
fibrillogenesis and cytotoxicity toward RIN5fm cells were examined. IAPP (16.5 µM, pH 7.4) 
was allowed to age. At various time points of its fibrillization pathway, aliquots were mixed 
(1/1) with freshly dissolved Aβ(1-40) and kinetics of fibrillogenesis of the mixtures were 
assessed by the ThT binding assay. At the time point 24 h only the Aβ(1-40)-IAPP mixtures  
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Fig. 57. Inhibitory effects of prefibrillar Aβ(1-40) on different stages of IAPP cytotoxic self-assembly and 
fibrillogenesis as studied by ThT binding and cytotoxicity assays. (A) Prefibrillar Aβ(1-40) delays fibrillogenesis of 
prefibrillar IAPP. IAPP alone (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 
0.5% HFIP) was allowed to aggregate. At various time points of its fibrillization process (0, 0.5, and 4 h) aliquots 
were mixed with Aβ(1-40) (1/1) and fibrillogenesis of IAPP, Aβ(1-40), and the mixtures was quantified by the ThT 
binding assay. The grey bar indicates the time point of addition of the solutions to RIN5fm cells for the assessment 
of cytotoxicities (Fig. 59B). (B) Prefibrillar Aβ(1-40) delays further cytotoxic self-assembly of prefibrillar IAPP 
species and has no effect on fibrillar IAPP. Solutions used for the ThT binding assay in (A) were added to RIN5fm 
cells at 24 h and at the indicated final concentrations and cell viabilities were assessed by the MTT reduction assay. 
Cytotoxicity of IAPP alone at various time points of its fibrillization process (0, 0.5, and 4 h) is also shown. Data in 
(A) and (B) are means (+SEM) from 4-8 independent assays (performed in triplicates). 
 
which were made by mixing Aβ with 0 or 0.5 h aged IAPP were still in the lag-phase of 
fibrillization whereas IAPP alone and the mixture of Aβ(1-40) with 4 h aged IAPP were 
already fibrillized (Fig. 57A). The nucleation of fibrillization of the mixture of Aβ(1-40) with 
freshly dissolved IAPP (0 h) was delayed by ~72 h as compared to the incubation of IAPP 
alone while fibrillization of the mixture of Aβ(1-40) with 0.5 h aged IAPP was delayed by 
~24 h as compared to IAPP alone (Fig. 57A). By contrast, when Aβ(1-40) was mixed with 
partially fibrillized IAPP (at an IAPP incubation time point of 4 h) no inhibition of 
fibrillogenesis was observed (Fig. 57A). Moreover the magnitude of the ThT binding at the 
plateau (7 days) reached a value corresponding to the mathematical sum of the ThT 
magnitudes of the plateau values of IAPP and Aβ(1-40). This finding indicated that both IAPP 
and Aβ(1-40) fibrillized in the mixtures made by adding freshly dissolved Aβ(1-40) to already 
aggregated IAPP (0.5 and 4 h aged IAPP) (Fig. 57A). For comparison, the Aβ(1-40)-IAPP 
mixture which was made by mixing Aβ(1-40) with non-aged IAPP reached the plateau after 
10 days and the magnitude of the ThT fluorescence at the plateau was the same as the 
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fluorescence of IAPP or Aβ(1-40) alone (data not shown). To assess the effect of prefibrillar 
Aβ(1-40) which was at the time of mixing in a non-cytotoxic state (Fig. 57B) on cytotoxic 
self-assembly of both prefibrillar and fibrillar IAPP species, solutions used for the ThT 
binding assay were also added to RIN5fm cell at 24 h. Cytotoxicities were then assessed by 
the MTT reduction and compared with the cytotoxicity of the solution of IAPP alone before 
mixing. Non-aged IAPP was non-toxic while some cytotoxic species formed in the 0.5 h aged 
IAPP solution which became more toxic over time (Fig. 57B). Maximum cytotoxicity was 
reached after 24 h (Fig. 57B). The 24 h aged Aβ(1-40)-IAPP mixtures, however, which were 
made by mixing Aβ(1-40) with 0 and 0.5 h aged IAPP were still in the lag-phase and were 
clearly less toxic than 24 h aged IAPP. By contrast, the 24 h aged Aβ(1-40)-IAPP mixture 
which was made by addition of Aβ(1-40) to 4 h aged IAPP incubations was already fibrillized 
and similarly toxic as 24 h aged IAPP (Fig. 57B). Of note, the mixture of Aβ(1-40) with 0.5 h 
aged IAPP was more toxic than 0.5 h aged IAPP, most likely due to the fact that 0.5 h aged 
IAPP was cytotoxic before addition of Aβ(1-40), and Aβ(1-40) could not reverse cytotoxic 
effects of already formed IAPP cytotoxic assemblies.  These results indicated that prefibrillar 
and non-toxic Aβ(1-40) species attenuate fibrillization and cytotoxic self-assembly of 
prefibrillar IAPP species and has no effects on partially fibrillized IAPP. 
 
 
3.5.5 Effects of prefibrillar IAPP on non-fibrillar and non-toxic Aβ(1-40) species and 
vice versa 
To evaluate in more detail the inhibitory effect of prefibrillar IAPP on formation of cytotoxic 
Aβ(1-40) species, cytotoxicities of mixtures of IAPP (1/1) with non-aged Aβ(1-40) (0 h) were 
next assessed at various time points of fibrillization by the MTT reduction assay. Aliquots of 
mixtures of freshly dissolved IAPP (16.5 µM, pH 7.4) with non-aged Aβ(1-40) (0 h) (1/1) and 
of incubations of Aβ(1-40) alone (16.5 µM) and IAPP alone (16.5 µM) from the ThT binding 
assay (Fig. 58A) were added to the PC-12 cells at various time points of the fibrillogenesis 
process. Cell viabilities were assessed by the MTT reduction assay. Non-aged Aβ(1-40), non-
aged IAPP, and a non-aged mixture of both peptides (0 h) were non-toxic (Fig. 58B). At 24 h, 
both Aβ(1-40) and the Aβ(1-40)-IAPP mixture were still in the fibrillization lag-phase (Fig. 
58A) and solutions exhibited similar cytotoxicities while IAPP was already fibrillized and 
strongly cytotoxic (Fig. 58C). At 72 h, the Aβ(1-40) solution was mostly fibrillized (Fig. 
60A) and was clearly more cytotoxic than at 24 h (Fig. 58E). By contrast, 72 h aged Aβ(1-
40)-IAPP mixture, which was still in the lag-phase (Fig. 58A), was markedly less cytotoxic  
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Fig. 58. Time-dependence of formation of cytotoxic species and fibrils when prefibrillar IAPP was added to non-
fibrillar and non-cytotoxic Aβ(1-40). (A) Incubations of mixture of freshly dissolved IAPP (16.5 µM) with Aβ(1-
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40) (16.5 µM), Aβ(1-40) alone (16.5 µM), and IAPP alone (16.5 µM) in 50 mM sodium phosphate buffer, pH 
7.4, containing 100 mM NaCl and 0.5% HFIP were allowed to age for 7 days. Fibrillogenesis during aging was 
followed by the ThT binding assay. Grey bars indicate the time points of addition of the solutions to PC-12 and  
RIN5fm cells for the assessment of cytotoxicities as shown in Fig. 5.4 B - H.  Data are means (±SEM) from 8 
independent assays. (B), (C), (E), (G) At the indicated time points: 0 h (B), 24 h (C), 72 h (E), and 7 days (G)  
solutions were added to PC-12 cells and cytotoxicities were assessed by the MTT reduction assay. (B), (D), (F), 
(H) At the indicated time points: 0 h (B), 24 h (D), 72 h (F), and 7 days (H) solutions were added to RIN5fm 
cells and cytotoxicities were assessed by the MTT reduction assay. Data in (B) - (H) are means (±SEM) from 3 
independent assays (performed in triplicates) for each time point. 
 
(Fig. 58E). However, the 7 days aged and fibrillar Aβ(1-40)-IAPP mixture (Fig. 58A) was as 
cytotoxic as 7 days aged and fully fibrillized Aβ(1-40) (Fig. 58G). These findings were 
further confirmed when cytotoxicities towards the pancreatic β-cell line RIN5fm were 
determined (Fig. 58B, 58D, 58F and 58H). Thus, prefibrillar IAPP when added to non-toxic 
and non-fibrillar Aβ(1-40) clearly attenuated but it was not able to block the cytotoxic self-
assembly process. The solutions of the ThT binding assay (Fig. 58A) were also added to 
RIN5fm cells (in parallel to their addition to PC-12 cells) and cell viabilities were assessed by 
the MTT reduction assay. As expected, non-aged Aβ(1-40), non-aged IAPP, and non-aged 
mixture of both peptides (0 h) were non-toxic (Fig. 58B) whereas 24-72 h aged and 
fibrillized IAPP (Fig. 58A) was strongly cytotoxic (Fig. 58D and 58F). However, the 24-72 h 
aged IAPP-Aβ(1-40) mixtures, which were still in the lag-phase (Fig. 58A), were significantly 
less cytotoxic than similarly aged IAPP or Aβ(1-40) (Fig. 58D and 58F) while the 7 days aged 
mixture was as toxic as 7 days aged IAPP (Fig. 58H). Thus, interaction of non-toxic and non-
fibrillar Aβ(1-40) species with non-toxic and non-fibrillar IAPP species attenuated, albeit it 
did not block, formation of cytotoxic IAPP and Aβ(1-40) assemblies. 
 
 
3.5.6 Effects of prefibrillar IAPP on non-fibrillar but cytotoxic Aβ(1-40) species and vice 
versa 
Kinetics of formation of cytotoxic species in mixture of IAPP (1/1) with 24 h aged Aβ(1-40) 
(16.5 µM, pH 7.4) towards PC-12 cells were followed by the MTT reduction assay. Aβ(1-40) 
(16.5 µM) was aged for 24 h (pH 7.4) and then mixed with freshly dissolved IAPP (1/1). The 
solutions of the mixtures of IAPP with 24 h aged Aβ(1-40), of 24 h aged Aβ(1-40), and of 
IAPP (16.5 µM) were allowed to age for 7 days and their fibrillogeneses were followed by the  
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Fig. 59. Time-dependence of the inhibitory effect of IAPP on cytotoxic non-fibrillar Aβ(1-40) and vice verse: (A) 
Aβ(1-40) (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) was 
first aged for 24 h then mixed with IAPP (1/1). Incubations of 24 h aged Aβ(1-40) alone (16.5 µM), IAPP alone 
(16.5 µM), and of mixture of IAPP with 24 haged Aβ(1-40) (1/1) were then allowed to age for 7 days. 
Fibrillogenesis during aging was followed by the ThT binding assay. Grey bars indicate the time points of the 
addition of the solutions to PC-12 or RIN5fm cells for the assessment of cytotoxicities as shown in Fig. 5.7 B-F. 
(B) – (E) At the indicated time points: 0 h (B), 24 h (C), 72 h (D), and 7 days (E)  solutions were added to PC-12 
cells and cytotoxicities were assessed by the MTT reduction assay. (F) At 24 h, solutions were added to RIN5fm 
cells and cytotoxicities were assessed by the MTT assay. Data in (A)-(F) are means (±SEM) from 3-4 
independent assays (performed in triplicates) for each time point. 
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ThT binding assay (Fig. 59A). At various time points of the fibrillogenesis process, aliquots 
of the incubations from the ThT binding assay (Fig. 59A) were added to the cells and cell 
viabilities were assessed by the MTT reduction assay.  As expected, non-aged IAPP was non-
toxic whereas 24 h aged Aβ(1-40) and the mixture of 24 h aged Aβ(1-40) with freshly 
dissolved IAPP were similarly toxic (Fig. 59B). After 24 h, both the Aβ(1-40) and the Aβ(1-
40)-IAPP mixture were still in the lag-phase (Fig. 59A) and exhibited similar cytotoxicities. 
Of note, both solutions were more cytotoxic of 24 h than at the begin of incubation (Fig. 59C). 
After 72 h, the Aβ(1-40) solution was mostly fibrillized (Fig. 59A) and its cytotoxicity 
reached the maximum value (Fig. 59D). By contrast, the 72 h aged Aβ(1-40)-IAPP mixture, 
which contained less fibrils than Aβ(1-40) or IAPP alone (Fig. 59A), was significantly less 
cytotoxic than Aβ (Fig. 59D). However, the 7 days aged and fibrillar Aβ(1-40)-IAPP 
mixture (Fig. 59A) was as cytotoxic as 7 days aged and fully fibrillized Aβ(1-40) (Fig. 59E). 
To investigate what is the effect of 24 h aged Aβ(1-40) on IAPP fibrillogenesis and 
cytotoxicity, the fibrillogenesis and cytotoxicity pathway of the mixture of 24 h aged Aβ(1-40) 
with IAPP were compared to the ones of IAPP alone. According to the ThT binding assay, 
the nucleation of fibrillization of the mixture of 24 h aged Aβ(1-40) with IAPP was delayed 
by ~48 h as compared to IAPP alone. The MTT reduction assay showed that non-aged IAPP 
was non-toxic to PC-12 cells but the mixture of 24 h aged Aβ(1-40) with freshly dissolved 
IAPP was cytotoxic, most likely due to the cytotoxicity of 24 h aged Aβ(1-40) (Fig. 59B). 
The 24 h aged and fibrillar IAPP (Fig. 59A) was strongly cytotoxic. However, the 24-72 h 
aged mixtures of 24 h aged Aβ(1-40) with freshly dissolved IAPP were significantly less 
cytotoxic than similarly aged IAPP alone while 7 days aged mixtures were as toxic as 7 days 
aged IAPP (Fig. 59C-59E). The above solutions were also added to RIN5fm cells and similar 
results were obtained (Fig. 59F). Thus, interaction of prefibrillar IAPP with Aβ(1-40) 
solutions containing non-fibrillar but toxic Aβ(1-40) species attenuated, albeit it did not block, 
formation of cytotoxic assemblies and fibrils. 
 
 
3.5.7 Effects of fibrillar IAPP on Aβ(1-40) cytotoxic self-assembly and of fibrillar Aβ(1-
40) on IAPP cytotoxic self-assembly 
To prepare IAPP fibrils, IAPP (100 µM) was incubated at pH 7.4 for 24 h. Following 
centrifugation and protein quantification by the BCA assay, pellets were dissolved in ThT 
assay buffer (pH 7.4) and solutions were then added (1/1 on a monomer basis) to Aβ(1-40). 
For comparison, prefibrillar IAPP (16.5 µM, freshly dissolved and 0.5 h aged in ThT assay 
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buffer) was also mixed with Aβ (1/1). Fibrillogenesis of the mixtures of prefibrillar or fully 
fibrillized IAPP with Aβ(1-40) were assessed by the ThT binding assay and cytotoxicities 
towards PC-12 cells were assessed at 72 h by the MTT reduction assay. A delay of the begin 
of fibrillogenesis and formation of cytotoxic species was only observed when freshly 
dissolved IAPP was immediately mixed with freshly dissolved Aβ(1-40) (Fig. 60A and 60B).  
 
Fig. 60. Effects of prefibrillar or fibrillar IAPP species on cytotoxic fibrillogenesis of Aβ(1-40) and vice versa as 
studied by ThT binding and MTT reduction assays. (A) Only freshly dissolved IAPP attenuates fibrillogenesis of 
prefibrillar Aβ(1-40). IAPP fibrils were added (1/1 on a monomer basis) to Aβ(1-40). In parallel, freshly dissolved and 
0.5 h aged IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) was 
also mixed with Aβ(1-40) (1/1). Fibrillogenesis of Aβ(1-40) versus the mixtures was quantified by the ThT binding 
assay. Grey bars indicate the time point of addition of the solutions to PC-12 cells for the assessment of cytotoxicities 
as shown in Fig. 60B. (B)  Effects of different IAPP species on prefibrillar Aβ(1-40) cytotoxicity. Solutions of the ThT 
binding assays from (A) were added to PC-12 cells at 72 h. Cell viability was assessed via the MTT reduction assay. 
(C) Effects of fibrillar Aβ(1-40) on fibrillogenesis of prefibrillar IAPP. 0 h, 24 h and 6 days aged Aβ(1-40) (16.5 µM 
in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) was mixed with freshly 
dissolved IAPP (1/1) and fibrillogenesis of IAPP alone versus the mixtures was quantified by the ThT binding assay. 
Grey bars indicate the time point of addition of the solutions to RIN5fm cells for the assessment of cytotoxicities as 
shown in Fig. 60D. (D) Effects of different species of Aβ(1-40) on prefibrillar IAPP cytotoxicity. Solutions of the ThT 
binding assays from (C) were added to RIN5fm cells at 24 h and cell viabilities are assessed via the MTT reduction 
assay. Data in (A)-(D) are means (+SEM) from 3 independent assays (performed in triplicates). 
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By contrast, when fully fibrillized or even 0.5 h aged (which was still in lag-phase) IAPP 
were used, no attenuating effects on Aβ(1-40) fibrillogenesis were observed (Fig. 60A). In 
addition, cytotoxicity assays clearly showed that 0.5 h aged IAPP and fibrillar IAPP had no 
effect on formation of cytotoxic Aβ(1-40) species (Fig. 60B). Aβ(1-40) (16.5 µM, pH 7.4) 
was then aged and mixed with freshly dissolved IAPP (1/1 on a monomer basis) at various 
time points of its fibrillization pathway. Kinetics of fibrillogenesis were assessed by the ThT 
binding assay and cytotoxicity towards RIN5fm cells was assessed at 24 h by the MTT 
reduction assay. Fibrillogenesis and formation of cytotoxic species were attenuated only when 
prefibrillar Aβ(1-40) species were mixed with freshly dissolved IAPP (Fig. 60C and 60D). 
By contrast, addition of already fibrillized Aβ(1-40), did not affect fibrillogenesis of IAPP 
(Fig. 60C). In addition, the MTT reduction assay showed that the mixture of Aβ(1-40) fibrils 
with freshly dissolved IAPP had the same cytotoxicity as 24 h aged IAPP or fibrillar Aβ(1-40) 
alone (Fig. 60D). Thus, mixing fibrillar IAPP with prefibrillar Aβ(1-40) species does not 
attenuate Aβ(1-40) fibrillogenesis and cytotoxic self-assembly process and, fibrillar Aβ(1-40) 
with prefibrillar IAPP species does not attenuate IAPP fibrillogenesis and formation of 
cytotoxic species. These results suggested that only the interactions between early prefibrillar 
IAPP and Aβ(1-40) species are able to attenuate cytotoxic self-assembly of the two polypeptides. 
 
 
3.5.8 Seeding effects of Aβ(1-40) fibrils on Aβ(1-40)-IAPP hetero-complexes  
Differences between the abilities of the Aβ(1-40)-IAPP-GI and Aβ(1-40)-IAPP complexes to 
block seeding effects of Aβ(1-40) fibrils might underlie the differences between the inhibitory 
potencies of IAPP-GI and IAPP towards Aβ(1-40) cytotoxic self-assembly. To address this 
issue, the effect of seeding Aβ(1-40)-IAPP hetero-complexes with Aβ(1-40) fibrils was 
studied and compared to the effect of seeding Aβ(1-40) or IAPP alone. An aged and fibrillar 
Aβ(1-40) solution was added (at 0.1 molar equivalent) to a mixture of freshly dissolved IAPP 
(16.5 µM, pH 7.4) with Aβ (1/1), to Aβ(1-40) alone, and to IAPP alone and fibrillogenesis 
and cytotoxicities were assessed at various time points by the ThT binding and the MTT 
reduction assays (Fig. 61). Both formation of fibrillogenesis and cytotoxic assemblies of 
Aβ(1-40) in the Aβ(1-40) alone incubation were strongly accelarated by seeding with Aβ(1-40) 
fibrils (Fig. 61A, 61B and 61F). Importantly, in the seeded Aβ(1-40)-IAPP mixtures (1/1) 
formation of cytotoxic assemblies and fibrils was accelerated in a similar way as in the seeded 
Aβ(1-40) alone incubation (Fig. 61C and 61F). These results showed that cytotoxic Aβ(1-40) or 
IAPP self-assembly in Aβ(1-40)-IAPP complexes can be accelerated by seeding with Aβ(1-40)  
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Fig. 61. Effect of Aβ(1-40) seeds on cytotoxicity and fibrillogenesis of Aβ(1-40) versus Aβ(1-40)-IAPP complexes 
as studied by the ThT binding and the MTT reduction assays. (A) The Aβ(1-40)-IAPP complex was made by mixing 
freshly dissolved IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% 
HFIP) with Aβ(1-40) (1/1) and fibrillogenesis following seeding with preformed Aβ(1-40) fibrils (0.1 equivalent) 
was followed over time by the ThT binding assay. Aβ(1-40) fibrils was prepared from 7 days aged incubation of 16.5 
µM Aβ in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP. (B) - (D) At the 
indicated time points (0 h, 24 h, 72 h, and 7 days): solutions of ThT binding assay were added to PC-12 cells and 
cytotoxicities were assessed by the MTT reduction assay. (B) Time-dependence of cytotoxicity Aβ(1-40) alone with 
or without Aβ(1-40) seeds. (C) Time-dependence of cytotoxicity of mixture of Aβ(1-40) with IAPP (1/1) with Aβ(1-
40) seeds as compared with Aβ alone with Aβ(1-40) seeds. (D) Time-dependence of cytotoxicity of IAPP alone with 
or without Aβ(1-40) seeds. Data in (A)-(D) are means (±SEM) from 3 independent assays (performed in triplicates). 
(E) Comparison of the effect of Aβ(1-40) seeds on fibrillogenesis of Aβ(1-40)-IAPP versus Aβ(1-40)-IAPP-GI (1/1 
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or 1/10) complexes. (F) Comparison of the effect of Aβ(1-40) seeds on cytotoxicity of Aβ(1-40)-IAPP versus Aβ(1-
40)-IAPP-GI complexes. The time-dependence of formation or dissociation of cytotoxic species in Aβ(1-40) alone 
(at 100 nM) versus the seeded mixtures Aβ(1-40)-IAPP and Aβ(1-40)-IAPP-GI (1/1 or 1/10) is shown.  
 
fibrils (Fig. 61B-61D). These findings suggested that Aβ(1-40)-IAPP complexes were not 
“protected” from seeding effects of Aβ(1-40) fibrils on Aβ(1-40) and /or IAPP aggregation. 
Of note, the magnitude of the ThT fluorescence at the end point of fibrillogenesis in the 
seeded mixtures indicated that both IAPP and Aβ(1-40) might have been converted in fibrils 
(Fig. 61A). In contrast to these findings, the Aβ(1-40)-IAPP-GI mixtures were found to be 
completely “protected” from seeding effects of Aβ(1-40) fibrils and formation of cytotoxic 
assemblies and fibrils was strongly suppressed (Fig. 61E and 61F). Moreover, in the presence 
of a 10-fold molar excess of IAPP-GI with regard to Aβ(1-40) (which corresponds to a 100-
fold excess with regard to the added Aβ(1-40) fibrillar seeds) a nearly complete reversement 
of cytotoxicity of the added Aβ(1-40) seeds was observed (Fig. 61E and 61F). The observed 
reversement of cytotoxicity was in agreement with the observed ability of 100-fold excess of 
IAPP-GI to dissociate cytotoxic Aβ(1-40) assemblies (chapter 3.4.3). 
 
 
3.5.9 Seeding effects of IAPP fibrils on Aβ(1-40)-IAPP hetero-complexes  
Cytotoxic self-assembly and fibrillogenesis of prefibrillar IAPP can be strongly accelerated by 
seeding with preformed IAPP fibrils (Fig. 37). The effects of seeding the Aβ(1-40)-IAPP 
hetero-complexes with IAPP fibrils (0.1 molar equivalent) as compared to seeding Aβ(1-40) 
or IAPP alone were next studied. An aged and fibrillar IAPP solution was added (at 0.1 molar 
equivalent) to a mixture of freshly dissolved IAPP (16.5 µM, pH 7.4) with Aβ(1-40) (1/1), to 
Aβ(1-40) alone (16.5 µM), and to IAPP alone (16.5 µM). Fibrillogenesis and cytotoxicities 
were assessed then at various time points by the ThT binding assay and the MTT reduction 
assay towards RIN5fm and also PC-12 cells (Fig. 62). Cytotoxic self-assembly and 
fibrillogenesis of the Aβ(1-40)-IAPP mixtures was found to be strongly accelerated by 
seeding with IAPP fibrils (Fig. 62A and 62B). Of note, the seeded Aβ(1-40)-IAPP mixture 
was more toxic than seeded IAPP alone at 24 h indicating that cytotoxic Aβ(1-40) species 
were also present (Fig. 62B). To address the question whether IAPP fibrils can seed Aβ(1-40), 
Aβ(1-40) alone (16.5 µM) was seeded with IAPP fibrils (0.1 molar equivalent) and the 
solution was followed for 7 days. Interestingly, cytotoxic self-assembly and fibrillogenesis of 
Aβ(1-40) could not be seeded by IAPP fibrils (Fig. 62C and 62D) in compare to Aβ(1-40) 
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alone (Fig. 61A and 61B). Seeding with IAPP fibrils was also found to have no effect on the 
Aβ(1-40)-IAPP-GI mixture. Moreover, the cytotoxicity of the Aβ(1-40)-IAPP-GI mixture was 
less than the cytotoxicity of the added IAPP seeds which supported the previous finding that  
 
Fig. 62. Effect of IAPP seeds on cytotoxicity and fibrillogenesis of an Aβ(1-40)-IAPP mixture, IAPP alone and 
Aβ(1-40) alone as studied by the ThT binding and the MTT reduction assays. (A) The Aβ(1-40)-IAPP complex 
was made by mixing freshly dissolved IAPP (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 
100 mM NaCl and 0.5% HFIP) with Aβ(1-40) (1/1) and fibrillogenesis following seeding with preformed IAPP 
fibrils (0.1 equivalent) was followed over time by the ThT bindind assay. For comparison IAPP alone was also 
seeded. (B) Time-dependence of cytotoxicity of mixture of Aβ(1-40) with IAPP (1/1) following seeding with 
IAPP fibrils as compared to seeded IAPP alone. Solutions of the ThT binding assays of (A) were added to 
RIN5fm cells at the points indicated time and cytotoxicities were assessed by the MTT reduction assay. (C) The 
Aβ(1-40)-IAPP-GI complex was made by mixing freshly dissolved Aβ(1-40) (16.5 µM in 50 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) with IAPP-GI (1/1) and fibrillogenesis 
following seeding with preformed IAPP fibrils (0.1 equivalent) was followed over time by the ThT binding assay 
and compared with fibrillogenesis of Aβ(1-40) alone following seeding with IAPP fibrils. (D) Time-dependence 
of formation of cytotoxic species in Aβ(1-40) alone and in the mixtures of Aβ(1-40) with IAPP-GI following 
seeding with IAPP fibrils. Solutions of the ThT binding assay of (C) were added to PC-12 cells at the indicated 
time and cytotoxicities were assessed by the MTT reduction assay. Data in (A)-(D) are means (±SEM) from 3 
independent assays (performed in triplicates).  
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IAPP-GI (at a 10-fold excess with regard to the added IAPP seeds) was able to redissociate 
already formed mature IAPP fibrils (chapter 3.2.3). These results showed that the Aβ(1-40)-
IAPP complexes are not “protected” from the seeding effects of IAPP fibrils and that 
cytotoxic IAPP self-assembly can be accelerated in Aβ(1-40)-IAPP complexes by seeding 
with IAPP fibrils. 
 
 
3.5.10 Inhibition of Aβ(1-40) amyloidogenesis and cytotoxicity by “non-toxic” IAPP  
In the course of studies on folding and disulfide bridge formation of synthetic IAPP, a method 
was developed to generate a stable and “non-toxic” IAPP conformeric state. 
 
3.5.10-1 Preparation of “non-toxic” IAPP 
Synthetic IAPP (crude product after cleavage from the peptide resin) was first subjected to air 
oxidation for disulfide bridge formation (Cys2 to Cys7). Oxidation (1 mg crude material / ml 
solution) was performed in aqueous 10 mM CH3COONH4 containing 10% DMSO and 40% 
ACN for 20 h at room temperature. Purification was carried out by RP-HPLC.  
IAPP in its reduced state corresponds to the peak at ~25 min (Fig. 63A) whereas the retention 
time of oxidized IAPP is at ~26 min (Fig. 63B). The peak of ~17 min is due to phenol which 
has been used as a scavenger in the cleavage reaction. The disulfide-bridged and folded IAPP 
used normally throughout this work was prepared by the following method: crude material (1 
mg/ml) was dissolved in aqueous 0.1 M NH4HCO3 containing 6 M Gdn HCl and air oxidized 
for 2-4 h. Of note, no differences between the HPLC retention times of disulfide-bridged 
IAPP were found between the products generated by both above methods (Fig. 63C and 63D).  
 
 
3.5.10-2 Properties of  the “non-toxic” IAPP Preparation 
The properties of IAPP, prepared as described above (called “non-toxic IAPP), were studied 
by far-UV CD spectroscopy, the ThT binding assay, and the MTT reduction assay. The 
conformation and the amyloid fibril forming potential of “non-toxic” IAPP were first 
studied by far-UV CD spectroscopy. The CD spectrum of a “non-toxic” IAPP solution (5 
µM, pH 7.4) was measured at time 0 h following preparation of the solution and compared to 
the spectra of “normal” IAPP (made by the usual cystin oxidation procedure) and IAPP-GI. 
As shown in Fig. 64A, the spectrum of “non-toxic” IAPP had a very small magnitude and 
exhibited a big trough between 207 and 225 nm. By contrast, the spectrum of “normal” IAPP 
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had a pronounced minimum at 204 nm which indicated the presence of significant amounts of 
unordered structure. Of note, the shape of the spectrum of “non-toxic” IAPP was similar to 
the spectrum of IAPP-GI but its magnitude was about half as much as the IAPP-GI magnitude. 
The observed low magnitude indicated that “non-toxic” IAPP might have been already 
aggregated. The conformation of the solution of “non-toxic” IAPP solution was then followed 
at several time points by CD. These studies showed that the weak minima at 207 nm and 222 
nm disappeared after 3-4 h and a minimum at about 217 nm appeared. Formation of insoluble 
aggregates was then observed (at 5 h) (Fig. 64B). Aggregation of the “non-toxic” IAPP 
preparation resulted in formation of fibrils as confirmed by TEM (data not shown). The 
fibrillogenesis and cytotoxicity potentials of “non-toxic” IAPP preparation were then studied 
and compared to the properties of the “normal” IAPP and of IAPP-GI. For these studies, “non-
toxic” IAPP, “normal” IAPP, and IAPP-GI (16.5 µM, pH 7.4) were incubated and fibrillogenesis 
was followed by the ThT binding assay. At the indicated time points, the solutions from the 
 
Fig. 63. RP-HPLC traces of IAPP before and after oxidation (A) Synthetic IAPP, crude product (1 mg/ml) was 
dissolved in aqueous solution (10 mM CH3COONH4 containing 10% DMSO and 40% ACN). At the begin of the 
oxidation process (t=0 h), 50 µg of crude product were injected.  (B) Synthetic IAPP, crude product after 20 h 
oxidation, 200 µg of crude product were injected. (C) Oxidized “non-toxic” IAPP after RP-HPLC purification. 
(D) Oxidized “normal” IAPP (IAPP) after RP-HPLC purification. Solutions for (C) and (D): IAPP was dissolved 
at 1 µg/10 µl in a mixture of 72% ACN in water containing 0.04% TFA and 10 µg of IAPP were injected. 
A 
“ non-toxic”  
C 
“ normal”  
D
IAPP (oxidized) 
B
IAPP (reduced form)  
IAPP (oxidized form)  
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ThT binding assay were added to RIN5fm cells and cytotoxicities were assessed by the MTT 
reduction assay. “Normal” IAPP aggregated into fibrils and reached a maximum cytotoxicity 
within 24 h (Fig. 64C and 64D). By contrast, “non-toxic” IAPP did not bind ThT for the first 
3 days and exhibited a weak ThT-binding following incubation for 5-7 days (Fig. 64C).  Of 
note, similarly to IAPP-GI, the “non-toxic” IAPP incubation was not toxic for at least 7 days 
(Fig. 64D). 
 
Fig. 64. Properties of the “non-toxic” IAPP preparation as compared to the “normal” IAPP preparation (IAPP) and 
IAPP-GI (A) The conformation of “non-toxic” IAPP was determined by CD and compared to the conformation of 
“normal” IAPP and IAPP-GI. CD spectra of “non-toxic” IAPP (5 µM in 10 mM sodium phosphate buffer, pH 7.4, 
containing 1% HFIP), “normal” IAPP (5 µM) and IAPP-GI (5 µM) at the begin of incubation (t = 0 h). (B) Time 
dependence far-UV CD studies of “non-toxic” IAPP. CD spectra of “non-toxic” IAPP (5 µM) were measured at 
various time points as indicated. Spectra shown in (A) and (B) are representative of 2 independent experiments. (C) 
Time dependence of fibrillogenesis of “non-toxic” IAPP as compared to “normal” IAPP and IAPP-GI. “Non-toxic” 
IAPP, “normal” IAPP and IAPP-GI (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM 
NaCl and 0.5% HFIP) were incubated and kinetics of fibrillogenesis were followed by ThT binding assay. (D) 
Time dependence of formation of cytotoxic species in a solution of “non-toxic” IAPP as compared to “normal” 
IAPP and IAPP-GI. The solutions from the ThT binding assay were added to RIN 5fm cells at the indicated time 
points and cytotoxicities were assessed by MTT reduction assay. Data in (C) and (D) are means (±SEM) from 3 
independent assays (performed in triplicates) for each time point. 
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3.5.10-3 Effect of the “non-toxic” IAPP preparation on Aβ(1-40) amyloidogenesis and 
cytotoxicity   
The differences between the conformation, fibrillogenesis potential, and cytotoxicity of the 
“non-toxic” IAPP and the “normal” IAPP preparations might affect their interaction with 
Aβ(1-40). To address this issue, inhibitory effects of the “non-toxic” IAPP preparation on 
non-fibrillar and non-toxic or cytotoxic Aβ(1-40) species were examined. Kinetics of 
fibrillogenesis and cytotoxicity of a mixture of freshly dissolved “non-toxic” IAPP (0 h) with 
non-aged or 24 h aged Aβ(1-40) (1/1) were followed by ThT binding and the MTT reduction 
assay in PC-12 cells.  First, fibrillogenesis of incubations of Aβ(1-40) alone (16.5 µM), “non-
toxic” IAPP alone (16.5 µM), and of a mixture of freshly dissolved “non-toxic” IAPP (16.5 µM) 
with non-aged Aβ(1-40) (0 h) (1/1) were followed by the ThT binding assay (Fig. 65A). At 
various time points of the fibrillogenesis process, solutions were added to the cells and cell 
viabilities were assessed by the MTT reduction assay (Fig. 65B-65E). The fibrillization 
profile of the mixture of “non-toxic” IAPP with Aβ(1-40) was similar to the profile of “non-
toxic” IAPP alone (Fig. 65A). Both non-aged Aβ(1-40) and a non-aged mixture of “non-
toxic” IAPP with Aβ(1-40) were non-toxic (Fig. 65B). 24 h aged Aβ(1-40) which was still in 
the lag-phase was partially toxic and 72 h aged and fibrillized Aβ(1-40) was strongly 
cytotoxic (Fig. 65A, 65C and 65D). However, the 24-72 h aged mixture of “non-toxic” IAPP 
with Aβ(1-40), which was still in the lag-phase (Fig. 65A), was significantly less cytotoxic 
than similarly aged Aβ(1-40) (Fig. 65C and 65D). Importantly, the 7 days aged mixture of 
“non-toxic” IAPP with Aβ(1-40) was as toxic as 7 days aged Aβ(1-40) (Fig. 65E). In another 
experiment, kinetics of fibrillogenesis of a mixture of “non-toxic” IAPP (16.5 µM) with 24h 
aged Aβ(1-40) (1/1) were followed by the ThT binding assay (Fig. 66A). At various time 
points of the fibrillogenesis process aliquots of the mixture and of incubations of Aβ(1-40) 
alone were added to the cells and cell viabilities were assessed by the MTT reduction assay. 
These experiments showed that “non-toxic” IAPP inhibited the fibrillogenesis of 24 h aged 
Aβ(1-40). By contrast, “non-toxic” IAPP had no effect on already formed cytotoxic Aβ(1-40) 
species (Fig. 66B-66D). These results suggested that the “non-toxic” IAPP preparation was 
either unable to redissociate already formed cytotoxic Aβ(1-40) species or it became toxic by 
itself via “Aβ(1-40)-cross-seeding”. Taken together, these results showed that the interaction 
of “non-toxic” IAPP with Aβ(1-40) was able to block the fibrillogenesis of Aβ(1-40), while its 
effect on formation of cytotoxic species of Aβ(1-40) was similar to the effect of the “normal” 
IAPP preparation. Overall, the effect of the “non-toxic” IAPP preparation on Aβ(1-40) was 
much weaker than the effect of the conformationally constrained IAPP analogue IAPP-GI. 
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Fig. 65. Time-dependence of the inhibitory effect of the “non-toxic” IAPP on non-toxic and non-fibrillar Aβ(1-
40): (A) Incubations of mixture of freshly dissolved “non-toxic” IAPP (16.5 µM in 50 mM sodium phosphate 
buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) with Aβ(1-40) (1/1) and of Aβ(1-40) alone (16.5 µM), 
“non-toxic” IAPP alone (16.5 µM) were allowed to age for 7 days. Fibrillogenesis during aging was followed by 
the ThT binding assay. Grey bars indicate the time points of addition of the solutions to PC-12 cells for the 
assessment of cytotoxicities which is the experiment described under Fig. 67B - 67E.  (B) – (E) Effects of “non-
toxic” IAPP on Aβ(1-40) cytotoxicity. At the indicated time points: 0 h (B), 24 h (C), 72 h (D), and 7 days (E)  
solutions of the ThT binding assay were added to PC-12 cells and cytotoxicities were assessed by the MTT 
reduction assay. Data in (A)-(E) are means (±SEM) from 3 independent assays (performed in triplicates). 
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Fig. 66. Time-dependence of the inhibitory effect of “non-toxic” IAPP on already formed toxic and non-fibrillar 
Aβ(1-40) species. (A) Aβ(1-40) (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl 
and 0.5% HFIP) was first aged for 24 h then mixed with “non-toxic” IAPP (1/1). Incubations of 24 h aged Aβ(1-40) 
alone (16.5 µM), “non-toxic” IAPP alone (16.5 µM), and of mixture of “non-toxic” IAPP with 24 h aged Aβ (1-40) 
(1/1) were allowed to age for 7 days. Fibrillogenesis during aging was followed by the ThT binding assay. Grey 
bars indicate the time points of addition of the solutions to PC-12 cells for the assessment of cytotoxicities which is 
the experiment described under (B)–(D).  (B) – (D) At the indicated time points: 0 h (B), 24 h (C), and  72 h (D) 
solutions of ThT binding assay were added to PC-12 cells and cytotoxicities were assessed by the MTT reduction 
assay. Data in (A)-(D) are means (±SEM) from 3 independent assays (performed in triplicates). 
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Fig. 67. The studies of the effects of NFGAIL-GI on Aβ(1-40) fibrillogenesis and cytotoxicity. (A) 
Fibrillogenesis of Aβ(1-40) alone (16.5 µM) versus the mixture of Aβ(1-40) and NFGAIL-GI (A freshly made 
Aβ(1-40) solution (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% 
HFIP) was mixed with NFGAIL-GI (1/1)) as assessed by the ThT binding assay as compare to IAPP-GI.  (B) - 
(E) At the indicated time points: 0 h (B), 24 h (C), 72 h (D), and 7 days (E) solutions from ThT assay were added 
to PC-12 cells and cytotoxicities were assessed by the MTT assay. (F) Compare of the effect of NFGAIL-GI on 
cytotoxicity of Aβ(1-40). The time-dependence of formation of cytotoxic species in Aβ(1-40) alone (100 nM) 
versus the mixtures (Aβ(1-40)-NFGAIL-GI and Aβ(1-40)-IAPP-GI) is shown. Data in (A)-(E) are means (±SEM) 
from 3 independent assays (performed in triplicates).  
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solution (16.5 µM, pH 7.4) was mixed with NFGAIL-GI (1/1), and fibrillogenesis and 
cytotoxicities of mixture versus Aβ(1-40) alone (16.5 µM) were assessed by the ThT 
binding and the MTT reduction assay. As shown in Fig. 67A, Aβ(1-40) fibrillogenesis was 
delayed by ~24 h, and the ThT fluorescence at 7 days was significantly less than in the 
incubation of Aβ(1-40) alone. To examine whether NFGAIL-GI also affected formation of 
cytotoxic Aβ(1-40) self-assemblies, aliquots of the incubations of the ThT binding assays 
were added to PC-12 cells at various time points of the fibrillogenesis process and cell 
viabilities were assessed by the MTT reduction assay (Fig. 67B-67E). Non-aged Aβ(1-40) 
and non-aged mixture (0 h) were non-toxic (Fig. 67B). At 24 h, Aβ(1-40) alone and the 
mixture were still in the fibrillization lag-phase (Fig. 67A) and the solution of Aβ alone was 
more cytotoxic than the mixture (Fig. 67C). At the time point of 72 h, however, the Aβ(1-40) 
solution contained a significant amount of fibrils (Fig. 67A) and was clearly more cytotoxic 
than at 24 h (Fig. 67D). Of note, the 72 h aged mixture, which was still in the lag-phase, 
was significantly less cytotoxic than 72 h aged Aβ(1-40) (Fig. 67D). At 7 days, the only 
partially fibrillized mixture was as cytotoxic as fully fibrillized Aβ(1-40). Plotting the time 
dependence of the formation of cytotoxic species in the “Aβ(1-40) alone” incubation (100 
nM) and the mixture clearly demonstrated that NFGAIL-GI suppressed but did not block 
Aβ(1-40) cytotoxic self-assembly (Fig. 67F). Thus, NFGAIL-GI was a clear but weaker 
inhibitor of Aβ(1-40) cytotoxic self-assembly than IAPP-GI. 
 
 
3.6.2 Effects of parathormon on Aβ(1-40) cytotoxic self-assembly 
The effect of human parathormon(1-34) on Aβ(1-40) (1/1) fibrillogenesis and cytotoxicity 
was next examined by using the two solution preparation methods. A freshly made Aβ(1-40) 
solution was added to parathormon (the condition used for effects of IAPP-GI on Aβ(1-40)) 
and fibrillogenesis and cytotoxicity was examined by using the ThT binding assay and the 
MTT reduction assay. Fibrillogenesis of Aβ(1-40) alone and of the mixture exhibited the 
same lag-time of ~48 h and reached completion between 72 and 96 h (Fig. 68A). Kinetics of 
formation of cytotoxic species showed that parathormon was not cytotoxic and that Aβ(1-
40) alone and the mixture of Aβ(1-40) with parathormon were similarly cytotoxic up to 72 h 
(Fig. 68B-68D). The same effect was found when a freshly made parathormon solution was 
added to Aβ(1-40) (the condition used for effects of IAPP on Aβ(1-40)). Thus, parathormon 
did not significantly affect formation of Aβ(1-40) fibrils and cytotoxic assemblies. These 
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results suggested a sequence specificity for the inhibitory effects of IAPP-GI and IAPP 
respectively on Aβ(1-40) self-assembly. 
 
Fig. 68. Effects of parathormon on Aβ(1-40) fibrillogenesis and cytotoxicity. Incubations of parathormon-Aβ(1-
40) mixture were preformed by using method 1: a freshly made Aβ(1-40) solution (16.5 µM in 50 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl and 0.5% HFIP) was mixed with parathormon (in dry form). 
Incubations of Aβ(1-40) alone were performed under the same conditions and were included in each 
experimental set. Of note, the same effects were found in the mixture prepared using method 2: a freshly made 
solution of parathormon (16.5 µM in 50 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 
0.5% HFIP) was mixed with Aβ(1-40) (in dry form). (A) Fibrillogenesis of Aβ(1-40) alone (16.5 µM) versus the 
mixtures of Aβ(1-40)-parathormon (1/1) as assessed by the ThT binding assay. (B) - (D) Effects of parathormon 
(1/1) on Aβ(1-40) cytotoxicity. At the indicated time points: 0 h (B), 24 h (C), and  72 h (D), solutions from the 
ThT binding assay were added to PC-12 cells and cell viability were assessed by the MTT reduction assay. Data 
in (A)-(D) are means (±SEM) from 3-5 independent assays (performed in triplicates). 
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In another experimental set the question whether NFGAIL-GI was able to dissociate already 
formed Aβ(1-40) fibrils was addressed. Mature Aβ(1-40) fibrils (generated in a 7 days aged 
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ratios and, following 3 days incubation at room temperature, fibrils were quantified by the 
ThT binding assay. NFGAIL-GI was found to be practically unable to dissociate Aβ(1-40) 
fibrils even when applied at a 100-fold higher molar excess than Aβ(1-40) (with regard to 
Aβ(1-40) monomers) (Fig. 69). These results were in line with the previously found inability 
of NFGAIL-GI to affect already started IAPP cytotoxic self-assembly processes and were 
consistent with the design concept of IAPP-GI [256]. 
 
Fig. 69. Effect of NFGAIL-GI on preformed Aβ(1-40)  fibrils as studied by the ThT binding assays. Fibrillar 
Aβ(1-40)  was prepared from a 7 days aged Aβ(1-40) solution (16.5 µM in 50 mM sodium phosphate buffer, pH 
7.4, containing 100 mM NaCl and 0.5% HFIP). Aliquots were then mixed with NFGAIL-GI at the indicated 
molar ratios. Solutions (including a control fibrillar Aβ(1-40) solution) were incubated for 72 h at room 
temperature and fibrils were then quantified by the ThT binding assay. Data are means (±SEM) from 2 assays 
(performed in triplicates). 
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4. Discussion 
The development of molecular strategies and compounds that interfere with and, possibly, 
inhibit the conformational transition of IAPP into cytotoxic β-sheet aggregates is an important 
target towards both understanding the mechanism of IAPP aggregate-mediated cytotoxicity 
and developing novel molecular strategies for the treatment of T2D [226, 234, 286]. 
Constraining the conformation of a conformationally flexible and bioactive polypeptide is a 
known strategy to both modulate its biophysical properties and to generate high affinity 
agonists of biological function [287, 288]. Further, amide bond N-methylation is a minimally 
invasive method towards inhibiting peptide self-assembly in β-sheets [207, 287]. Here, a 
number of biophysical studies on four recently designed synthetic IAPP analogues are 
presented. The analogues were designed to be non-amyloidogenic and non-toxic molecular 
mimics of the highly amyloidogenic and toxic IAPP molecule. For this purpose, a 
minimalistic conformational restriction strategy has been applied based on a selective N-
methylation approach. Three of the IAPP analogues (IAPP-GI, IAPP-LA, and IAPP-FA) were 
generated by N-methylation of two amide bonds on the same “side” of the putative β-strand in 
the amyloid core sequence IAPP(22-27) (NFGAIL sequence) of full length IAPP (Scheme 2). 
The fourth analogue (IAPP-LI) was designed with the N-methylation at both “sides” of the β-
strand (Scheme 2). This analogue served as a control peptide to address the issue of the role of 
hydrophobic interaction versus H-bonding ability of the amides of I26 and L27 in molecular 
recognition. All four IAPP analogues had nearly the same amino acid sequence as the 
extremely amyloidogenic and cytotoxic polypeptide IAPP. However, interstrand amide H-
bond formation, a process necessary for β-sheet-mediated self- or hetero-association events, 
was restricted in all of them. 
The biophysical, amyloidogenic and cytotoxic properties of the IAPP analogues and their 
bioactivity were studied by a sedimentation assay, ThT binding assay, TEM, far-UV CD 
spectroscopy, SEC, an oligomerization assay, MTT reduction assay, and the adenylate cyclase 
activation assay. All four conformationally constrained analogues proved to be highly soluble, 
non-amyloidogenic, and non-cytotoxic under physiological pH (chapters 3.1.1-3.1.5). The 
IAPP analogues were also proved to be full agonists of the human IAPP receptor and they 
were able to keep their bioactivities for longer time periods than IAPP when stored in aqueous 
solution at high concentrations and room temperature (chapters 3.1.6 and 3.1.7).  Importantly, 
the results of these studies also provided evidence that the gain-of-toxic-activity of IAPP is 
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directly linked to its ability to misfold and self-assemble in β-sheet aggregates and fibrils [9, 
69, 234]. Due to their similarity to IAPP, one or more of the analogues IAPP-GI, IAPP-LA, 
IAPP-FA were expected be able to interact with monomeric IAPP and possibly kinetically 
stabilize it against cytotoxic misfolding and self-assembly (Fig. 70). Binding to IAPP 
monomers might also shift the fibrillogenesis equilibrium towards dissociation of cytotoxic 
assemblies. Similarly to IAPP, one or more of these analogues should also be able to bind 
fibrillogenesis intermediates (Fig.70). High affinity of biomolecular recognition, strong 
kinetic stabilization of non-toxic IAPP monomers (or oligomers) against cytotoxic misfolding 
and self-assembly, and a strong inhibitory potency towards IAPP self-assembly should be 
provided by the maximized number of contact points between the full length IAPP analogues 
and IAPP, due to positive cooperativity, and by the constrained nature and the steric bulk of 
these analogues. However, the potency of their inhibitory effect would depend on the 
conformational specificity of the interaction responsible for inhibition of fibrilllization and/or 
cytotoxicity and was therefore expected to vary between the different analogues. The ability 
of IAPP analogues to interact with IAPP, to interfere with its fibrillogenesis process, and to 
inhibit its amyloidogenesis and related toxicity toward pancreatic β-cells were studied here, 
using a variety of biophysical assays. CD studies and pull-down assays suggested that the 
IAPP analogues were in fact able to interact with IAPP (chapters 3.2.1 and 3.2.5). Of note, the 
shapes of the spectra of the mixtures were very similar to the spectra of the analogues alone 
indicating a strong effect of these IAPP analogues on IAPP conformation. CD studies in 
combination with TEM (chapter 3.2.2) suggested that IAPP-GI was able to completely block 
IAPP misfolding and self-assembly into β-sheet containing oligomers and insoluble amyloid 
fibrils. In addition, detailed EM studies demonstrated that soluble ordered spherical 
oligomeric assemblies were the main species formed in IAPP-IAPP-GI solutions. These 
species may represent ordered IAPP-IAPP-GI hetero-complexes which form by IAPP-GI with 
IAPP. CD studies also indicated that the other three analogues were weaker inhibitors of IAPP 
misfolding into β-sheets than IAPP-GI (chapter 3.2.6). The ThT binding assays in 
combination with the MTT reduction assay (chapters 3.2.1 and 3.2.7) showed that IAPP-GI at 
an IAPP-GI/IAPP ratio of 1:1 completely blocked formation of cytotoxic IAPP assemblies 
and fibrils. Moreover, studies where IAPP-GI was added at several time points of the IAPP 
aggregation pathway suggested that IAPP-GI binds early prefibrillar and non-toxic IAPP 
species and blocks their further conversion into cytotoxic oligomers and fibrils. The analogues 
IAPP-LA, IAPP-FA, and IAPP-LI were, however, only able to partially suppress formation of 
cytotoxic IAPP assemblies and fibrils. These latter findings were in good agreement with the 
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results of the CD studies. The ThT binding and the MTT reduction assays following titration 
of IAPP with various amounts of IAPP-GI revealed that IAPP-GI is a low nanomolar activity 
inhibitor of both IAPP fibrillogenesis and cytotoxicity. These results were consistent with the 
high affinity for the IAPP-IAPP-GI interaction as determined by fluorescence spectroscopy 
[285]. Importantly, IAPP-GI was also found to be able to redissolve cytotoxic IAPP 
aggregates and fibrils and reverse their cytotoxic effects (chapter 3.2.3). Further, IAPP-GI 
(1/1) completely blocked the seeding effect of IAPP fibrils on non-aggregated IAPP and 
completly suppressed formation of new cytotoxic assemblies and fibrils (chapter 3.2.4). These 
results further supported the suggestion that IAPP-GI binds IAPP prefibrillar monomers 
and/or other early species of the fibrillogenesis pathway inhibiting thus their conversion into 
cytotoxic oligomers and fibrils. However, IAPP-LA and IAPP-FA (at 1/1) were, in contrast to 
IAPP-GI, unable to redissociate fibrils. IAPP-LI nearly completely blocked formation of 
IAPP fibrils when it was added in the begin of the fibrillogenesis process while its addition at 
later time-points resulted only in partial fibril dissociation. In addition, all three analogues 
were found to only partially dissociate cytotoxic IAPP species when added at an 1/1 molar 
ratio to IAPP (chapter 3.2.8).  
 
 
Fig. 70. Proposed mechanism of inhibition of IAPP fibrillogenesis and cytotoxicity by the designed N-
methylated IAPP analogues. The figure shown is modified from ref. [256]. 
 
Taken together, the results of the CD, TEM, the ThT binding, and the MTT reduction assays 
suggested that the observed inhibitory or attenuating effects of the IAPP analogues on IAPP 
fibrillogenesis is most likely due to their interaction with monomeric or early oligomeric 
IAPP species. Interaction appears to suppress the onset and/or the extend of the fibrillogenesis 
process (reduction in the amounts of finally foemed fibrils). In addition, the obtained results 
showed that IAPP-GI is the most effective inhibitor under all four tested IAPP analogues by 
being able not only to inhibit IAPP self-assembly into fibrils and cytotoxic aggregates but also 
Cytotoxic fibrillogenesis intermediates 
Potentially cytotoxic fibrilsNon-cytotoxic IAPP 
IAPP analogues 
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to dissociate already built-up cytotoxic species and fibrils. Of note, the control peptide rIAPP 
(at 1/1) was able to affect IAPP fibrillization only in an assay system where IAPP 
fibrillization had a lag-time of 0.5 h but unable to affect IAPP toxicity in two different assay 
systems (chapter 3.3.2). These results were consistent with a high conformational specificity 
of here identified effects of IAPP-GI. 
About several years ago, insoluble mature amyloid fibrils have been suggested to cause the 
cytotoxic effect of IAPP [262].  However, lately evidence has been accumulated suggesting 
that soluble IAPP oligomers are the main mediators of IAPP-amyloid-associated cell toxicity 
[87, 234, 270, 289]. Soluble oligo- or multimeric aggregates that form most likely within the 
pathway of IAPP amyloid formation have been suggested to permeabilize cell membranes via 
a channel- or pore-like mechanism, or simply by causing small membrane defects [87, 106, 
260, 270, 271]. An important implication of these findings for the design of inhibitors of  
IAPP cytotoxicity is that -depending on the mechanism of its action- a compound that inhibits 
IAPP amyloid formation may not necessarily inhibit cytotoxicity and vice versa [88].  
Reported inhibitors of IAPP fibrillogenesis so far include aromatic compounds and short 
peptides which are active in the micromolar or submicromolar concentration range, at best 
[255, 274, 276, 277]. These inhibitors can merely delay or suppress amyloidogenicity and 
cytotoxicity and are unable to block or reverse IAPP cytotoxic self-assembly after nucleation. 
For example, the synthetic peptide IAPP(24-29) or GAILSST, has been reported to reduce 
IAPP amyloid formation but was unable to affect its cytotoxicity and IAPP(20-25) or 
SNNFGA reduces IAPP cytotoxicity at a 20-fold molar excess as compared to IAPP [276]. 
Recently, a short N-methylated peptide NFGAIL-GI, was developed by our labolatory as 
submicromolar IAPP ligand and inhibitor of IAPP fibrillogenesis and cytotoxicity [255]. 
However, NFGAIL-GI exhibits its strongest inhibitory effects only in the assay system where 
IAPP fibrillization has a long lag-time, is unable to completely block IAPP fibrillogenesis and 
cytotoxicity, and does not block or reverse cytotoxic self-assembly of IAPP after nucleation 
(chapters 3.3.1 and 3.3.4). Since no IAPP binding or inhibitory effects on IAPP fibrillogenesis 
were found for NFGAIL [255], it has been suggested that the presence of the two N-methyl 
rests at G24 and I26 in the IAPP self-recognition sequence NFGAIL is a necessary structural 
requirement for the binding of NFGAIL-GI to IAPP and its inhibitory effect on both IAPP 
fibrillogenesis and cytotoxicity. On the other hand, the highly cooperative nature of the IAPP 
self-assembly and fibrillogenesis processes (affinity of the IAPP-IAPP interaction) might 
account for the lack of NFGAIL-GI to completely abolish fibrillogenesis and to stop already 
nucleated amyloidogenesis processes [250, 290]. By contrast, IAPP-GI binds IAPP with a 
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nanomolar affinity and completely blocks IAPP cytotoxic misfolding and self-association 
both in pre- and post-nucleation phase and redissolves cytotoxic IAPP aggregates and fibrils. 
As treatment of disease usually starts after its begin, these properties are very important with 
regard to a potential therapeutic use of this peptide. 
The studies presented here and elsewhere [256] suggest that the high inhibitory potency of 
IAPP-GI might be mediated by the high affinity binding of IAPP-GI a) to IAPP monomers, 
their kinetic stabilization towards cytotoxic misfolding and self-assembly or their sequestering 
from the amyloid pathway and b) to early prefibrillar and non-toxic IAPP fibrillogenesis 
intermediates and their sequestration from further fibrillogenesis. IAPP-GI binding to non-
toxic IAPP monomers would also underly dissociation and reversal of cytotoxicity of 
oligomers and fibrils (Fig. 70). Thus, IAPP-GI was found to be a compound that completely 
and with low nanomolar activity blocks and reverses IAPP cytotoxic self-assembly and 
fibrillogenesis. In addition, IAPP-GI is the only known IAPP amyloidogenesis inhibitor 
which is at the same time a soluble at physiological pH, non-amyloidogenic and non-
cytotoxic, full length IAPP analogue and an IAPP receptor agonist. For comparison, the best 
known soluble IAPP receptor agonist, a tri-proline analog of full length IAPP ([P25, P28, 
P29]-IAPP), precipitates above pH 5.5 and no amyloid-inhibitory properties have been 
reported [291]. Bifunctional IAPP analogues, such as IAPP-GI or the other analogues 
presented here, could be therefore promising drug candidates for the treatment of diabetes. 
AD and T2D are two prominent representatives of protein-aggregation diseases. Emerging 
evidence supports the hypothesis that AD and T2D might be linked to each other. For 
example, clinical studies suggest that persons suffering from T2D might be at the risk of AD 
and vice versa [280, 281]. In addition, a recent paper reported that Aβ(1-40) fibrils can seed in 
vitro fibrillization of IAPP [278]. This intriguing finding indicated that Aβ(1-40) and IAPP 
might populate conformations or assembly states that might be able to cross-interact. 
Interestingly, the Aβ(1-40) and IAPP sequences exhibit a 25% identity and a 50% similarity 
and are degraded in vivo by the same enzyme (Scheme 3) [278, 292]. Based on these 
observations and the results of the studies of the designed IAPP analogues with IAPP, the 
ability of IAPP analogues to interact with Aβ(1-40), to interfere with its fibrillogenesis 
process, and to inhibit its amyloid-forming potential and related cell toxicity were also studied. 
CD studies and a pull-down assay suggested that the IAPP analogues were able to interact 
with Aβ(1-40) (chapters 3.4.1 and 3.4.5). Of note, the shapes of the spectra of the mixtures 
were very similar to the spectra of the analogues alone indicating a strong effect of their 
conformation on Aβ(1-40) conformation. The shapes of the spectra of the mixtures of Aβ(1-
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40) with the IAPP analogues strongly differed from each other which indicated differences 
between the structures of the hetero-complexes. Importantly, the IAPP analogues were found 
to be able to suppress Aβ(1-40) misfolding into β-sheets. According to the results of the CD 
studies, the potencies of inhibitory effects were in the order IAPP-GI～IAPP-LA～IAPP-FA 
> IAPP-LI (chapter 3.4.6). The ThT binding and the MTT reduction assays showed that the 
inhibitory effects of the IAPP analogues on Aβ(1-40) fibrillogenesis were similar to each 
other, whereas IAPP-LA, IAPP-FA, and IAPP-LI exhibited similar but weaker inhibitory 
effects on formation of cytotoxic Aβ(1-40) aggregates assemblies as compared to IAPP-GI 
(chapters 3.4.2 and 3.4.7). The differences between the inhibitory effects of the IAPP 
analogues on formation of Aβ(1-40) cytotoxic assemblies may reflect differences in the 
conformational specificity of the hetero-assembly process of the analogues with Aβ(1-40). 
Studies on the effects of the IAPP analogues on already formed Aβ(1-40) fibrils and cytotoxic 
aggregates showed that IAPP-GI not only blocked the further progress of Aβ(1-40) cytotoxic 
self-assembly but it also dissociated already formed mature Aβ(1-40) fibrils when added at a 
10-100-fold excess with regard to Aβ(1-40). Importantly, IAPP-GI was also able to dissociate 
already built-up, non-fibrillar (or fibrillar, see above) cytotoxic Aβ assemblies (chapters 3.2.8 
and 3.4.3). Moreover, Aβ(1-40)-IAPP-GI hetero-complexes were found to be ‘‘protected’’ 
from seeding effects of Aβ(1-40) fibrils on Aβ(1-40) (chapter 3.4.4). Importantly, the 
presence of a 10-fold molar excess of IAPP-GI with regard to Aβ(1-40) (which corresponds to 
a 100-fold excess with regard to the added Aβ(1-40) seeds) not only blocked formation of 
new cytotoxic assemblies and fibrils by Aβ(1-40) but it also nearly completely redissolved the 
added Aβ(1-40) seeds and reversed thus their cytotoxic effects. IAPP-LI blocked Aβ(1-40) 
fibrillogenesis when added to the Aβ(1-40) incubation during the fibrillization lag-time 
(chapter 3.2.8), while IAPP-LA and IAPP-FA were less potent inhibitors of Aβ(1-40) 
fibrillogenesis when added during fibrillization. In particularly, when added to Aβ(1-40) after 
nucleation of Aβ(1-40) fibrillogenesis, IAPP-LA and IAPP-FA dissociated a part of the Aβ(1-
40) fibrils and blocked further fibrillogenesis. However, their effects on fibril dissociation 
were weak, as fibrils reassociated within 24-48 h. Thus, in contrast to IAPP-GI, all three 
analogues were unable to dissociate already formed Aβ(1-40) cytotoxic assemblies and thus 
to reverse Aβ(1-40) cytotoxicity.  
Together, these data showed that all designed IAPP analogues strongly interfered with the β-
sheet formation and fibrillogenesis processes of Aβ(1-40) and nearly completely supressed 
formation of mature Aβ(1-40) fibrils. However, the potencies of the inhibitory effects with 
regard to dissociation of cytotoxic Aβ(1-40) aggregates and fibrillar assemblies varied 
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between the different analogues. These findings suggested that the IAPP analogues bind to 
and sequester early prefibrillar, Aβ(1-40) monomers or low MW oligomers from the cytotoxic 
self-assembly and fibrillogenesis pathway (chapter 3.4.2). Sequestering most likely occurs via 
kinetic stabilization of early prefibrillar and non-toxic precursors of Aβ(1-40) cytotoxic self-
assembly in form of soluble, non-toxic, and non-fibrillar hetero-oligomers (Fig. 71) [285]. 
Such sequesteration would account for the observed diminished cell toxicity of the Aβ(1-40)-
analogue mixtures and would possibly shift the Aβ(1-40) self-assembly equilibrium towards 
disassembly of toxic assemblies [88, 256]. However, only IAPP-GI completely blocked and 
reversed cytotoxic self-association and fibrillogenesis of Aβ(1-40). These findings suggested 
that the exact positions of the two N-methyl rests in the IAPP self-recognition sequence 
NFGAIL of the four analogues are very important for their inhibitory potencies of Aβ(1-40) 
fibrillogenesis and cytotoxicity.  
As IAPP-GI represents a stabilized non-amyloidogenic and non-toxic IAPP conformation, the 
above findings suggested that there might be at least one IAPP conformation which might 
interfere with Aβ(1-40) self-assembly, possibly in a similar manner to IAPP-GI (Fig. 71). The 
ability of Aβ(1-40) to bind IAPP might be related to the high degree of sequence identity and 
similarity between short β-strand and amyloid forming sequences of the two peptides [23, 160, 
278, 293, 294]. In particular, the Aβ(1-40) region Aβ(15-37) shares a 39% identity and a 65% 
similarity with the IAPP region IAPP(10-33) [23, 24, 278]. These two regions contain short 
amino acid stretches which are thought to be involved in the inter- and intramolecular β-sheet 
structure of Aβ(1-40) and IAPP fibrils. Interestingly, NFGAIL-GI was able to interfere with 
the fibrillogenesis and cytotoxicity processes of Aβ(1-40), but weaker than IAPP-GI (chapter 
3.6.1), and it does not dissociate Aβ(1-40) fibrils even at a 100-fold higher molar excess 
(chapters 3.6.3). In fact, the finding that the introduction of two N-methyl residues in the 
NFGAIL region generates a inhibitor of Aβ(1-40) cytotoxic self-assembly strongly supports 
the idea that this hexapeptide sequence might be involved in the molecular recognition and 
amyloid inhibition process of Aβ(1-40) and IAPP.  
Importantly, hetero-complex formation between prefibrillar IAPP and Aβ(1-40) species 
caused a significant attenuation of formation of cytotoxic oligomers and fibrils by both Aβ(1-
40) and IAPP (chapters 3.5.2-3.5.5). The data presented in this work and in the recent report 
of our laboratory [285] suggest that attenuation is due to hetero-association of a specific, early 
prefibrillar and non-toxic IAPP conformation possibly an IAPP-GI-like conformation with 
early prefibrillar and non-toxic Aβ(1-40) species into non-fibrillar and non-toxic hetero-
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oligomers. Prefibrillar precursors of cytotoxic IAPP and Aβ(1-40) oligomers and fibrils might 
thus become kinetically trapped in form of soluble and non-toxic hetero-oligomers (Fig. 71). 
Both IAPP-GI and early prefibrillr IAPP species bound prefibrillar Aβ(1-40) species, but only 
IAPP-GI blocked and reversed cytotoxic self-association and fibrillogenesis of Aβ(1-40). By 
contrast, prefibrillar IAPP only delayed but did not block or reverse Aβ(1-40) cytotoxic self-
assembly. Even “non-toxic” IAPP, which represents an IAPP preparation which mainly 
populates a non-toxic conformeric state, was able to block the fibrillogenesis of Aβ(1-40) 
(chapter 3.5.10-3). However, its effect on formation of cytotoxic species of Aβ(1-40) was 
similar to the effect of the “normal” IAPP preparation. In addition, as expected, the effect of 
the “non-toxic” IAPP preparation on Aβ(1-40) was much weaker than the effect of IAPP-GI.  
IAPP-GI is, due to the N-methyl constains, (a) unable to misfold and self-assemble into 
cytotoxic β-sheets oligomers and fibrils and (b) unable to propagate β-sheets and amyloid 
fibrils. Therefore, competitive hetero-molecular interactions involving formation of cytotoxic 
β-sheet, oligomers, and amyloid fibrils would be suppressed in the Aβ(1-40)-IAPP-GI 
complexes consistent with the observed higher hetero-complex stability, resistance towards 
Aβ(1-40) seeding, and the higher inhibitory potency of IAPP-GI as compared to both IAPP 
and the “non-toxic” IAPP preparation. 
The studies presented in this work show that IAPP-GI is one of the most potent Aβ(1-40) 
ligands and inhibitors of Aβ(1-40) cytotoxic self-assembly reported so far. For comparison, 
other reported inhibitors often slow-down but do not block or reverse Aβ(1-40) cytotoxic self-
assembly and are usually active in the micromolar concentration range [8, 295]. IAPP-GI 
combines nanomolar activity with the ability to block and reverse Aβ(1-40) cytotoxic 
oligomerization and fibrillogenesis. Importantly, as IAPP is able to cross the blood-brain-
barrier, IAPP-GI would also be expected to cross it, allowing for a direct targeting of Aβ(1-40) 
species within the cerebrospinal fluid [296, 297].  In addition, IAPP-GI was shown here to 
block and reverse with nanomolar activity cytotoxic self-assembly of both IAPP and Aβ(1-40). 
Several compounds, including aromatic compounds and an antibody, have been reported to 
bind to a common structural epitope of amyloid fibrils from different polypeptide sequences 
[8, 298, 299].  However, so far only one compound, an anti-Aβ(1-40) oligomer antibody, has 
been reported to bind and suppress cytotoxicities of prefibrillar oligomers of various different 
polypeptides, including Aβ(1-40) and IAPP [122].  IAPP-GI is thus the only peptide-derived 
cross-amyloid disease ligand and cytotoxic self-assembly inhibitor reported so far. As the 
incidence of both AD and T2D strongly increases with age and AD patients may also suffer 
from, or might be at the risk of, T2D and vice versa [280, 281], IAPP-GI could become the 
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first representative of a novel class of peptide-derived compounds that target pathogenesis of 
both diseases.  
The finding that early prefibrillar IAPP species bind prefibrillar Aβ(1-40) species and that 
IAPP-Aβ(1-40) hetero-complex formation attenuates cytotoxic oligomerization and 
fibrillogenesis of both polypeptides, offers a molecular basis for a potential link between AD 
and T2D. The results presented here and in the recent report of our laboratory [285] support 
the hypothesis that, in vivo, Aβ(1-40) and IAPP, two intrinsically unfolded polypeptides with 
extremely high self-association propensities [300], might mutually “protect” themselves from 
cytotoxic misfolding and self-association via hetero-association of early prefibrillar and yet 
non-toxic conformations (Fig. 71). The proposed cross-amyloid disease suppression 
mechanism would be consistent with clinical reports linking the onsets of AD and T2D to 
each other [278, 280, 281].  Accordingly, cytotoxic self-assembly of one of the polypeptides 
would distort hetero-association equilibria, causing an increase of concentration of the other 
polypeptide and accelerating thus in this way (or via cross-seeding [301]) self-assembly of the 
other peptide. The onset of one of the two diseases would thus accelerate the onset of the 
other disease. Because both Aβ and IAPP are present in serum and in the cerebrospinal fluid 
(CSF) in comparable subnanomolar concentrations, an in vivo cross-interaction would be 
possible [17, 234]. Of note, both polypeptides have been shown to interact with other proteins 
and these interactions have been suggested to accelerate or inhibit amyloidogenesis [302-305].  
In conclusion, the studies presented in this thesis showed that all four designed IAPP 
analogues are able to interact with IAPP and to suppress IAPP cytotoxic self-assembly and 
fibrillogenesis. The potencies of the effects of the different IAPP analogues differ significantly, 
consistent with a conformational specificity of the IAPP-analogue interaction causing their 
inhibitory effects.  
In addition, it is shown that all four analogues are also able to interfere with Aβ(1-40) and to 
suppress with varying potencies Aβ(1-40) cytotoxic self-assembly and fibrillogenesis. 
Importantly, IAPP-GI proved to be the most potent analogue with regard to inhibition of self-
assembly of both IAPP and Aβ(1-40). Therefore, IAPP-GI or the other analogues might be 
suitable compounds as lead compounds for the development of therapeutics in T2D and/or 
AD. Finally, the studies presented in this work identify a novel molecular interaction between 
Aβ and IAPP, the two key amyloidogenic polypeptides of T2D and AD. This cross interaction 
is shown to result in an attenuation of cytotoxic self-assembly of both IAPP and Aβ(1-40), 
suggesting a potential molecular link between the two diseases. 
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Fig. 71. Proposed molecular models [285] of interaction of (A) IAPP-GI with early prefibrillar Aβ(1-40) 
species resulting in inhibition and reversal of Aβ(1-40) cytotoxic oligomerization and fibril formation (blue 
arrows), and (B) early prefibrillar IAPP and Aβ(1-40) species resulting in attenuation (blue arrows) of 
cytotoxic self-assembly and fibrillogenesis of both Aβ(1-40) and IAPP. Sequesteration of early prefibrillar 
and nontoxic precursors of cytotoxic Ab40 assemblies in the form of soluble and nontoxic hetero-oligomers is 
suggested to occur through their high-affinity binding to IAPP-GI (A) or to an early prefibrillar and nontoxic 
IAPP conformer, that is, an IAPP-GI-like conformer, in a competitive manner to Aβ(1-40) or IAPP self-
association (B). Owing to the high conformational flexibility and the strong β-sheet and self-association 
propensity of both IAPP and Aβ(1-40), however, competitive self-association, seeding, and cross-seeding 
events are expected to interfere with Aβ(1-40) /IAPP heterocomplex formation and stability shifting thus 
heteroassociation equilibria towards self-association (B). In contrast, Aβ(1-40) /IAPP-GI hetero-oligomers 
will not propagate β-sheet structure and cytotoxic self-association and fibrillogenesis of Aβ(1-40)  as a result 
of the N-methylations in the amyloid core of IAPP-GI, consistent with the high potency of the inhibitory 
effect of IAPP-GI (A).  The figure shown is modified from ref. [285].   
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